Consistent with this, the ARU - GFP translational fusion protein driven by the endogenous promoter ( pARU :: ARU - GFP) is highly expressed in wild - type synergids ( Supplementary Fig. 7 ), suggesting an important role for ARU in these cells.	"ARU	26	29	Gene/Protein"	"GFP	32	35	Gene/Protein"	"ARU	102	105	Gene/Protein"	"GFP	115	118	Gene/Protein"	"ARU	224	227	Gene/Protein"	"[{""token"": ""ARU"", ""start_span"": 26, ""end_span"": 29, ""type"": ""Gene/Protein""}, {""token"": ""GFP"", ""start_span"": 32, ""end_span"": 35, ""type"": ""Gene/Protein""}, {""token"": ""ARU"", ""start_span"": 102, ""end_span"": 105, ""type"": ""Gene/Protein""}, {""token"": ""GFP"", ""start_span"": 115, ""end_span"": 118, ""type"": ""Gene/Protein""}, {""token"": ""ARU"", ""start_span"": 224, ""end_span"": 227, ""type"": ""Gene/Protein""}]"
SALK - lines were obtained from NASC: SALK_067271 ( At1g61790, aru - 1 ), SALK_137883C ( At1g61780 ), SALK_052207C and SALK_026074C ( At1g61795 ), SALK_104077 ( At1g61810 ).	"At1g61790	52	61	Gene/Protein"	"aru - 1	63	70	Gene/Protein"	"At1g61780	89	98	Gene/Protein"	"At1g61795	134	143	Gene/Protein"	"At1g61810	161	170	Gene/Protein"	"[{""token"": ""At1g61790"", ""start_span"": 52, ""end_span"": 61, ""type"": ""Gene/Protein""}, {""token"": ""aru - 1"", ""start_span"": 63, ""end_span"": 70, ""type"": ""Gene/Protein""}, {""token"": ""At1g61780"", ""start_span"": 89, ""end_span"": 98, ""type"": ""Gene/Protein""}, {""token"": ""At1g61795"", ""start_span"": 134, ""end_span"": 143, ""type"": ""Gene/Protein""}, {""token"": ""At1g61810"", ""start_span"": 161, ""end_span"": 170, ""type"": ""Gene/Protein""}]"
The FER promoter was amplified from the pFER :: FER - GFP construct13 using specific primers 5 ′- TTTGGTAAGCTTCGATTTAAGCGAG - 3 ′ and 5 ′- TTTTCTAGACGATCAAGAGCACTTCTCCGGG - 3 ′, which introduce HindIII and XbaI restriction sites as well.	"FER	4	7	Gene/Protein"	"FER	41	44	Gene/Protein"	"GFP	54	57	Gene/Protein"	"HindIII	194	201	Gene/Protein"	"XbaI	206	210	Gene/Protein"	"[{""token"": ""FER"", ""start_span"": 4, ""end_span"": 7, ""type"": ""Gene/Protein""}, {""token"": ""FER"", ""start_span"": 41, ""end_span"": 44, ""type"": ""Gene/Protein""}, {""token"": ""GFP"", ""start_span"": 54, ""end_span"": 57, ""type"": ""Gene/Protein""}, {""token"": ""HindIII"", ""start_span"": 194, ""end_span"": 201, ""type"": ""Gene/Protein""}, {""token"": ""XbaI"", ""start_span"": 206, ""end_span"": 210, ""type"": ""Gene/Protein""}]"
For the constructs with ARU under the control of its endogenous promoter, the ARU fragment ( including 1, 492 bp of upstream, ARU CDS, and 865 bp of downstream sequence) was amplified from Col - 0 and Ga - 0 genomic DNA using primers 5 ′- TTTTACTAGTAGGCAATTCCATCAGTTGTT - 3 ′ and 5 ′- TTTTGGTACCGTTACTTCACTTTCTCGAGT - 3 ′, introducing a SpeI and a KpnI restriction site, respectively.	"ARU	24	27	Gene/Protein"	"ARU	78	81	Gene/Protein"	"ARU	126	129	Gene/Protein"	"SpeI	337	341	Gene/Protein"	"KpnI	348	352	Gene/Protein"	"[{""token"": ""ARU"", ""start_span"": 24, ""end_span"": 27, ""type"": ""Gene/Protein""}, {""token"": ""ARU"", ""start_span"": 78, ""end_span"": 81, ""type"": ""Gene/Protein""}, {""token"": ""ARU"", ""start_span"": 126, ""end_span"": 129, ""type"": ""Gene/Protein""}, {""token"": ""SpeI"", ""start_span"": 337, ""end_span"": 341, ""type"": ""Gene/Protein""}, {""token"": ""KpnI"", ""start_span"": 348, ""end_span"": 352, ""type"": ""Gene/Protein""}]"
We further demonstrate that it regulates cell survival via a signaling mechanism involving MEK - ERK via TLR4 and CD11B / CD18.	"MEK	91	94	Gene/Protein"	"ERK	97	100	Gene/Protein"	"TLR4	105	109	Gene/Protein"	"CD11B	114	119	Gene/Protein"	"CD18	122	126	Gene/Protein"	"[{""token"": ""MEK"", ""start_span"": 91, ""end_span"": 94, ""type"": ""Gene/Protein""}, {""token"": ""ERK"", ""start_span"": 97, ""end_span"": 100, ""type"": ""Gene/Protein""}, {""token"": ""TLR4"", ""start_span"": 105, ""end_span"": 109, ""type"": ""Gene/Protein""}, {""token"": ""CD11B"", ""start_span"": 114, ""end_span"": 119, ""type"": ""Gene/Protein""}, {""token"": ""CD18"", ""start_span"": 122, ""end_span"": 126, ""type"": ""Gene/Protein""}]"
Furthermore, neutrophils do not express survivin, an inhibitor - of - apoptosis protein ( IAP ), unless expression is induced by GCSF and GMCSF or in inflammatory conditions [ 16 ].	"survivin	40	48	Gene/Protein"	"inhibitor - of - apoptosis protein	53	87	Gene/Protein"	"IAP	90	93	Gene/Protein"	"GCSF	129	133	Gene/Protein"	"GMCSF	138	143	Gene/Protein"	"[{""token"": ""survivin"", ""start_span"": 40, ""end_span"": 48, ""type"": ""Gene/Protein""}, {""token"": ""inhibitor - of - apoptosis protein"", ""start_span"": 53, ""end_span"": 87, ""type"": ""Gene/Protein""}, {""token"": ""IAP"", ""start_span"": 90, ""end_span"": 93, ""type"": ""Gene/Protein""}, {""token"": ""GCSF"", ""start_span"": 129, ""end_span"": 133, ""type"": ""Gene/Protein""}, {""token"": ""GMCSF"", ""start_span"": 138, ""end_span"": 143, ""type"": ""Gene/Protein""}]"
We sought to verify S100A8 and A9 mediation of the community anti - apoptotic effect using recombinant human S100A8 and A9 ( kindly provided by Philippe A.	"S100A8	20	26	Gene/Protein"	"A9	31	33	Gene/Protein"	"human	103	108	Organism/Species"	"S100A8	109	115	Gene/Protein"	"A9	120	122	Gene/Protein"	"[{""token"": ""S100A8"", ""start_span"": 20, ""end_span"": 26, ""type"": ""Gene/Protein""}, {""token"": ""A9"", ""start_span"": 31, ""end_span"": 33, ""type"": ""Gene/Protein""}, {""token"": ""human"", ""start_span"": 103, ""end_span"": 108, ""type"": ""Organism/Species""}, {""token"": ""S100A8"", ""start_span"": 109, ""end_span"": 115, ""type"": ""Gene/Protein""}, {""token"": ""A9"", ""start_span"": 120, ""end_span"": 122, ""type"": ""Gene/Protein""}]"
Neutrophils undergoing spontaneous constitutive PCD at a concentration of 0. 5 × 106 / ml for 12h, with rabbit polyclonal antibody dilutions of 1 ∶ 100, 1 ∶ 1000, and 1 ∶ 10, 000 against S100A9 and S100A8, were then treated with 2 µg / ml S100A8 / 9 complex.	"rabbit	104	110	Organism/Species"	"antibody	122	130	Gene/Protein"	"S100A9	187	193	Gene/Protein"	"S100A8	198	204	Gene/Protein"	"S100A8	239	245	Gene/Protein"	"[{""token"": ""rabbit"", ""start_span"": 104, ""end_span"": 110, ""type"": ""Organism/Species""}, {""token"": ""antibody"", ""start_span"": 122, ""end_span"": 130, ""type"": ""Gene/Protein""}, {""token"": ""S100A9"", ""start_span"": 187, ""end_span"": 193, ""type"": ""Gene/Protein""}, {""token"": ""S100A8"", ""start_span"": 198, ""end_span"": 204, ""type"": ""Gene/Protein""}, {""token"": ""S100A8"", ""start_span"": 239, ""end_span"": 245, ""type"": ""Gene/Protein""}]"
S100A8 / 9 does not mediate the community effect via McL1, A1, the bcl - 2 protein family, or survivin	"S100A8	0	6	Gene/Protein"	"McL1	53	57	Gene/Protein"	"A1	59	61	Gene/Protein"	"bcl - 2	67	74	Gene/Protein"	"survivin	94	102	Gene/Protein"	"[{""token"": ""S100A8"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Gene/Protein""}, {""token"": ""McL1"", ""start_span"": 53, ""end_span"": 57, ""type"": ""Gene/Protein""}, {""token"": ""A1"", ""start_span"": 59, ""end_span"": 61, ""type"": ""Gene/Protein""}, {""token"": ""bcl - 2"", ""start_span"": 67, ""end_span"": 74, ""type"": ""Gene/Protein""}, {""token"": ""survivin"", ""start_span"": 94, ""end_span"": 102, ""type"": ""Gene/Protein""}]"
Apoptosis was assessed by Annexin V - PI staining. E. The survival effect induced by the complex S100A8 / 9 in the presence of pertussis toxin. Bordetella pertussis toxin at 100 and 500 ng / ml were added to neutrophils 45 min before adding S100A8 / 9.	"Annexin V	26	35	Gene/Protein"	"S100A8	97	103	Gene/Protein"	"pertussis toxin	127	142	Gene/Protein"	"Bordetella pertussis	144	164	Organism/Species"	"S100A8	241	247	Gene/Protein"	"[{""token"": ""Annexin V"", ""start_span"": 26, ""end_span"": 35, ""type"": ""Gene/Protein""}, {""token"": ""S100A8"", ""start_span"": 97, ""end_span"": 103, ""type"": ""Gene/Protein""}, {""token"": ""pertussis toxin"", ""start_span"": 127, ""end_span"": 142, ""type"": ""Gene/Protein""}, {""token"": ""Bordetella pertussis"", ""start_span"": 144, ""end_span"": 164, ""type"": ""Organism/Species""}, {""token"": ""S100A8"", ""start_span"": 241, ""end_span"": 247, ""type"": ""Gene/Protein""}]"
However, when we examined the effect of recombinant S100A8 / 9 on CD11b / CD18 - deficient neutrophils from a leukocyte adhesion deficiency ( LAD) patient, results were less clear.	"S100A8	52	58	Gene/Protein"	"CD11b	66	71	Gene/Protein"	"CD18	74	78	Gene/Protein"	"leukocyte adhesion deficiency	110	139	Disease/Disorder"	"LAD	142	145	Disease/Disorder"	"[{""token"": ""S100A8"", ""start_span"": 52, ""end_span"": 58, ""type"": ""Gene/Protein""}, {""token"": ""CD11b"", ""start_span"": 66, ""end_span"": 71, ""type"": ""Gene/Protein""}, {""token"": ""CD18"", ""start_span"": 74, ""end_span"": 78, ""type"": ""Gene/Protein""}, {""token"": ""leukocyte adhesion deficiency"", ""start_span"": 110, ""end_span"": 139, ""type"": ""Disease/Disorder""}, {""token"": ""LAD"", ""start_span"": 142, ""end_span"": 145, ""type"": ""Disease/Disorder""}]"
Inhibiting TLR4 abrogated the survival effect of S100A8 / 9 by 25 − 60% ( Fig. 5F ), suggesting that both CD11b / CD18 and TLR4 may be involved in the pathway enabling these proteins to affect neutrophil PCD.	"TLR4	11	15	Gene/Protein"	"S100A8	49	55	Gene/Protein"	"CD11b	106	111	Gene/Protein"	"CD18	114	118	Gene/Protein"	"TLR4	123	127	Gene/Protein"	"[{""token"": ""TLR4"", ""start_span"": 11, ""end_span"": 15, ""type"": ""Gene/Protein""}, {""token"": ""S100A8"", ""start_span"": 49, ""end_span"": 55, ""type"": ""Gene/Protein""}, {""token"": ""CD11b"", ""start_span"": 106, ""end_span"": 111, ""type"": ""Gene/Protein""}, {""token"": ""CD18"", ""start_span"": 114, ""end_span"": 118, ""type"": ""Gene/Protein""}, {""token"": ""TLR4"", ""start_span"": 123, ""end_span"": 127, ""type"": ""Gene/Protein""}]"
In particular, overexpression of JMJD2B exhibits oncogenic activity in various human cancers, including prostate, breast, colon and gastric cancers. 13, 14, 15, 16, 17 In addition, JMJD2B was found to be necessary for self - renewal of embryonic stem cells and induced pluripotent stem cell generation. 18	"JMJD2B	33	39	Gene/Protein"	"human	79	84	Organism/Species"	"cancers	85	92	Disease/Disorder"	"gastric cancers	132	147	Disease/Disorder"	"JMJD2B	181	187	Gene/Protein"	"[{""token"": ""JMJD2B"", ""start_span"": 33, ""end_span"": 39, ""type"": ""Gene/Protein""}, {""token"": ""human"", ""start_span"": 79, ""end_span"": 84, ""type"": ""Organism/Species""}, {""token"": ""cancers"", ""start_span"": 85, ""end_span"": 92, ""type"": ""Disease/Disorder""}, {""token"": ""gastric cancers"", ""start_span"": 132, ""end_span"": 147, ""type"": ""Disease/Disorder""}, {""token"": ""JMJD2B"", ""start_span"": 181, ""end_span"": 187, ""type"": ""Gene/Protein""}]"
JMJD2B gene expression was barely detectable in the brains of tau - Cre; Jmj2b flox / flox mice as determined by reverse transcription – PCR ( P = 0. 009; Figure 2a, left ).	"JMJD2B	0	6	Gene/Protein"	"tau	62	65	Gene/Protein"	"Cre	68	71	Gene/Protein"	"Jmj2b	73	78	Gene/Protein"	"mice	91	95	Organism/Species"	"[{""token"": ""JMJD2B"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Gene/Protein""}, {""token"": ""tau"", ""start_span"": 62, ""end_span"": 65, ""type"": ""Gene/Protein""}, {""token"": ""Cre"", ""start_span"": 68, ""end_span"": 71, ""type"": ""Gene/Protein""}, {""token"": ""Jmj2b"", ""start_span"": 73, ""end_span"": 78, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 91, ""end_span"": 95, ""type"": ""Organism/Species""}]"
A previous report demonstrated that G9a histone methyltransferase elevates the density of dendritic spines in nucleus accumbens neurons by reducing H3K9me2 levels on exposure to cocaine. 45 In addition, mutation of MeCP2, the causative gene of Rett syndrome and an epigenetic regulator that acts by binding to methylated DNA, also causes a decrease in the number of dendritic spines. 46 Thus, there is increasing evidence that epigenetic mechanisms affect the development and plasticity of dendritic spines.	"G9a	36	39	Gene/Protein"	"histone methyltransferase	40	65	Gene/Protein"	"cocaine	178	185	Chemical/Drug"	"MeCP2	215	220	Gene/Protein"	"Rett syndrome	244	257	Disease/Disorder"	"[{""token"": ""G9a"", ""start_span"": 36, ""end_span"": 39, ""type"": ""Gene/Protein""}, {""token"": ""histone methyltransferase"", ""start_span"": 40, ""end_span"": 65, ""type"": ""Gene/Protein""}, {""token"": ""cocaine"", ""start_span"": 178, ""end_span"": 185, ""type"": ""Chemical/Drug""}, {""token"": ""MeCP2"", ""start_span"": 215, ""end_span"": 220, ""type"": ""Gene/Protein""}, {""token"": ""Rett syndrome"", ""start_span"": 244, ""end_span"": 257, ""type"": ""Disease/Disorder""}]"
Variables that were shown in some studies to be associated with less favorable treatment response included • demographic variables such as male sex ( Blain, Galovski, & Robinson, 2010 ), younger age ( Rizvi et al ., 2009; Taylor, Fedoroff, & Koch, 1999 ), higher level of education ( Ehlers et al ., 2005) or ethnic minority ( Walling, Suvak, Howard, Taft, & Murphy, 2012 );• comorbidity with other anxiety disorders or high symptoms of anxiety and arousal ( Rosenkranz & Muller, 2011; Tarrier et al ., 2000; but see van Minnen et al ., 2002; Richardson et al ., 2011; for negative findings ); with depression or suicidal ideation ( Duffy et al ., 2007; Tarrier et al ., 2000; but see van Minnen et al ., 2002; Richardson et al ., 2011; for negative findings ); substance abuse ( van Minnen et al ., 2002; but see Richardson et al ., 2011; for negative findings ); personality disorders ( Clarke, Rizvi, & Resick, 2008; Feeny et al ., 2002 ); use of psychotropic medication ( van Minnen et al ., 2002 ), and permanent physical disability resulting from the trauma ( Gillespie et al ., 2002; but see Duffy et al ., 2007; for negative findings );• trauma characteristics such as multiple trauma ( van Minnen et al ., 2002 ), childhood trauma ( van Minnen et al ., 2002; but also see Jaycox, Foa, & Morral, 1998; for negative findings ), interpersonal trauma committed by a perpetrator ( van Minnen et al ., 2002 ), longer time since the trauma ( Duffy et al ., 2007; but see Ehlers et al ., 2005; Rizvi et al ., 2009; for negative findings ).	"anxiety disorders	399	416	Disease/Disorder"	"anxiety	437	444	Disease/Disorder"	"depression	599	609	Disease/Disorder"	"substance abuse	762	777	Disease/Disorder"	"personality disorders	865	886	Disease/Disorder"	"[{""token"": ""anxiety disorders"", ""start_span"": 399, ""end_span"": 416, ""type"": ""Disease/Disorder""}, {""token"": ""anxiety"", ""start_span"": 437, ""end_span"": 444, ""type"": ""Disease/Disorder""}, {""token"": ""depression"", ""start_span"": 599, ""end_span"": 609, ""type"": ""Disease/Disorder""}, {""token"": ""substance abuse"", ""start_span"": 762, ""end_span"": 777, ""type"": ""Disease/Disorder""}, {""token"": ""personality disorders"", ""start_span"": 865, ""end_span"": 886, ""type"": ""Disease/Disorder""}]"
Increased Cxcr4 ( ANOVA, * P < 0. 0001) and Cd38 ( ANOVA, * P < 0. 05) expression was found in MOG 91 - 108 in CFA - immunized rats compared to naive and CFA - alone - immunized rats.	"Cxcr4	10	15	Gene/Protein"	"Cd38	44	48	Gene/Protein"	"MOG	95	98	Gene/Protein"	"rats	127	131	Organism/Species"	"rats	178	182	Organism/Species"	"[{""token"": ""Cxcr4"", ""start_span"": 10, ""end_span"": 15, ""type"": ""Gene/Protein""}, {""token"": ""Cd38"", ""start_span"": 44, ""end_span"": 48, ""type"": ""Gene/Protein""}, {""token"": ""MOG"", ""start_span"": 95, ""end_span"": 98, ""type"": ""Gene/Protein""}, {""token"": ""rats"", ""start_span"": 127, ""end_span"": 131, ""type"": ""Organism/Species""}, {""token"": ""rats"", ""start_span"": 178, ""end_span"": 182, ""type"": ""Organism/Species""}]"
There was an upregulation of Cxcr4 and Cxcl12 mRNA in DA ( RT1av1) rats immunized with MOG 1 - 125 in CFA compared to DA ( RT1av1) rats immunized with CFA alone ( ANOVA, * P < 0. 01 ).	"Cxcr4	29	34	Gene/Protein"	"Cxcl12	39	45	Gene/Protein"	"rats	67	71	Organism/Species"	"MOG	87	90	Gene/Protein"	"rats	131	135	Organism/Species"	"[{""token"": ""Cxcr4"", ""start_span"": 29, ""end_span"": 34, ""type"": ""Gene/Protein""}, {""token"": ""Cxcl12"", ""start_span"": 39, ""end_span"": 45, ""type"": ""Gene/Protein""}, {""token"": ""rats"", ""start_span"": 67, ""end_span"": 71, ""type"": ""Organism/Species""}, {""token"": ""MOG"", ""start_span"": 87, ""end_span"": 90, ""type"": ""Gene/Protein""}, {""token"": ""rats"", ""start_span"": 131, ""end_span"": 135, ""type"": ""Organism/Species""}]"
B6. 129P2 - Cd38tm1Lnd / J mice ( white bars, n = 4) had reduced IgG and IgG1 antibodies compared to C57BL / 6J 000664 mice ( black bars, n = 4) ( ANOVA, * P < 0. 05) on day 12 p. i.	"mice	27	31	Organism/Species"	"IgG	65	68	Gene/Protein"	"IgG1	73	77	Gene/Protein"	"antibodies	78	88	Gene/Protein"	"mice	119	123	Organism/Species"	"[{""token"": ""mice"", ""start_span"": 27, ""end_span"": 31, ""type"": ""Organism/Species""}, {""token"": ""IgG"", ""start_span"": 65, ""end_span"": 68, ""type"": ""Gene/Protein""}, {""token"": ""IgG1"", ""start_span"": 73, ""end_span"": 77, ""type"": ""Gene/Protein""}, {""token"": ""antibodies"", ""start_span"": 78, ""end_span"": 88, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 119, ""end_span"": 123, ""type"": ""Organism/Species""}]"
FTY720 treatment ( n = 9) compared to controls ( n = 9) led to the downregulation of mRNA expression of its receptor, S1p1 ( ANOVA, P < 0. 0001 ), and of Akt2 ( ANOVA, P < 0. 0001 ), one of the genes involved in the intracellular signaling cascade connected to S1P1 and CXCR4, on day 14 p. i.	"FTY720	0	6	Chemical/Drug"	"S1p1	118	122	Gene/Protein"	"Akt2	154	158	Gene/Protein"	"S1P1	261	265	Gene/Protein"	"CXCR4	270	275	Gene/Protein"	"[{""token"": ""FTY720"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Chemical/Drug""}, {""token"": ""S1p1"", ""start_span"": 118, ""end_span"": 122, ""type"": ""Gene/Protein""}, {""token"": ""Akt2"", ""start_span"": 154, ""end_span"": 158, ""type"": ""Gene/Protein""}, {""token"": ""S1P1"", ""start_span"": 261, ""end_span"": 265, ""type"": ""Gene/Protein""}, {""token"": ""CXCR4"", ""start_span"": 270, ""end_span"": 275, ""type"": ""Gene/Protein""}]"
In contrast, the expression of Cxcr4 was not altered ( ANOVA, not significant) ( Fig. 5D ). Fig. 5. Influence of FTY720 in EAE. ( A) Female LEW. 1AV1 ( RT1av1) rats were immunized with MOG 1 - 125 in CFA.	"Cxcr4	31	36	Gene/Protein"	"FTY720	113	119	Chemical/Drug"	"EAE	123	126	Disease/Disorder"	"rats	160	164	Organism/Species"	"MOG	185	188	Gene/Protein"	"[{""token"": ""Cxcr4"", ""start_span"": 31, ""end_span"": 36, ""type"": ""Gene/Protein""}, {""token"": ""FTY720"", ""start_span"": 113, ""end_span"": 119, ""type"": ""Chemical/Drug""}, {""token"": ""EAE"", ""start_span"": 123, ""end_span"": 126, ""type"": ""Disease/Disorder""}, {""token"": ""rats"", ""start_span"": 160, ""end_span"": 164, ""type"": ""Organism/Species""}, {""token"": ""MOG"", ""start_span"": 185, ""end_span"": 188, ""type"": ""Gene/Protein""}]"
CXCR4 ( CD184) is a seven - transmembrane G - coupled receptor expressed by a number of tissues, including cells of the immune system ( Campbell et al ., 2003 ). Cxcr4 - knockout mice die in utero or perinatally and do not only have defects in the hematopoietic system ( impairment of myeloid and B - cell generation, reduced proliferation of triple - negative and double - positive lymphocytes ), but also in the circulatory system and in the CNS ( Zou et al ., 1998; Tachibana et al ., 1998 ).	"CXCR4	0	5	Gene/Protein"	"CD184	8	13	Gene/Protein"	"seven - transmembrane G - coupled receptor	20	62	Gene/Protein"	"Cxcr4	162	167	Gene/Protein"	"mice	179	183	Organism/Species"	"[{""token"": ""CXCR4"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Gene/Protein""}, {""token"": ""CD184"", ""start_span"": 8, ""end_span"": 13, ""type"": ""Gene/Protein""}, {""token"": ""seven - transmembrane G - coupled receptor"", ""start_span"": 20, ""end_span"": 62, ""type"": ""Gene/Protein""}, {""token"": ""Cxcr4"", ""start_span"": 162, ""end_span"": 167, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 179, ""end_span"": 183, ""type"": ""Organism/Species""}]"
CXCL12 activates numerous signaling pathways, such as receptor - associated trimeric G proteins, phospholipase Cγ, PI3K and small G proteins ( Pawig et al ., 2015 ).	"CXCL12	0	6	Gene/Protein"	"G proteins	85	95	Gene/Protein"	"phospholipase Cγ	97	113	Gene/Protein"	"PI3K	115	119	Gene/Protein"	"small G proteins	124	140	Gene/Protein"	"[{""token"": ""CXCL12"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Gene/Protein""}, {""token"": ""G proteins"", ""start_span"": 85, ""end_span"": 95, ""type"": ""Gene/Protein""}, {""token"": ""phospholipase C\u03b3"", ""start_span"": 97, ""end_span"": 113, ""type"": ""Gene/Protein""}, {""token"": ""PI3K"", ""start_span"": 115, ""end_span"": 119, ""type"": ""Gene/Protein""}, {""token"": ""small G proteins"", ""start_span"": 124, ""end_span"": 140, ""type"": ""Gene/Protein""}]"
Our data indicate that, also in MOG - induced EAE and possibly in MS, the interaction of CXCR4 and CXCL12 is of paramount importance for disease development.	"MOG	32	35	Gene/Protein"	"EAE	46	49	Disease/Disorder"	"MS	66	68	Disease/Disorder"	"CXCR4	89	94	Gene/Protein"	"CXCL12	99	105	Gene/Protein"	"[{""token"": ""MOG"", ""start_span"": 32, ""end_span"": 35, ""type"": ""Gene/Protein""}, {""token"": ""EAE"", ""start_span"": 46, ""end_span"": 49, ""type"": ""Disease/Disorder""}, {""token"": ""MS"", ""start_span"": 66, ""end_span"": 68, ""type"": ""Disease/Disorder""}, {""token"": ""CXCR4"", ""start_span"": 89, ""end_span"": 94, ""type"": ""Gene/Protein""}, {""token"": ""CXCL12"", ""start_span"": 99, ""end_span"": 105, ""type"": ""Gene/Protein""}]"
CD38 ligation in T cells results in phosphorylation of the Raf - 1 / MAP kinase and CD3 - ζ / ZAP - 70 signaling pathway ( Zubiaur et al ., 1997 ).	"CD38	0	4	Gene/Protein"	"Raf - 1	59	66	Gene/Protein"	"MAP kinase	69	79	Gene/Protein"	"CD3 - ζ	84	91	Gene/Protein"	"ZAP - 70	94	102	Gene/Protein"	"[{""token"": ""CD38"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Gene/Protein""}, {""token"": ""Raf - 1"", ""start_span"": 59, ""end_span"": 66, ""type"": ""Gene/Protein""}, {""token"": ""MAP kinase"", ""start_span"": 69, ""end_span"": 79, ""type"": ""Gene/Protein""}, {""token"": ""CD3 - \u03b6"", ""start_span"": 84, ""end_span"": 91, ""type"": ""Gene/Protein""}, {""token"": ""ZAP - 70"", ""start_span"": 94, ""end_span"": 102, ""type"": ""Gene/Protein""}]"
These pathways might be valuable targets of therapeutic approaches as we have shown attenuation of EAE after treatment with FTY720 or reduced EAE severity in CD38 - deficient mice.	"EAE	99	102	Disease/Disorder"	"FTY720	124	130	Chemical/Drug"	"EAE	142	145	Disease/Disorder"	"CD38	158	162	Gene/Protein"	"mice	175	179	Organism/Species"	"[{""token"": ""EAE"", ""start_span"": 99, ""end_span"": 102, ""type"": ""Disease/Disorder""}, {""token"": ""FTY720"", ""start_span"": 124, ""end_span"": 130, ""type"": ""Chemical/Drug""}, {""token"": ""EAE"", ""start_span"": 142, ""end_span"": 145, ""type"": ""Disease/Disorder""}, {""token"": ""CD38"", ""start_span"": 158, ""end_span"": 162, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 175, ""end_span"": 179, ""type"": ""Organism/Species""}]"
Smoking is the leading cause of death in high income countries such as Canada [ 1] and is a major risk factor for cardiovascular disease and cancer. [ 2 ], [ 3] In Canada, approximately 20% of all deaths are attributable smoking according to 2005 estimates. [ 4] The majority of these deaths are due to the following causes: lung cancer, chronic obstructive pulmonary disease and ischemic heart disease. [ 5] About 50% of smokers die of smoking - related diseases and smokers who die between the ages of 35 and 69 in Canada lose on average more than 20 years of life .[ 6 ]–[ 8] Importantly, however, smoking cessation can reverse the risk for mortality; quitting by age 50 can halve the lifetime risk, while quitting by age 30 can reduce the risk close to that of never smokers. [ 9 ], [ 10 ].	"cardiovascular disease	114	136	Disease/Disorder"	"cancer	141	147	Disease/Disorder"	"lung cancer	325	336	Disease/Disorder"	"chronic obstructive pulmonary disease	338	375	Disease/Disorder"	"ischemic heart disease	380	402	Disease/Disorder"	"[{""token"": ""cardiovascular disease"", ""start_span"": 114, ""end_span"": 136, ""type"": ""Disease/Disorder""}, {""token"": ""cancer"", ""start_span"": 141, ""end_span"": 147, ""type"": ""Disease/Disorder""}, {""token"": ""lung cancer"", ""start_span"": 325, ""end_span"": 336, ""type"": ""Disease/Disorder""}, {""token"": ""chronic obstructive pulmonary disease"", ""start_span"": 338, ""end_span"": 375, ""type"": ""Disease/Disorder""}, {""token"": ""ischemic heart disease"", ""start_span"": 380, ""end_span"": 402, ""type"": ""Disease/Disorder""}]"
Here, we investigated the roles of two RNA - binding proteins of the Puf - family, Plasmodium Puf1 and Puf2, during sporozoite stage conversion.	"RNA - binding proteins	39	61	Gene/Protein"	"Puf	69	72	Gene/Protein"	"Plasmodium	83	93	Organism/Species"	"Puf1	94	98	Gene/Protein"	"Puf2	103	107	Gene/Protein"	"[{""token"": ""RNA - binding proteins"", ""start_span"": 39, ""end_span"": 61, ""type"": ""Gene/Protein""}, {""token"": ""Puf"", ""start_span"": 69, ""end_span"": 72, ""type"": ""Gene/Protein""}, {""token"": ""Plasmodium"", ""start_span"": 83, ""end_span"": 93, ""type"": ""Organism/Species""}, {""token"": ""Puf1"", ""start_span"": 94, ""end_span"": 98, ""type"": ""Gene/Protein""}, {""token"": ""Puf2"", ""start_span"": 103, ""end_span"": 107, ""type"": ""Gene/Protein""}]"
Recently however, a family of genes related to the plant Apetala - 2 ( AP2) transcription factors has been identified in Plasmodium and related apicomplexan parasites [ 6 ], [ 7 ], and proposed to play a central role during life cycle progression.	"plant	51	56	Organism/Species"	"Apetala - 2	57	68	Gene/Protein"	"AP2	71	74	Gene/Protein"	"transcription factors	76	97	Gene/Protein"	"Plasmodium	121	131	Organism/Species"	"[{""token"": ""plant"", ""start_span"": 51, ""end_span"": 56, ""type"": ""Organism/Species""}, {""token"": ""Apetala - 2"", ""start_span"": 57, ""end_span"": 68, ""type"": ""Gene/Protein""}, {""token"": ""AP2"", ""start_span"": 71, ""end_span"": 74, ""type"": ""Gene/Protein""}, {""token"": ""transcription factors"", ""start_span"": 76, ""end_span"": 97, ""type"": ""Gene/Protein""}, {""token"": ""Plasmodium"", ""start_span"": 121, ""end_span"": 131, ""type"": ""Organism/Species""}]"
Puf proteins typically bind to the 3 ′ UTR of target mRNAs and repress their translation or induce their degradation ( reviewed in [ 18] and [ 19 ]). Plasmodium parasites possess two genes encoding proteins with Puf domains, Puf1 and Puf2 [ 20 ].	"Puf	0	3	Gene/Protein"	"Plasmodium	150	160	Organism/Species"	"Puf	212	215	Gene/Protein"	"Puf1	225	229	Gene/Protein"	"Puf2	234	238	Gene/Protein"	"[{""token"": ""Puf"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Gene/Protein""}, {""token"": ""Plasmodium"", ""start_span"": 150, ""end_span"": 160, ""type"": ""Organism/Species""}, {""token"": ""Puf"", ""start_span"": 212, ""end_span"": 215, ""type"": ""Gene/Protein""}, {""token"": ""Puf1"", ""start_span"": 225, ""end_span"": 229, ""type"": ""Gene/Protein""}, {""token"": ""Puf2"", ""start_span"": 234, ""end_span"": 238, ""type"": ""Gene/Protein""}]"
Interestingly, microarray data indicate that Puf2 is most highly expressed in P. falciparum sporozoites [ 23 ], and in P. berghei, expression of both Puf1 ( PBANKA_123350) and Puf2 ( PBANKA_071920) has been reported in sporozoites, where Puf1 was initially identified as UIS9 [ 4 ], [ 24 ].	"Puf2	45	49	Gene/Protein"	"Puf1	150	154	Gene/Protein"	"Puf2	176	180	Gene/Protein"	"Puf1	238	242	Gene/Protein"	"UIS9	271	275	Gene/Protein"	"[{""token"": ""Puf2"", ""start_span"": 45, ""end_span"": 49, ""type"": ""Gene/Protein""}, {""token"": ""Puf1"", ""start_span"": 150, ""end_span"": 154, ""type"": ""Gene/Protein""}, {""token"": ""Puf2"", ""start_span"": 176, ""end_span"": 180, ""type"": ""Gene/Protein""}, {""token"": ""Puf1"", ""start_span"": 238, ""end_span"": 242, ""type"": ""Gene/Protein""}, {""token"": ""UIS9"", ""start_span"": 271, ""end_span"": 275, ""type"": ""Gene/Protein""}]"
Moreover, puf2 (-) sporozoites isolated late after mosquito infection ( at day 25) were not capable of inducing a blood stage infection in mice.	"puf2	10	14	Gene/Protein"	"mosquito	51	59	Organism/Species"	"infection	60	69	Disease/Disorder"	"infection	126	135	Disease/Disorder"	"mice	139	143	Organism/Species"	"[{""token"": ""puf2"", ""start_span"": 10, ""end_span"": 14, ""type"": ""Gene/Protein""}, {""token"": ""mosquito"", ""start_span"": 51, ""end_span"": 59, ""type"": ""Organism/Species""}, {""token"": ""infection"", ""start_span"": 60, ""end_span"": 69, ""type"": ""Disease/Disorder""}, {""token"": ""infection"", ""start_span"": 126, ""end_span"": 135, ""type"": ""Disease/Disorder""}, {""token"": ""mice"", ""start_span"": 139, ""end_span"": 143, ""type"": ""Organism/Species""}]"
Altogether, these data indicate that Puf2 regulates a subset of genes in P. berghei sporozoites, including Puf1 and the kinase UIS1 / IK2.	"Puf2	37	41	Gene/Protein"	"Puf1	107	111	Gene/Protein"	"kinase	120	126	Gene/Protein"	"UIS1	127	131	Gene/Protein"	"IK2	134	137	Gene/Protein"	"[{""token"": ""Puf2"", ""start_span"": 37, ""end_span"": 41, ""type"": ""Gene/Protein""}, {""token"": ""Puf1"", ""start_span"": 107, ""end_span"": 111, ""type"": ""Gene/Protein""}, {""token"": ""kinase"", ""start_span"": 120, ""end_span"": 126, ""type"": ""Gene/Protein""}, {""token"": ""UIS1"", ""start_span"": 127, ""end_span"": 131, ""type"": ""Gene/Protein""}, {""token"": ""IK2"", ""start_span"": 134, ""end_span"": 137, ""type"": ""Gene/Protein""}]"
Biochemical data, such as in vitro binding assays using recombinant Puf domains expressed in bacteria and heterologous in vivo studies using the yeast three - hybrid system, have demonstrated intrinsic binding activity of the P. falciparum PfPuf1 and PfPuf2 to the NRE sequence [ 20 ], [ 21 ].	"Puf	68	71	Gene/Protein"	"bacteria	93	101	Organism/Species"	"yeast	145	150	Organism/Species"	"PfPuf1	240	246	Gene/Protein"	"PfPuf2	251	257	Gene/Protein"	"[{""token"": ""Puf"", ""start_span"": 68, ""end_span"": 71, ""type"": ""Gene/Protein""}, {""token"": ""bacteria"", ""start_span"": 93, ""end_span"": 101, ""type"": ""Organism/Species""}, {""token"": ""yeast"", ""start_span"": 145, ""end_span"": 150, ""type"": ""Organism/Species""}, {""token"": ""PfPuf1"", ""start_span"": 240, ""end_span"": 246, ""type"": ""Gene/Protein""}, {""token"": ""PfPuf2"", ""start_span"": 251, ""end_span"": 257, ""type"": ""Gene/Protein""}]"
Indeed, using RT - qPCR, we found a 4 - fold reduction of Spect and Spect2 mRNA levels in puf2 (-) sporozoites, whereas actin and AMA1 were not affected ( unpublished data ).	"Spect	58	63	Gene/Protein"	"Spect2	68	74	Gene/Protein"	"puf2	90	94	Gene/Protein"	"actin	120	125	Gene/Protein"	"AMA1	130	134	Gene/Protein"	"[{""token"": ""Spect"", ""start_span"": 58, ""end_span"": 63, ""type"": ""Gene/Protein""}, {""token"": ""Spect2"", ""start_span"": 68, ""end_span"": 74, ""type"": ""Gene/Protein""}, {""token"": ""puf2"", ""start_span"": 90, ""end_span"": 94, ""type"": ""Gene/Protein""}, {""token"": ""actin"", ""start_span"": 120, ""end_span"": 125, ""type"": ""Gene/Protein""}, {""token"": ""AMA1"", ""start_span"": 130, ""end_span"": 134, ""type"": ""Gene/Protein""}]"
In 1991, an eight months treatment regimen composed of 2 months intensive with Isoniazid ( H ), Rifampicin ( R ), Pyrazinamide ( Z) and Ethambutol ( E) ( 2RHZE / S) and 6 months continuation ( 6HE) phases were recommended for all new cases of TB across the world [ 6 ].	"Isoniazid	79	88	Chemical/Drug"	"Rifampicin	96	106	Chemical/Drug"	"Pyrazinamide	114	126	Chemical/Drug"	"Ethambutol	136	146	Chemical/Drug"	"TB	243	245	Disease/Disorder"	"[{""token"": ""Isoniazid"", ""start_span"": 79, ""end_span"": 88, ""type"": ""Chemical/Drug""}, {""token"": ""Rifampicin"", ""start_span"": 96, ""end_span"": 106, ""type"": ""Chemical/Drug""}, {""token"": ""Pyrazinamide"", ""start_span"": 114, ""end_span"": 126, ""type"": ""Chemical/Drug""}, {""token"": ""Ethambutol"", ""start_span"": 136, ""end_span"": 146, ""type"": ""Chemical/Drug""}, {""token"": ""TB"", ""start_span"": 243, ""end_span"": 245, ""type"": ""Disease/Disorder""}]"
The following standard case and outcome definitions were adopted and used for the study [ 11, 19 ]. New case of TB a patient who never had treatment for TB, or had been on anti - TB treatment for less than four weeks in the past Other cases are those patients who do not fulfill the criteria for new, relapse, and return after default or treatment after failure. Cured: a patient whose sputum smear or culture was positive at the beginning of the treatment but who was smear or culture - negative in the last month of treatment and on at least one previous occasion. Treatment completed: completed treatment but does not have a negative sputum smear or culture result in the last month of treatment and on at least one previous occasion. Treatment failure: a patient whose sputum smear or culture is positive at 5 months or later during treatment or patients found to harbor Multidrug Resistant ( MDR) TB strain at any point of time during the treatment, whether they are smear - negative or - positive. Died: a patient who dies for any reason during the course of TB treatment. Defaulter / loss to follow - up: a patient who has been on treatment for at least 4 weeks and interrupted treatment for eight or more consecutive weeks. Successful treatment: a treatment that ends up in cure or treatment completion Unsuccessful treatment: a treatment that end up in treatment default or loss to follow up, treatment failure or death.	"TB	112	114	Disease/Disorder"	"TB	153	155	Disease/Disorder"	"TB	179	181	Disease/Disorder"	"TB	902	904	Disease/Disorder"	"TB	1065	1067	Disease/Disorder"	"[{""token"": ""TB"", ""start_span"": 112, ""end_span"": 114, ""type"": ""Disease/Disorder""}, {""token"": ""TB"", ""start_span"": 153, ""end_span"": 155, ""type"": ""Disease/Disorder""}, {""token"": ""TB"", ""start_span"": 179, ""end_span"": 181, ""type"": ""Disease/Disorder""}, {""token"": ""TB"", ""start_span"": 902, ""end_span"": 904, ""type"": ""Disease/Disorder""}, {""token"": ""TB"", ""start_span"": 1065, ""end_span"": 1067, ""type"": ""Disease/Disorder""}]"
Among those tested HIV positives, 44 ( 57. 1 %) received either Cotrimoxazole Prophylactic Therapy ( CPT) or Antiretroviral Therapy ( ART) with no statistically significant difference among the regimens 24 ( 64. 9 %) from 6EH and 20 ( 50 %), p = 0. 2. Table 1Demographic and clinical characteristics of the tuberculosis patients registered between, 2008 – 2014, Southwest EthiopiaVariableContinuation phase treatment regimenTotal P value6EH ( n = 395) n (%) 4RH ( n = 395) n (%) Age ( years) Mean ± SDa 31. 1 ± 12. 930. 5 ± 11. 930. 8 ± 12. 40. 5GenderMale221 ( 55. 9) 226 ( 57. 2) 447 ( 56. 6) 0. 7Female174 ( 44. 1) 169 ( 42. 8) 343 ( 43. 4) ResidenceUrban175 ( 44. 3) 175 ( 44. 3) 350 ( 44. 3) 1Rural220 ( 55. 7) 220 ( 55. 7) 440 ( 55. 7) ZoneKaffa106 ( 26. 8) 104 ( 26. 3) 210 ( 26. 6) 0. 9Bench Maji206 ( 52. 2) 203 ( 26. 3) 409 ( 51. 8) Sheka83 ( 21. 0) 88 ( 22. 3) 171 ( 21. 6) Treatment centerHospital55 ( 13. 9) 49 ( 12. 4) 104 ( 13. 2) 0. 5Health center340 ( 86. 1) 346 ( 87. 6) 686 ( 86. 8) Baseline weightMean ± SDa 47. 6 ± 8. 648. 4 ± 8. 548 ± 8. 50. 2Baseline sputum smearPositive186 ( 47. 1) 173 ( 43. 8) 359 ( 45. 4) 0. 6Negative151 ( 38. 2) 165 ( 41. 8) 316 ( 40) Unknown58 ( 14. 7) 57 ( 14. 4) 115 ( 14. 6) Type of TBPulmonary303 ( 76. 7305 ( 77. 2) 608 ( 77. 0) 0. 9Positive186 ( 47. 1) 173 ( 43. 8) 359 ( 45. 4) Negative117 ( 30. 4) 132 ( 33. 4) 252 ( 31. 9) Extra pulmonary92 ( 23. 3) 90 ( 22. 8) 179 ( 23) HIV statusPositive37 ( 9. 4) 40 ( 10. 1) 77 ( 9. 7 )< 0. 001Negative246 ( 62. 3) 289 ( 73. 2) 535 ( 67. 7) Unknown112 ( 28. 4) 66 ( 16. 7) 178 ( 22. 5) Received CPTb ( n = 77) Yes18 ( 48. 6) 17 ( 42. 5) 35 ( 45. 5) 0. 6Received CPT or ARTc ( n = 77) Yes6 ( 16. 2) 6 ( 15. 0) 12 ( 15. 6) 0. 8Received ART ( n = 77) Yes12 ( 32. 4) 9 ( 22. 5) 21 ( 27. 3) 0. 3Baseline sputum smearPositive186 ( 47. 1) 173 ( 43. 8) 359 ( 45. 4) 0. 6Negative151 ( 38. 2) 165 ( 41. 8) 316 ( 40) Unknown58 ( 14. 7) 57 ( 14. 4) 115 ( 14. 6) aStandard deviation, b CPT Cotrimoxazole prophylactic therapy, c ART antiretroviral therapy	"HIV	19	22	Organism/Species"	"Cotrimoxazole	64	77	Chemical/Drug"	"tuberculosis	307	319	Disease/Disorder"	"HIV	1428	1431	Organism/Species"	"Cotrimoxazole	1971	1984	Chemical/Drug"	"[{""token"": ""HIV"", ""start_span"": 19, ""end_span"": 22, ""type"": ""Organism/Species""}, {""token"": ""Cotrimoxazole"", ""start_span"": 64, ""end_span"": 77, ""type"": ""Chemical/Drug""}, {""token"": ""tuberculosis"", ""start_span"": 307, ""end_span"": 319, ""type"": ""Disease/Disorder""}, {""token"": ""HIV"", ""start_span"": 1428, ""end_span"": 1431, ""type"": ""Organism/Species""}, {""token"": ""Cotrimoxazole"", ""start_span"": 1971, ""end_span"": 1984, ""type"": ""Chemical/Drug""}]"
Besides, statistically significant differences in successful outcomes, 64 ( 83. 1 %), 482 ( 90. 1 %) and 149 ( 83. 7 %, p = 0. 005 were also found among HIV positive, HIV negatives and unknown HIV status TB cases, respectively. Table 2Patient follow - up measures and treatment outcomes of TB patients registered during 2008 – 2014, Southwest EthiopiaVariablesContinuation phase treatment regimen6EH ( n = 395) n (%) 4RH ( n = 395) n (%) Total N (%) P valueWeight at 2nd monthMean ± SD49. 9 ± 8. 950. 8 ± 8. 250. 4 ± 8. 60. 2Weight at 5th monthMean ± SD51. 4 ± 8. 651. 3 ± 7. 351. 3 ± 7. 90. 9Weight at 6 / 7th monthMean ± SD51. 1 ± 8. 952. 5 ± 6. 551. 7 ± 7. 90. 3Change in weight at 2nd monthNot increased49 ( 12. 4) 61 ( 15. 4) 110 ( 13. 9) 0. 4Increased191 ( 48. 4) 177 ( 44. 8) 368 ( 46. 6) Unknown155 ( 39. 2) 157 ( 39. 7) 312 ( 39. 5) Sputum smear end of 2nd month ( n = 359) Positive4 ( 2. 2) 2 ( 1. 2) 6 ( 1. 7) 0. 09Negative130 ( 69. 9) 138 ( 79. 8) 268 ( 74. 7) Unknown52 ( 28) 33 ( 19. 1) 85 ( 23. 7) Sputum smear end of 5th month ( n = 359) Positive1 ( 0. 5) 0 ( 0) 1 ( 0. 3) 0. 03Negative83 ( 44. 6) 100 ( 57. 8) 183 ( 51) Unknown102 ( 54. 8) 73 ( 42. 2) 175 ( 48. 7) Sputum smear end of 6 / 7th month ( n = 359) Positive0000. 8Negative94 ( 50. 5) 85 ( 49. 1) 179 ( 49. 9) Unknown92 ( 49. 5) 88 ( 50. 9) 180 ( 50. 1) Sputum smear done during treatment ( n = 359) No44 ( 23. 7) 33 ( 19. 1) 77 ( 21. 4) 0. 3At least once142 ( 76. 3) 140 ( 80. 9) 282 ( 78. 6) Continuation phase visitMean ± SD5. 8 ± 1. 15. 4 ± 3. 10. 09Treatment outcomeSuccessful337 ( 85. 3) 358 ( 90. 6) 695 ( 88) 0. 02Cured77 ( 19. 5) 85 ( 21. 5) 162 ( 20. 5) Completed260 ( 65. 8) 273 ( 69. 1) 533 ( 67) Unsuccessful58 ( 14. 7) 37 ( 9. 4) 95 ( 12) Died28 ( 7. 1) 18 ( 4. 6) 46 ( 5. 8) Defaulted29 ( 7. 3) 19 ( 4. 8) 48 ( 6. 1) Failure1 ( 0. 3) 01 ( 0. 1)	"HIV	153	156	Organism/Species"	"HIV	167	170	Organism/Species"	"HIV	193	196	Organism/Species"	"TB	204	206	Disease/Disorder"	"TB	290	292	Disease/Disorder"	"[{""token"": ""HIV"", ""start_span"": 153, ""end_span"": 156, ""type"": ""Organism/Species""}, {""token"": ""HIV"", ""start_span"": 167, ""end_span"": 170, ""type"": ""Organism/Species""}, {""token"": ""HIV"", ""start_span"": 193, ""end_span"": 196, ""type"": ""Organism/Species""}, {""token"": ""TB"", ""start_span"": 204, ""end_span"": 206, ""type"": ""Disease/Disorder""}, {""token"": ""TB"", ""start_span"": 290, ""end_span"": 292, ""type"": ""Disease/Disorder""}]"
Similarly, type II and V secretion systems generally transport proteins to the surface of the host cell and are involved in the extracellular release of various toxins and hydrolytic enzymes such as exotoxin A, Las A, Las B, protease and elastase [ 21 ], [ 22 ].	"exotoxin A	199	209	Gene/Protein"	"Las A	211	216	Gene/Protein"	"Las B	218	223	Gene/Protein"	"protease	225	233	Gene/Protein"	"elastase	238	246	Gene/Protein"	"[{""token"": ""exotoxin A"", ""start_span"": 199, ""end_span"": 209, ""type"": ""Gene/Protein""}, {""token"": ""Las A"", ""start_span"": 211, ""end_span"": 216, ""type"": ""Gene/Protein""}, {""token"": ""Las B"", ""start_span"": 218, ""end_span"": 223, ""type"": ""Gene/Protein""}, {""token"": ""protease"", ""start_span"": 225, ""end_span"": 233, ""type"": ""Gene/Protein""}, {""token"": ""elastase"", ""start_span"": 238, ""end_span"": 246, ""type"": ""Gene/Protein""}]"
The mitogen - activated protein kinase ( MAPK) and the NF - κB signalling pathways are implicated in the production of TNF - α and IL - 6 in macrophages [ 48 ].	"mitogen - activated protein kinase	4	38	Gene/Protein"	"MAPK	41	45	Gene/Protein"	"NF - κB	55	62	Gene/Protein"	"TNF - α	119	126	Gene/Protein"	"IL - 6	131	137	Gene/Protein"	"[{""token"": ""mitogen - activated protein kinase"", ""start_span"": 4, ""end_span"": 38, ""type"": ""Gene/Protein""}, {""token"": ""MAPK"", ""start_span"": 41, ""end_span"": 45, ""type"": ""Gene/Protein""}, {""token"": ""NF - \u03baB"", ""start_span"": 55, ""end_span"": 62, ""type"": ""Gene/Protein""}, {""token"": ""TNF - \u03b1"", ""start_span"": 119, ""end_span"": 126, ""type"": ""Gene/Protein""}, {""token"": ""IL - 6"", ""start_span"": 131, ""end_span"": 137, ""type"": ""Gene/Protein""}]"
One of the ways to activate NF - κB by extracellular stimuli involves the rapid degradation of IκB - α as a consequence of IκB - α phosphorylation at Ser32 by IκB kinase, which corresponds to IKK in the so - called canonical pathway.	"NF - κB	28	35	Gene/Protein"	"IκB - α	95	102	Gene/Protein"	"IκB - α	123	130	Gene/Protein"	"IκB kinase	159	169	Gene/Protein"	"IKK	192	195	Gene/Protein"	"[{""token"": ""NF - \u03baB"", ""start_span"": 28, ""end_span"": 35, ""type"": ""Gene/Protein""}, {""token"": ""I\u03baB - \u03b1"", ""start_span"": 95, ""end_span"": 102, ""type"": ""Gene/Protein""}, {""token"": ""I\u03baB - \u03b1"", ""start_span"": 123, ""end_span"": 130, ""type"": ""Gene/Protein""}, {""token"": ""I\u03baB kinase"", ""start_span"": 159, ""end_span"": 169, ""type"": ""Gene/Protein""}, {""token"": ""IKK"", ""start_span"": 192, ""end_span"": 195, ""type"": ""Gene/Protein""}]"
We studied the effect of inulin and FOS on the activation ( phosphorylation) of IκB - α and MAPK, ERK, JNK and p38 by Western blot analysis in macrophages infected with P. aeruginosa.	"IκB - α	80	87	Gene/Protein"	"MAPK	92	96	Gene/Protein"	"ERK	98	101	Gene/Protein"	"JNK	103	106	Gene/Protein"	"p38	111	114	Gene/Protein"	"[{""token"": ""I\u03baB - \u03b1"", ""start_span"": 80, ""end_span"": 87, ""type"": ""Gene/Protein""}, {""token"": ""MAPK"", ""start_span"": 92, ""end_span"": 96, ""type"": ""Gene/Protein""}, {""token"": ""ERK"", ""start_span"": 98, ""end_span"": 101, ""type"": ""Gene/Protein""}, {""token"": ""JNK"", ""start_span"": 103, ""end_span"": 106, ""type"": ""Gene/Protein""}, {""token"": ""p38"", ""start_span"": 111, ""end_span"": 114, ""type"": ""Gene/Protein""}]"
We used mutants deficient in PtxS and PtxR, two transcriptional regulators that control the expression of the toxA gene, encoding the exotoxin A virulence factor [ 50 ].	"PtxS	29	33	Gene/Protein"	"PtxR	38	42	Gene/Protein"	"transcriptional regulators	48	74	Gene/Protein"	"toxA	110	114	Gene/Protein"	"exotoxin A	134	144	Gene/Protein"	"[{""token"": ""PtxS"", ""start_span"": 29, ""end_span"": 33, ""type"": ""Gene/Protein""}, {""token"": ""PtxR"", ""start_span"": 38, ""end_span"": 42, ""type"": ""Gene/Protein""}, {""token"": ""transcriptional regulators"", ""start_span"": 48, ""end_span"": 74, ""type"": ""Gene/Protein""}, {""token"": ""toxA"", ""start_span"": 110, ""end_span"": 114, ""type"": ""Gene/Protein""}, {""token"": ""exotoxin A"", ""start_span"": 134, ""end_span"": 144, ""type"": ""Gene/Protein""}]"
C) The macrophage mortality induced by WT P. aeruginosa and its ptxS and ptxR mutants was measured by the total release of cytoplasmic lactate dehydrogenase ( LDH ). * P < 0. 05 vs macrophage without bacteria and & P < 0. 05 vs macrophage with WT ( ANOVA followed by least significance tests ).	"ptxS	64	68	Gene/Protein"	"ptxR	73	77	Gene/Protein"	"lactate dehydrogenase	135	156	Gene/Protein"	"LDH	159	162	Gene/Protein"	"bacteria	200	208	Organism/Species"	"[{""token"": ""ptxS"", ""start_span"": 64, ""end_span"": 68, ""type"": ""Gene/Protein""}, {""token"": ""ptxR"", ""start_span"": 73, ""end_span"": 77, ""type"": ""Gene/Protein""}, {""token"": ""lactate dehydrogenase"", ""start_span"": 135, ""end_span"": 156, ""type"": ""Gene/Protein""}, {""token"": ""LDH"", ""start_span"": 159, ""end_span"": 162, ""type"": ""Gene/Protein""}, {""token"": ""bacteria"", ""start_span"": 200, ""end_span"": 208, ""type"": ""Organism/Species""}]"
Remarkably, treatment with FOS attenuated significantly all the steps of this response, i. e. secretion of IL - 6, IL - 10 and TNF - α, IκB - α phosphorylation and p65 nuclear translocation ( Figs.	"IL - 6	107	113	Gene/Protein"	"IL - 10	115	122	Gene/Protein"	"TNF - α	127	134	Gene/Protein"	"IκB - α	136	143	Gene/Protein"	"p65	164	167	Gene/Protein"	"[{""token"": ""IL - 6"", ""start_span"": 107, ""end_span"": 113, ""type"": ""Gene/Protein""}, {""token"": ""IL - 10"", ""start_span"": 115, ""end_span"": 122, ""type"": ""Gene/Protein""}, {""token"": ""TNF - \u03b1"", ""start_span"": 127, ""end_span"": 134, ""type"": ""Gene/Protein""}, {""token"": ""I\u03baB - \u03b1"", ""start_span"": 136, ""end_span"": 143, ""type"": ""Gene/Protein""}, {""token"": ""p65"", ""start_span"": 164, ""end_span"": 167, ""type"": ""Gene/Protein""}]"
These changes correlated with toxA expression, since the highest cytokine secretion / toxA transcription was observed in the ptxS mutant, followed by the WT strain and the ptxR mutant [ 51 ].	"toxA	30	34	Gene/Protein"	"cytokine	65	73	Gene/Protein"	"toxA	86	90	Gene/Protein"	"ptxS	125	129	Gene/Protein"	"ptxR	172	176	Gene/Protein"	"[{""token"": ""toxA"", ""start_span"": 30, ""end_span"": 34, ""type"": ""Gene/Protein""}, {""token"": ""cytokine"", ""start_span"": 65, ""end_span"": 73, ""type"": ""Gene/Protein""}, {""token"": ""toxA"", ""start_span"": 86, ""end_span"": 90, ""type"": ""Gene/Protein""}, {""token"": ""ptxS"", ""start_span"": 125, ""end_span"": 129, ""type"": ""Gene/Protein""}, {""token"": ""ptxR"", ""start_span"": 172, ""end_span"": 176, ""type"": ""Gene/Protein""}]"
Several classes of antibiotics including cephalosporins, penicillins, carbapenems, quinolones and aminoglycosides are currently been used to combat P. aeruginosa clinically, but specific sensitivity testing is mandatory [ 66 ].	"cephalosporins	41	55	Chemical/Drug"	"penicillins	57	68	Chemical/Drug"	"carbapenems	70	81	Chemical/Drug"	"quinolones	83	93	Chemical/Drug"	"aminoglycosides	98	113	Chemical/Drug"	"[{""token"": ""cephalosporins"", ""start_span"": 41, ""end_span"": 55, ""type"": ""Chemical/Drug""}, {""token"": ""penicillins"", ""start_span"": 57, ""end_span"": 68, ""type"": ""Chemical/Drug""}, {""token"": ""carbapenems"", ""start_span"": 70, ""end_span"": 81, ""type"": ""Chemical/Drug""}, {""token"": ""quinolones"", ""start_span"": 83, ""end_span"": 93, ""type"": ""Chemical/Drug""}, {""token"": ""aminoglycosides"", ""start_span"": 98, ""end_span"": 113, ""type"": ""Chemical/Drug""}]"
To remove lymphocytes, CD161. 1 - biotin ( 1 ∶ 200 ), CD45RA - PE ( 1 ∶ 200) and CD3 ( 1 ∶ 150) ( Biosciences ), were added and incubated at 4 ° C for 30 min.	"CD161	23	28	Gene/Protein"	"biotin	34	40	Chemical/Drug"	"CD45RA	54	60	Gene/Protein"	"PE	63	65	Gene/Protein"	"CD3	81	84	Gene/Protein"	"[{""token"": ""CD161"", ""start_span"": 23, ""end_span"": 28, ""type"": ""Gene/Protein""}, {""token"": ""biotin"", ""start_span"": 34, ""end_span"": 40, ""type"": ""Chemical/Drug""}, {""token"": ""CD45RA"", ""start_span"": 54, ""end_span"": 60, ""type"": ""Gene/Protein""}, {""token"": ""PE"", ""start_span"": 63, ""end_span"": 65, ""type"": ""Gene/Protein""}, {""token"": ""CD3"", ""start_span"": 81, ""end_span"": 84, ""type"": ""Gene/Protein""}]"
Phosphoproteomic analysis of anaplastic lymphoma kinase ( ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells	"anaplastic lymphoma kinase	29	55	Gene/Protein"	"ALK	58	61	Gene/Protein"	"signal transducer and activator of transcription 3	104	154	Gene/Protein"	"ALK	191	194	Gene/Protein"	"neuroblastoma	198	211	Disease/Disorder"	"[{""token"": ""anaplastic lymphoma kinase"", ""start_span"": 29, ""end_span"": 55, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 58, ""end_span"": 61, ""type"": ""Gene/Protein""}, {""token"": ""signal transducer and activator of transcription 3"", ""start_span"": 104, ""end_span"": 154, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 191, ""end_span"": 194, ""type"": ""Gene/Protein""}, {""token"": ""neuroblastoma"", ""start_span"": 198, ""end_span"": 211, ""type"": ""Disease/Disorder""}]"
In the majority of cases, ALK is activated by fusion with a dimerizing partner protein as a result of chromosomal translocation events, most studied in the case of the nucleophosmin – ALK and echinoderm microtubule - associated protein - like 4 – ALK oncoproteins.	"ALK	26	29	Gene/Protein"	"nucleophosmin	168	181	Gene/Protein"	"ALK	184	187	Gene/Protein"	"echinoderm microtubule - associated protein - like 4	192	244	Gene/Protein"	"ALK oncoproteins	247	263	Gene/Protein"	"[{""token"": ""ALK"", ""start_span"": 26, ""end_span"": 29, ""type"": ""Gene/Protein""}, {""token"": ""nucleophosmin"", ""start_span"": 168, ""end_span"": 181, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 184, ""end_span"": 187, ""type"": ""Gene/Protein""}, {""token"": ""echinoderm microtubule - associated protein - like 4"", ""start_span"": 192, ""end_span"": 244, ""type"": ""Gene/Protein""}, {""token"": ""ALK oncoproteins"", ""start_span"": 247, ""end_span"": 263, ""type"": ""Gene/Protein""}]"
Many of the tyrosine kinases in the human kinome are implicated in human cancers 1, and provide important targets for cancer treatment, as well as biomarkers for patient stratification.	"tyrosine kinases	12	28	Gene/Protein"	"human	36	41	Organism/Species"	"human	67	72	Organism/Species"	"cancers	73	80	Disease/Disorder"	"cancer	118	124	Disease/Disorder"	"[{""token"": ""tyrosine kinases"", ""start_span"": 12, ""end_span"": 28, ""type"": ""Gene/Protein""}, {""token"": ""human"", ""start_span"": 36, ""end_span"": 41, ""type"": ""Organism/Species""}, {""token"": ""human"", ""start_span"": 67, ""end_span"": 72, ""type"": ""Organism/Species""}, {""token"": ""cancers"", ""start_span"": 73, ""end_span"": 80, ""type"": ""Disease/Disorder""}, {""token"": ""cancer"", ""start_span"": 118, ""end_span"": 124, ""type"": ""Disease/Disorder""}]"
Presented and compared side - by - side with our phosphotyrosine mapping of activated full - length ALK are the global surveys of phosphotyrosine peptides identified in EML4 – ALK and NPM – ALK 29, 30.	"ALK	100	103	Gene/Protein"	"EML4	169	173	Gene/Protein"	"ALK	176	179	Gene/Protein"	"NPM	184	187	Gene/Protein"	"ALK	190	193	Gene/Protein"	"[{""token"": ""ALK"", ""start_span"": 100, ""end_span"": 103, ""type"": ""Gene/Protein""}, {""token"": ""EML4"", ""start_span"": 169, ""end_span"": 173, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 176, ""end_span"": 179, ""type"": ""Gene/Protein""}, {""token"": ""NPM"", ""start_span"": 184, ""end_span"": 187, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 190, ""end_span"": 193, ""type"": ""Gene/Protein""}]"
Interestingly, whereas long - term stimulation of the wild - type ALK receptor did lead to visible tyrosine phosphorylation of STAT3, this was not prominently observed after 30 min of stimulation, a time point when ALK and ERK1 / 2 were highly phosphorylated ( Fig. 2A, compare lanes 3 and 4 ).	"ALK receptor	66	78	Gene/Protein"	"tyrosine	99	107	Chemical/Drug"	"STAT3	127	132	Gene/Protein"	"ALK	215	218	Gene/Protein"	"ERK1	223	227	Gene/Protein"	"[{""token"": ""ALK receptor"", ""start_span"": 66, ""end_span"": 78, ""type"": ""Gene/Protein""}, {""token"": ""tyrosine"", ""start_span"": 99, ""end_span"": 107, ""type"": ""Chemical/Drug""}, {""token"": ""STAT3"", ""start_span"": 127, ""end_span"": 132, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 215, ""end_span"": 218, ""type"": ""Gene/Protein""}, {""token"": ""ERK1"", ""start_span"": 223, ""end_span"": 227, ""type"": ""Gene/Protein""}]"
( B, C) PC12 cells were transfected with either wild - type ALK or the ALKF1174S mutant together with FLAG - tagged STAT3 prior to stimulation with 1 μg · mL − 1 ALK - activating mAb ( mAb46) for 24 h, in the presence or absence of 250 nm crizotinib, as indicated.	"ALK	60	63	Gene/Protein"	"FLAG	102	106	Gene/Protein"	"STAT3	116	121	Gene/Protein"	"ALK	162	165	Gene/Protein"	"crizotinib	239	249	Chemical/Drug"	"[{""token"": ""ALK"", ""start_span"": 60, ""end_span"": 63, ""type"": ""Gene/Protein""}, {""token"": ""FLAG"", ""start_span"": 102, ""end_span"": 106, ""type"": ""Gene/Protein""}, {""token"": ""STAT3"", ""start_span"": 116, ""end_span"": 121, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 162, ""end_span"": 165, ""type"": ""Gene/Protein""}, {""token"": ""crizotinib"", ""start_span"": 239, ""end_span"": 249, ""type"": ""Chemical/Drug""}]"
Lysates were immunoprecipitated ( IP) with either antibody against FLAG ( M2) ( B) or with antibody against ALK ( mAb31) ( C ), and this was followed by immunoblotting for ALK, FLAG, and STAT3, as indicated.	"FLAG	67	71	Gene/Protein"	"ALK	108	111	Gene/Protein"	"ALK	172	175	Gene/Protein"	"FLAG	177	181	Gene/Protein"	"STAT3	187	192	Gene/Protein"	"[{""token"": ""FLAG"", ""start_span"": 67, ""end_span"": 71, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 108, ""end_span"": 111, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 172, ""end_span"": 175, ""type"": ""Gene/Protein""}, {""token"": ""FLAG"", ""start_span"": 177, ""end_span"": 181, ""type"": ""Gene/Protein""}, {""token"": ""STAT3"", ""start_span"": 187, ""end_span"": 192, ""type"": ""Gene/Protein""}]"
These neuroblastoma cell lines are all ALK gain - of - function in nature, containing either an activated ALK mutation ( ALKR1275Q, CBL - GA; ALKF1174V, CLB - GE; ALKF1174L, Kelly) or overexpressing an ALK receptor with an extracellular domain deletion ( CLB - BARΔexon 4 – 12 ), and express different levels of MYCN ( Fig. S3) 38, 39.	"neuroblastoma	6	19	Disease/Disorder"	"ALK	39	42	Gene/Protein"	"ALK	106	109	Gene/Protein"	"ALK receptor	202	214	Gene/Protein"	"MYCN	312	316	Gene/Protein"	"[{""token"": ""neuroblastoma"", ""start_span"": 6, ""end_span"": 19, ""type"": ""Disease/Disorder""}, {""token"": ""ALK"", ""start_span"": 39, ""end_span"": 42, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 106, ""end_span"": 109, ""type"": ""Gene/Protein""}, {""token"": ""ALK receptor"", ""start_span"": 202, ""end_span"": 214, ""type"": ""Gene/Protein""}, {""token"": ""MYCN"", ""start_span"": 312, ""end_span"": 316, ""type"": ""Gene/Protein""}]"
We investigated ALK, STAT3 and MYCN levels in CLB - GE, CLB - BAR, Kelly and CLB - GA neuroblastoma cell lines upon treatment with STAT3 inhibitors ( Fig. 4A – D ).	"ALK	16	19	Gene/Protein"	"STAT3	21	26	Gene/Protein"	"MYCN	31	35	Gene/Protein"	"neuroblastoma	86	99	Disease/Disorder"	"STAT3	131	136	Gene/Protein"	"[{""token"": ""ALK"", ""start_span"": 16, ""end_span"": 19, ""type"": ""Gene/Protein""}, {""token"": ""STAT3"", ""start_span"": 21, ""end_span"": 26, ""type"": ""Gene/Protein""}, {""token"": ""MYCN"", ""start_span"": 31, ""end_span"": 35, ""type"": ""Gene/Protein""}, {""token"": ""neuroblastoma"", ""start_span"": 86, ""end_span"": 99, ""type"": ""Disease/Disorder""}, {""token"": ""STAT3"", ""start_span"": 131, ""end_span"": 136, ""type"": ""Gene/Protein""}]"
In keeping with the results obtained with STAT3 siRNA treatment, both inhibitors reduced MYCN levels ( Fig. 4A – D, compare lanes 3 and 4 with lane 1 ), suggesting that STAT3 may act between the ALK receptor and expression of MYCN.	"STAT3	42	47	Gene/Protein"	"MYCN	89	93	Gene/Protein"	"STAT3	169	174	Gene/Protein"	"ALK receptor	195	207	Gene/Protein"	"MYCN	226	230	Gene/Protein"	"[{""token"": ""STAT3"", ""start_span"": 42, ""end_span"": 47, ""type"": ""Gene/Protein""}, {""token"": ""MYCN"", ""start_span"": 89, ""end_span"": 93, ""type"": ""Gene/Protein""}, {""token"": ""STAT3"", ""start_span"": 169, ""end_span"": 174, ""type"": ""Gene/Protein""}, {""token"": ""ALK receptor"", ""start_span"": 195, ""end_span"": 207, ""type"": ""Gene/Protein""}, {""token"": ""MYCN"", ""start_span"": 226, ""end_span"": 230, ""type"": ""Gene/Protein""}]"
To investigate further whether STAT3 is involved in ALK - activated initiation of MYCN transcription, we employed an MYCNP – luciferase assay in two independent neuroblastoma cell lines 36.	"STAT3	31	36	Gene/Protein"	"ALK	52	55	Gene/Protein"	"MYCN	82	86	Gene/Protein"	"luciferase	125	135	Gene/Protein"	"neuroblastoma	161	174	Disease/Disorder"	"[{""token"": ""STAT3"", ""start_span"": 31, ""end_span"": 36, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 52, ""end_span"": 55, ""type"": ""Gene/Protein""}, {""token"": ""MYCN"", ""start_span"": 82, ""end_span"": 86, ""type"": ""Gene/Protein""}, {""token"": ""luciferase"", ""start_span"": 125, ""end_span"": 135, ""type"": ""Gene/Protein""}, {""token"": ""neuroblastoma"", ""start_span"": 161, ""end_span"": 174, ""type"": ""Disease/Disorder""}]"
It is interesting to compare the results of this study with earlier phosphoproteomics analysis on oncogenic ALK fusion proteins, such as EML4 – ALK and NPM – ALK 29, 30.	"ALK	108	111	Gene/Protein"	"EML4	137	141	Gene/Protein"	"ALK	144	147	Gene/Protein"	"NPM	152	155	Gene/Protein"	"ALK	158	161	Gene/Protein"	"[{""token"": ""ALK"", ""start_span"": 108, ""end_span"": 111, ""type"": ""Gene/Protein""}, {""token"": ""EML4"", ""start_span"": 137, ""end_span"": 141, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 144, ""end_span"": 147, ""type"": ""Gene/Protein""}, {""token"": ""NPM"", ""start_span"": 152, ""end_span"": 155, ""type"": ""Gene/Protein""}, {""token"": ""ALK"", ""start_span"": 158, ""end_span"": 161, ""type"": ""Gene/Protein""}]"
However, serine / threonine phosphorylation is known to have important regulatory functions for, for example, fibroblast growth factor receptor, epidermal growth factor receptor 50 – 51, and Kit 52, to name but a few.	"serine	9	15	Chemical/Drug"	"threonine	18	27	Chemical/Drug"	"fibroblast growth factor receptor	110	143	Gene/Protein"	"epidermal growth factor receptor	145	177	Gene/Protein"	"Kit	191	194	Gene/Protein"	"[{""token"": ""serine"", ""start_span"": 9, ""end_span"": 15, ""type"": ""Chemical/Drug""}, {""token"": ""threonine"", ""start_span"": 18, ""end_span"": 27, ""type"": ""Chemical/Drug""}, {""token"": ""fibroblast growth factor receptor"", ""start_span"": 110, ""end_span"": 143, ""type"": ""Gene/Protein""}, {""token"": ""epidermal growth factor receptor"", ""start_span"": 145, ""end_span"": 177, ""type"": ""Gene/Protein""}, {""token"": ""Kit"", ""start_span"": 191, ""end_span"": 194, ""type"": ""Gene/Protein""}]"
Third, hBD3 markedly inhibited NF - κB activation by decreasing the phosphorylation of IKK - α / β, IκB, and p65 subunit within 30 min.	"hBD3	7	11	Gene/Protein"	"NF - κB	31	38	Gene/Protein"	"IKK - α	87	94	Gene/Protein"	"IκB	100	103	Gene/Protein"	"p65	109	112	Gene/Protein"	"[{""token"": ""hBD3"", ""start_span"": 7, ""end_span"": 11, ""type"": ""Gene/Protein""}, {""token"": ""NF - \u03baB"", ""start_span"": 31, ""end_span"": 38, ""type"": ""Gene/Protein""}, {""token"": ""IKK - \u03b1"", ""start_span"": 87, ""end_span"": 94, ""type"": ""Gene/Protein""}, {""token"": ""I\u03baB"", ""start_span"": 100, ""end_span"": 103, ""type"": ""Gene/Protein""}, {""token"": ""p65"", ""start_span"": 109, ""end_span"": 112, ""type"": ""Gene/Protein""}]"
Endothelial cells stimulated with TNF - α produce proinflammatory mediators, including interleukin - ( IL -) 6, IL - 8, and monocyte chemoattractant protein - 1 ( MCP - 1 ), which cause more monocytes to be recruited.	"TNF - α	34	41	Gene/Protein"	"interleukin - ( IL -) 6	87	110	Gene/Protein"	"IL - 8	112	118	Gene/Protein"	"monocyte chemoattractant protein - 1	124	160	Gene/Protein"	"MCP - 1	163	170	Gene/Protein"	"[{""token"": ""TNF - \u03b1"", ""start_span"": 34, ""end_span"": 41, ""type"": ""Gene/Protein""}, {""token"": ""interleukin - ( IL -) 6"", ""start_span"": 87, ""end_span"": 110, ""type"": ""Gene/Protein""}, {""token"": ""IL - 8"", ""start_span"": 112, ""end_span"": 118, ""type"": ""Gene/Protein""}, {""token"": ""monocyte chemoattractant protein - 1"", ""start_span"": 124, ""end_span"": 160, ""type"": ""Gene/Protein""}, {""token"": ""MCP - 1"", ""start_span"": 163, ""end_span"": 170, ""type"": ""Gene/Protein""}]"
In addition, hBD3 treatment dose - dependently prevented the upregulation of ICAM - 1, VCAM - 1, and E - selectin levels by TNF - α.	"hBD3	13	17	Gene/Protein"	"ICAM - 1	77	85	Gene/Protein"	"VCAM - 1	87	95	Gene/Protein"	"E - selectin	101	113	Gene/Protein"	"TNF - α	124	131	Gene/Protein"	"[{""token"": ""hBD3"", ""start_span"": 13, ""end_span"": 17, ""type"": ""Gene/Protein""}, {""token"": ""ICAM - 1"", ""start_span"": 77, ""end_span"": 85, ""type"": ""Gene/Protein""}, {""token"": ""VCAM - 1"", ""start_span"": 87, ""end_span"": 95, ""type"": ""Gene/Protein""}, {""token"": ""E - selectin"", ""start_span"": 101, ""end_span"": 113, ""type"": ""Gene/Protein""}, {""token"": ""TNF - \u03b1"", ""start_span"": 124, ""end_span"": 131, ""type"": ""Gene/Protein""}]"
The protein levels of MBP, Olig1, GFAP, GS, and GAPDH determined by Western blot analysis ( d ).	"MBP	22	25	Gene/Protein"	"Olig1	27	32	Gene/Protein"	"GFAP	34	38	Gene/Protein"	"GS	40	42	Gene/Protein"	"GAPDH	48	53	Gene/Protein"	"[{""token"": ""MBP"", ""start_span"": 22, ""end_span"": 25, ""type"": ""Gene/Protein""}, {""token"": ""Olig1"", ""start_span"": 27, ""end_span"": 32, ""type"": ""Gene/Protein""}, {""token"": ""GFAP"", ""start_span"": 34, ""end_span"": 38, ""type"": ""Gene/Protein""}, {""token"": ""GS"", ""start_span"": 40, ""end_span"": 42, ""type"": ""Gene/Protein""}, {""token"": ""GAPDH"", ""start_span"": 48, ""end_span"": 53, ""type"": ""Gene/Protein""}]"
Glycogen is a polysaccharide and the main storage form of glucose from bacteria such as Escherichia coli to yeasts and mammals.	"glucose	58	65	Chemical/Drug"	"bacteria	71	79	Organism/Species"	"Escherichia coli	88	104	Organism/Species"	"yeasts	108	114	Organism/Species"	"mammals	119	126	Organism/Species"	"[{""token"": ""glucose"", ""start_span"": 58, ""end_span"": 65, ""type"": ""Chemical/Drug""}, {""token"": ""bacteria"", ""start_span"": 71, ""end_span"": 79, ""type"": ""Organism/Species""}, {""token"": ""Escherichia coli"", ""start_span"": 88, ""end_span"": 104, ""type"": ""Organism/Species""}, {""token"": ""yeasts"", ""start_span"": 108, ""end_span"": 114, ""type"": ""Organism/Species""}, {""token"": ""mammals"", ""start_span"": 119, ""end_span"": 126, ""type"": ""Organism/Species""}]"
Transcription of CsrB and CsrC is activated by the BarA / UvrY two - component system ( 23, 25, 28) and is repressed by cAMP - CRP ( 29 ).	"CsrB	17	21	Gene/Protein"	"CsrC	26	30	Gene/Protein"	"BarA	51	55	Gene/Protein"	"UvrY	58	62	Gene/Protein"	"CRP	127	130	Gene/Protein"	"[{""token"": ""CsrB"", ""start_span"": 17, ""end_span"": 21, ""type"": ""Gene/Protein""}, {""token"": ""CsrC"", ""start_span"": 26, ""end_span"": 30, ""type"": ""Gene/Protein""}, {""token"": ""BarA"", ""start_span"": 51, ""end_span"": 55, ""type"": ""Gene/Protein""}, {""token"": ""UvrY"", ""start_span"": 58, ""end_span"": 62, ""type"": ""Gene/Protein""}, {""token"": ""CRP"", ""start_span"": 127, ""end_span"": 130, ""type"": ""Gene/Protein""}]"
The beads were cultured in six - well plates under conditions of 5% O2 with DMEM / F12 medium containing 1% insulin, transferrin and selenous ( ITS) ( Sigma - Aldrich ), 100 nM dexamethasone ( Sigma - Aldrich) and 10 ng / ml transforming growth factor - β1 ( TGF - β1) ( PeproTech Rocky Hill, NJ, USA ).	"insulin	108	115	Gene/Protein"	"transferrin	117	128	Gene/Protein"	"dexamethasone	177	190	Chemical/Drug"	"transforming growth factor - β1	225	256	Gene/Protein"	"TGF - β1	259	267	Gene/Protein"	"[{""token"": ""insulin"", ""start_span"": 108, ""end_span"": 115, ""type"": ""Gene/Protein""}, {""token"": ""transferrin"", ""start_span"": 117, ""end_span"": 128, ""type"": ""Gene/Protein""}, {""token"": ""dexamethasone"", ""start_span"": 177, ""end_span"": 190, ""type"": ""Chemical/Drug""}, {""token"": ""transforming growth factor - \u03b21"", ""start_span"": 225, ""end_span"": 256, ""type"": ""Gene/Protein""}, {""token"": ""TGF - \u03b21"", ""start_span"": 259, ""end_span"": 267, ""type"": ""Gene/Protein""}]"
Nicotine had an obvious adverse effect on cell morphology of the regenerated tissue and synthesis of cartilage matrix. Fig. 1Effects of nicotine on the repair of the cartilage defect with BMSCs transplantation in a rat model after 12 weeks. a and b Macroscopic observation of cartilage repair (× 100 ). c Macroscopic scores of cartilage repair. d and e Safranin - O and fast green staining of cartilage repair (× 100 ). f Histological scores of cartilage repair.	"Nicotine	0	8	Chemical/Drug"	"nicotine	136	144	Chemical/Drug"	"rat	215	218	Organism/Species"	"Safranin - O	353	365	Chemical/Drug"	"fast green	370	380	Chemical/Drug"	"[{""token"": ""Nicotine"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Chemical/Drug""}, {""token"": ""nicotine"", ""start_span"": 136, ""end_span"": 144, ""type"": ""Chemical/Drug""}, {""token"": ""rat"", ""start_span"": 215, ""end_span"": 218, ""type"": ""Organism/Species""}, {""token"": ""Safranin - O"", ""start_span"": 353, ""end_span"": 365, ""type"": ""Chemical/Drug""}, {""token"": ""fast green"", ""start_span"": 370, ""end_span"": 380, ""type"": ""Chemical/Drug""}]"
We found that 10μM methyllycaconitine ( MLA ), the specific antagonist of α7 - nAChR, conversely eliminated the nicotine - induced calcium influx ( Fig. 3d ), implying that the effect of nicotine on BMSCs was fulfilled through α7 - nAChR.	"methyllycaconitine	19	37	Chemical/Drug"	"α7 - nAChR	74	84	Gene/Protein"	"nicotine	112	120	Chemical/Drug"	"nicotine	187	195	Chemical/Drug"	"α7 - nAChR	227	237	Gene/Protein"	"[{""token"": ""methyllycaconitine"", ""start_span"": 19, ""end_span"": 37, ""type"": ""Chemical/Drug""}, {""token"": ""\u03b17 - nAChR"", ""start_span"": 74, ""end_span"": 84, ""type"": ""Gene/Protein""}, {""token"": ""nicotine"", ""start_span"": 112, ""end_span"": 120, ""type"": ""Chemical/Drug""}, {""token"": ""nicotine"", ""start_span"": 187, ""end_span"": 195, ""type"": ""Chemical/Drug""}, {""token"": ""\u03b17 - nAChR"", ""start_span"": 227, ""end_span"": 237, ""type"": ""Gene/Protein""}]"
Nicotine suppressed Sox9 by activating the Ca2 +/ calcineurin / NFATc2 signaling pathway through α7 - nAChR	"Nicotine	0	8	Chemical/Drug"	"Sox9	20	24	Gene/Protein"	"calcineurin	50	61	Gene/Protein"	"NFATc2	64	70	Gene/Protein"	"α7 - nAChR	97	107	Gene/Protein"	"[{""token"": ""Nicotine"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Chemical/Drug""}, {""token"": ""Sox9"", ""start_span"": 20, ""end_span"": 24, ""type"": ""Gene/Protein""}, {""token"": ""calcineurin"", ""start_span"": 50, ""end_span"": 61, ""type"": ""Gene/Protein""}, {""token"": ""NFATc2"", ""start_span"": 64, ""end_span"": 70, ""type"": ""Gene/Protein""}, {""token"": ""\u03b17 - nAChR"", ""start_span"": 97, ""end_span"": 107, ""type"": ""Gene/Protein""}]"
Then, NFATc2 and HDAC1 bound on the Sox9 promoter reduced the levels of H3K9ac and H3K14ac on the Sox9 promoter and decreased Sox9 expression.	"NFATc2	6	12	Gene/Protein"	"HDAC1	17	22	Gene/Protein"	"Sox9	36	40	Gene/Protein"	"Sox9	98	102	Gene/Protein"	"Sox9	126	130	Gene/Protein"	"[{""token"": ""NFATc2"", ""start_span"": 6, ""end_span"": 12, ""type"": ""Gene/Protein""}, {""token"": ""HDAC1"", ""start_span"": 17, ""end_span"": 22, ""type"": ""Gene/Protein""}, {""token"": ""Sox9"", ""start_span"": 36, ""end_span"": 40, ""type"": ""Gene/Protein""}, {""token"": ""Sox9"", ""start_span"": 98, ""end_span"": 102, ""type"": ""Gene/Protein""}, {""token"": ""Sox9"", ""start_span"": 126, ""end_span"": 130, ""type"": ""Gene/Protein""}]"
The result showed that the interaction of NFATc2 with HDAC1 was enhanced in a concentration - dependent manner after nicotine exposure ( Fig. 6a ), and no significant change of interaction was observed when Si - NFATc2 and MLA were used before nicotine treatment ( Fig. 6b ).	"NFATc2	42	48	Gene/Protein"	"HDAC1	54	59	Gene/Protein"	"nicotine	117	125	Chemical/Drug"	"NFATc2	212	218	Gene/Protein"	"nicotine	244	252	Chemical/Drug"	"[{""token"": ""NFATc2"", ""start_span"": 42, ""end_span"": 48, ""type"": ""Gene/Protein""}, {""token"": ""HDAC1"", ""start_span"": 54, ""end_span"": 59, ""type"": ""Gene/Protein""}, {""token"": ""nicotine"", ""start_span"": 117, ""end_span"": 125, ""type"": ""Chemical/Drug""}, {""token"": ""NFATc2"", ""start_span"": 212, ""end_span"": 218, ""type"": ""Gene/Protein""}, {""token"": ""nicotine"", ""start_span"": 244, ""end_span"": 252, ""type"": ""Chemical/Drug""}]"
Histone acetyltransferases ( HATs) and HDACs are two classes of histone acetylation enzymes, which determine the acetylation status of histones of genes.	"Histone acetyltransferases	0	26	Gene/Protein"	"HATs	29	33	Gene/Protein"	"HDACs	39	44	Gene/Protein"	"histone	64	71	Gene/Protein"	"histones	135	143	Gene/Protein"	"[{""token"": ""Histone acetyltransferases"", ""start_span"": 0, ""end_span"": 26, ""type"": ""Gene/Protein""}, {""token"": ""HATs"", ""start_span"": 29, ""end_span"": 33, ""type"": ""Gene/Protein""}, {""token"": ""HDACs"", ""start_span"": 39, ""end_span"": 44, ""type"": ""Gene/Protein""}, {""token"": ""histone"", ""start_span"": 64, ""end_span"": 71, ""type"": ""Gene/Protein""}, {""token"": ""histones"", ""start_span"": 135, ""end_span"": 143, ""type"": ""Gene/Protein""}]"
Our in vitro data are consistent with the in vivo results where nicotine directly decreased the expression of Sox9 through α7 - nAChR by suppressing the histone acetylation of the Sox9 promoter during the process of BMSCs chondrogenic differentiation.	"nicotine	64	72	Chemical/Drug"	"Sox9	110	114	Gene/Protein"	"α7 - nAChR	123	133	Gene/Protein"	"histone	153	160	Gene/Protein"	"Sox9	180	184	Gene/Protein"	"[{""token"": ""nicotine"", ""start_span"": 64, ""end_span"": 72, ""type"": ""Chemical/Drug""}, {""token"": ""Sox9"", ""start_span"": 110, ""end_span"": 114, ""type"": ""Gene/Protein""}, {""token"": ""\u03b17 - nAChR"", ""start_span"": 123, ""end_span"": 133, ""type"": ""Gene/Protein""}, {""token"": ""histone"", ""start_span"": 153, ""end_span"": 160, ""type"": ""Gene/Protein""}, {""token"": ""Sox9"", ""start_span"": 180, ""end_span"": 184, ""type"": ""Gene/Protein""}]"
NFAT is a family of transcription factors critical in regulating early gene transcription in response to T cell receptor - mediated signals in lymphocytes [ 42 ]. NFATc2 is a repressor of chondrogenesis [ 21] and can induce gene silencing through interaction with HDAC [ 22 ].	"NFAT	0	4	Gene/Protein"	"transcription factors	20	41	Gene/Protein"	"T cell receptor	105	120	Gene/Protein"	"NFATc2	163	169	Gene/Protein"	"HDAC	264	268	Gene/Protein"	"[{""token"": ""NFAT"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Gene/Protein""}, {""token"": ""transcription factors"", ""start_span"": 20, ""end_span"": 41, ""type"": ""Gene/Protein""}, {""token"": ""T cell receptor"", ""start_span"": 105, ""end_span"": 120, ""type"": ""Gene/Protein""}, {""token"": ""NFATc2"", ""start_span"": 163, ""end_span"": 169, ""type"": ""Gene/Protein""}, {""token"": ""HDAC"", ""start_span"": 264, ""end_span"": 268, ""type"": ""Gene/Protein""}]"
Furthermore, depression is a risk factor for the onset of type 2 diabetes mellitus, hypertension, coronary heart disease, cancer, and so on [ 1 ], which is projected to become the second biggest contributor to the global burden of disease and disability by 2020 according to WHO ' s prediction.	"depression	13	23	Disease/Disorder"	"type 2 diabetes mellitus	58	82	Disease/Disorder"	"hypertension	84	96	Disease/Disorder"	"coronary heart disease	98	120	Disease/Disorder"	"cancer	122	128	Disease/Disorder"	"[{""token"": ""depression"", ""start_span"": 13, ""end_span"": 23, ""type"": ""Disease/Disorder""}, {""token"": ""type 2 diabetes mellitus"", ""start_span"": 58, ""end_span"": 82, ""type"": ""Disease/Disorder""}, {""token"": ""hypertension"", ""start_span"": 84, ""end_span"": 96, ""type"": ""Disease/Disorder""}, {""token"": ""coronary heart disease"", ""start_span"": 98, ""end_span"": 120, ""type"": ""Disease/Disorder""}, {""token"": ""cancer"", ""start_span"": 122, ""end_span"": 128, ""type"": ""Disease/Disorder""}]"
Using the circadian mouse mutant ClockΔ19 / Δ19, we also showed that a functional circadian clock, known to modulate C / EBP and CPS1 expression, was required for NOB induction of CPS1 under the HFD condition.	"mouse	20	25	Organism/Species"	"clock	92	97	Gene/Protein"	"C / EBP	117	124	Gene/Protein"	"CPS1	129	133	Gene/Protein"	"CPS1	180	184	Gene/Protein"	"[{""token"": ""mouse"", ""start_span"": 20, ""end_span"": 25, ""type"": ""Organism/Species""}, {""token"": ""clock"", ""start_span"": 92, ""end_span"": 97, ""type"": ""Gene/Protein""}, {""token"": ""C / EBP"", ""start_span"": 117, ""end_span"": 124, ""type"": ""Gene/Protein""}, {""token"": ""CPS1"", ""start_span"": 129, ""end_span"": 133, ""type"": ""Gene/Protein""}, {""token"": ""CPS1"", ""start_span"": 180, ""end_span"": 184, ""type"": ""Gene/Protein""}]"
Carbamoyl phosphate synthetase 1 ( CPS1) catalyzes the first reaction wherein ammonia and bicarbonate combine to form carbamoyl phosphate, and mice deficient in Cps1 suffered pronounced hyperammonemia and neonatal lethality [ 9 ].	"Carbamoyl phosphate synthetase 1	0	32	Gene/Protein"	"CPS1	35	39	Gene/Protein"	"mice	143	147	Organism/Species"	"Cps1	161	165	Gene/Protein"	"hyperammonemia	186	200	Disease/Disorder"	"[{""token"": ""Carbamoyl phosphate synthetase 1"", ""start_span"": 0, ""end_span"": 32, ""type"": ""Gene/Protein""}, {""token"": ""CPS1"", ""start_span"": 35, ""end_span"": 39, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 143, ""end_span"": 147, ""type"": ""Organism/Species""}, {""token"": ""Cps1"", ""start_span"": 161, ""end_span"": 165, ""type"": ""Gene/Protein""}, {""token"": ""hyperammonemia"", ""start_span"": 186, ""end_span"": 200, ""type"": ""Disease/Disorder""}]"
Under RC, NOB treatment showed only modest effects on expression of the four other urea cycle genes ( Otc, Ass1, Asl, Arg1) relative to Veh controls ( Fig. 5b - e ).	"urea	83	87	Chemical/Drug"	"Otc	102	105	Gene/Protein"	"Ass1	107	111	Gene/Protein"	"Asl	113	116	Gene/Protein"	"Arg1	118	122	Gene/Protein"	"[{""token"": ""urea"", ""start_span"": 83, ""end_span"": 87, ""type"": ""Chemical/Drug""}, {""token"": ""Otc"", ""start_span"": 102, ""end_span"": 105, ""type"": ""Gene/Protein""}, {""token"": ""Ass1"", ""start_span"": 107, ""end_span"": 111, ""type"": ""Gene/Protein""}, {""token"": ""Asl"", ""start_span"": 113, ""end_span"": 116, ""type"": ""Gene/Protein""}, {""token"": ""Arg1"", ""start_span"": 118, ""end_span"": 122, ""type"": ""Gene/Protein""}]"
Besides transcriptional regulation ( C / EBP, glucocorticoid receptor, CREB and HNF3) and the allosteric cofactor NAG [ 7, 17 ], recent mechanistic studies have also underscored the importance of post - translational modifications ( PTMs) for CPS1 protein activity [ 11 – 13, 47 ].	"C / EBP	37	44	Gene/Protein"	"glucocorticoid receptor	46	69	Gene/Protein"	"CREB	71	75	Gene/Protein"	"HNF3	80	84	Gene/Protein"	"CPS1	243	247	Gene/Protein"	"[{""token"": ""C / EBP"", ""start_span"": 37, ""end_span"": 44, ""type"": ""Gene/Protein""}, {""token"": ""glucocorticoid receptor"", ""start_span"": 46, ""end_span"": 69, ""type"": ""Gene/Protein""}, {""token"": ""CREB"", ""start_span"": 71, ""end_span"": 75, ""type"": ""Gene/Protein""}, {""token"": ""HNF3"", ""start_span"": 80, ""end_span"": 84, ""type"": ""Gene/Protein""}, {""token"": ""CPS1"", ""start_span"": 243, ""end_span"": 247, ""type"": ""Gene/Protein""}]"
Herpes zoster ( HZ ), also known as shingles, is caused by the reactivation of the varicella zoster virus ( VZV ).	"Herpes zoster	0	13	Disease/Disorder"	"HZ	16	18	Disease/Disorder"	"shingles	36	44	Disease/Disorder"	"varicella zoster virus	83	105	Organism/Species"	"VZV	108	111	Organism/Species"	"[{""token"": ""Herpes zoster"", ""start_span"": 0, ""end_span"": 13, ""type"": ""Disease/Disorder""}, {""token"": ""HZ"", ""start_span"": 16, ""end_span"": 18, ""type"": ""Disease/Disorder""}, {""token"": ""shingles"", ""start_span"": 36, ""end_span"": 44, ""type"": ""Disease/Disorder""}, {""token"": ""varicella zoster virus"", ""start_span"": 83, ""end_span"": 105, ""type"": ""Organism/Species""}, {""token"": ""VZV"", ""start_span"": 108, ""end_span"": 111, ""type"": ""Organism/Species""}]"
Evidence for the efficacy of a VZV vaccine in the prevention of HZ and PHN episodes and attenuation of the severity of HZ and PHN episodes and associated impact has been documented in recent years [ 11, 33 ].	"VZV	31	34	Organism/Species"	"HZ	64	66	Disease/Disorder"	"PHN	71	74	Disease/Disorder"	"HZ	119	121	Disease/Disorder"	"PHN	126	129	Disease/Disorder"	"[{""token"": ""VZV"", ""start_span"": 31, ""end_span"": 34, ""type"": ""Organism/Species""}, {""token"": ""HZ"", ""start_span"": 64, ""end_span"": 66, ""type"": ""Disease/Disorder""}, {""token"": ""PHN"", ""start_span"": 71, ""end_span"": 74, ""type"": ""Disease/Disorder""}, {""token"": ""HZ"", ""start_span"": 119, ""end_span"": 121, ""type"": ""Disease/Disorder""}, {""token"": ""PHN"", ""start_span"": 126, ""end_span"": 129, ""type"": ""Disease/Disorder""}]"
Nonetheless, recent research indicates that both HZ and PHN patients demonstrate statistically significant and clinically relevant deficits in HRQoL when scores for validated measures of HRQoL ( e. g. SF - 36 and EQ - 5D) among these populations are compared to those from aged - matched normative samples ( Figures 3 and 4) [ 14, 50 ]. Figure 3 Comparison of SF - 36 domain and component scores for HZ patients compared to age - matched norms [ 50 ]. No * s p ≥ 0. 05, * p < 0. 05; ** p > 0. 01; *** p < 0. 001. † = clinically meaningful PF = Physical functioning, R - P = Role - physical, BP = Bodily pain, GH = General health, V = Vitality, SF = Social functioning, R - E = Role - emotional, MH = Mental health, PCS = Physical component summary, MCS = Mental component summary. Note: Data collected on initial presentation of HZ to healthcare professional and then again 7 - 14 days later ( follow - up ). Figure 4 Comparison of SF - 36 domain and component scores for PHN patients compared to age - matched norms [ 14 ]. No * s p ≥ 0. 05, * p < 0. 05; ** p < 0. 01; *** p < 0. 001. † = clinically meaningful PF = Physical functioning, R - P = Role - physical, BP = Bodily pain, GH = General health, V = Vitality, SF = Social functioning, R - E = Role - emotional, MH = Mental health, PCS = Physical component summary, MCS = Mental component summary.	"HZ	49	51	Disease/Disorder"	"PHN	56	59	Disease/Disorder"	"HZ	400	402	Disease/Disorder"	"HZ	829	831	Disease/Disorder"	"PHN	972	975	Disease/Disorder"	"[{""token"": ""HZ"", ""start_span"": 49, ""end_span"": 51, ""type"": ""Disease/Disorder""}, {""token"": ""PHN"", ""start_span"": 56, ""end_span"": 59, ""type"": ""Disease/Disorder""}, {""token"": ""HZ"", ""start_span"": 400, ""end_span"": 402, ""type"": ""Disease/Disorder""}, {""token"": ""HZ"", ""start_span"": 829, ""end_span"": 831, ""type"": ""Disease/Disorder""}, {""token"": ""PHN"", ""start_span"": 972, ""end_span"": 975, ""type"": ""Disease/Disorder""}]"
To investigate the role of the P7 - 1 protein in virus pathogenicity, transgenic Arabidopsis thaliana plants were generated in which the P7 - 1 gene was expressed under the control of the 35S promoter.	"P7 - 1	31	37	Gene/Protein"	"virus	49	54	Organism/Species"	"Arabidopsis thaliana	81	101	Organism/Species"	"plants	102	108	Organism/Species"	"P7 - 1	137	143	Gene/Protein"	"[{""token"": ""P7 - 1"", ""start_span"": 31, ""end_span"": 37, ""type"": ""Gene/Protein""}, {""token"": ""virus"", ""start_span"": 49, ""end_span"": 54, ""type"": ""Organism/Species""}, {""token"": ""Arabidopsis thaliana"", ""start_span"": 81, ""end_span"": 101, ""type"": ""Organism/Species""}, {""token"": ""plants"", ""start_span"": 102, ""end_span"": 108, ""type"": ""Organism/Species""}, {""token"": ""P7 - 1"", ""start_span"": 137, ""end_span"": 143, ""type"": ""Gene/Protein""}]"
The RBSDV P7 - 1 - transgenic Arabidopsis plants ( named P7 - 1 - OE) were male sterility.	"RBSDV	4	9	Organism/Species"	"P7 - 1	10	16	Gene/Protein"	"Arabidopsis	30	41	Organism/Species"	"plants	42	48	Organism/Species"	"P7 - 1	57	63	Gene/Protein"	"[{""token"": ""RBSDV"", ""start_span"": 4, ""end_span"": 9, ""type"": ""Organism/Species""}, {""token"": ""P7 - 1"", ""start_span"": 10, ""end_span"": 16, ""type"": ""Gene/Protein""}, {""token"": ""Arabidopsis"", ""start_span"": 30, ""end_span"": 41, ""type"": ""Organism/Species""}, {""token"": ""plants"", ""start_span"": 42, ""end_span"": 48, ""type"": ""Organism/Species""}, {""token"": ""P7 - 1"", ""start_span"": 57, ""end_span"": 63, ""type"": ""Gene/Protein""}]"
Tubule - forming and plasmodesmatal localization of RBSDV P7 - 1 are usually thought to be involved in cell - to - cell movement of the virus in plant and insect cells.	"RBSDV	52	57	Organism/Species"	"P7 - 1	58	64	Gene/Protein"	"virus	136	141	Organism/Species"	"plant	145	150	Organism/Species"	"insect	155	161	Organism/Species"	"[{""token"": ""RBSDV"", ""start_span"": 52, ""end_span"": 57, ""type"": ""Organism/Species""}, {""token"": ""P7 - 1"", ""start_span"": 58, ""end_span"": 64, ""type"": ""Gene/Protein""}, {""token"": ""virus"", ""start_span"": 136, ""end_span"": 141, ""type"": ""Organism/Species""}, {""token"": ""plant"", ""start_span"": 145, ""end_span"": 150, ""type"": ""Organism/Species""}, {""token"": ""insect"", ""start_span"": 155, ""end_span"": 161, ""type"": ""Organism/Species""}]"
Young instar nymphs of SBPHs ( small brown planthopper, L. striatellus) were fed RBSDV - infected rice plants for 2 days to acquire the virus.	"SBPHs	23	28	Organism/Species"	"small brown planthopper	31	54	Organism/Species"	"RBSDV	81	86	Organism/Species"	"rice plants	98	109	Organism/Species"	"virus	136	141	Organism/Species"	"[{""token"": ""SBPHs"", ""start_span"": 23, ""end_span"": 28, ""type"": ""Organism/Species""}, {""token"": ""small brown planthopper"", ""start_span"": 31, ""end_span"": 54, ""type"": ""Organism/Species""}, {""token"": ""RBSDV"", ""start_span"": 81, ""end_span"": 86, ""type"": ""Organism/Species""}, {""token"": ""rice plants"", ""start_span"": 98, ""end_span"": 109, ""type"": ""Organism/Species""}, {""token"": ""virus"", ""start_span"": 136, ""end_span"": 141, ""type"": ""Organism/Species""}]"
But in transgenic plants, siliques remained small, producing no seeds, indicating the high degree of sterility of Arabidopsis plants ectopically expressing RBSDV P7 - 1 ( Figure 2B and 2C ).	"plants	18	24	Organism/Species"	"Arabidopsis	114	125	Organism/Species"	"plants	126	132	Organism/Species"	"RBSDV	156	161	Organism/Species"	"P7 - 1	162	168	Gene/Protein"	"[{""token"": ""plants"", ""start_span"": 18, ""end_span"": 24, ""type"": ""Organism/Species""}, {""token"": ""Arabidopsis"", ""start_span"": 114, ""end_span"": 125, ""type"": ""Organism/Species""}, {""token"": ""plants"", ""start_span"": 126, ""end_span"": 132, ""type"": ""Organism/Species""}, {""token"": ""RBSDV"", ""start_span"": 156, ""end_span"": 161, ""type"": ""Organism/Species""}, {""token"": ""P7 - 1"", ""start_span"": 162, ""end_span"": 168, ""type"": ""Gene/Protein""}]"
For example, at flowers development 13 stage, the relative expression level of 4CL, CCoAOMT were 0. 8, 0. 3 in P7 - 1 - OE plants but 1. 3, 0. 7 in wild - type plants.	"4CL	79	82	Gene/Protein"	"CCoAOMT	84	91	Gene/Protein"	"P7 - 1	111	117	Gene/Protein"	"plants	123	129	Organism/Species"	"plants	160	166	Organism/Species"	"[{""token"": ""4CL"", ""start_span"": 79, ""end_span"": 82, ""type"": ""Gene/Protein""}, {""token"": ""CCoAOMT"", ""start_span"": 84, ""end_span"": 91, ""type"": ""Gene/Protein""}, {""token"": ""P7 - 1"", ""start_span"": 111, ""end_span"": 117, ""type"": ""Gene/Protein""}, {""token"": ""plants"", ""start_span"": 123, ""end_span"": 129, ""type"": ""Organism/Species""}, {""token"": ""plants"", ""start_span"": 160, ""end_span"": 166, ""type"": ""Organism/Species""}]"
Furthermore, overexpressing RBSDV P7 - 1 in Arabidopsis produced plants with male sterility resulting from non - dehiscent anthers ( Figure 2 ), which approximately mimicked the disease symptoms observed in rice anthers.	"RBSDV	28	33	Organism/Species"	"P7 - 1	34	40	Gene/Protein"	"Arabidopsis	44	55	Organism/Species"	"plants	65	71	Organism/Species"	"rice	207	211	Organism/Species"	"[{""token"": ""RBSDV"", ""start_span"": 28, ""end_span"": 33, ""type"": ""Organism/Species""}, {""token"": ""P7 - 1"", ""start_span"": 34, ""end_span"": 40, ""type"": ""Gene/Protein""}, {""token"": ""Arabidopsis"", ""start_span"": 44, ""end_span"": 55, ""type"": ""Organism/Species""}, {""token"": ""plants"", ""start_span"": 65, ""end_span"": 71, ""type"": ""Organism/Species""}, {""token"": ""rice"", ""start_span"": 207, ""end_span"": 211, ""type"": ""Organism/Species""}]"
RBSDV P7 - 1 characteristics of tubule - forming and plasmodesmata localization suggest that this protein might be involved in virus intercellular movement, in infected insect and plant cells.	"RBSDV	0	5	Organism/Species"	"P7 - 1	6	12	Gene/Protein"	"virus	127	132	Organism/Species"	"insect	169	175	Organism/Species"	"plant	180	185	Organism/Species"	"[{""token"": ""RBSDV"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Organism/Species""}, {""token"": ""P7 - 1"", ""start_span"": 6, ""end_span"": 12, ""type"": ""Gene/Protein""}, {""token"": ""virus"", ""start_span"": 127, ""end_span"": 132, ""type"": ""Organism/Species""}, {""token"": ""insect"", ""start_span"": 169, ""end_span"": 175, ""type"": ""Organism/Species""}, {""token"": ""plant"", ""start_span"": 180, ""end_span"": 185, ""type"": ""Organism/Species""}]"
The pathogenesis of tubular proteins during viral morphogenesis has been reported in studies of other members of the family Reoviridae. For example, BTV ( bluetongue virus) nonstructural tubular protein NS1 plays a direct role in cellular pathogenesis [ 25 ].	"tubular proteins	20	36	Gene/Protein"	"Reoviridae	124	134	Organism/Species"	"BTV	149	152	Organism/Species"	"bluetongue virus	155	171	Organism/Species"	"nonstructural tubular protein NS1	173	206	Gene/Protein"	"[{""token"": ""tubular proteins"", ""start_span"": 20, ""end_span"": 36, ""type"": ""Gene/Protein""}, {""token"": ""Reoviridae"", ""start_span"": 124, ""end_span"": 134, ""type"": ""Organism/Species""}, {""token"": ""BTV"", ""start_span"": 149, ""end_span"": 152, ""type"": ""Organism/Species""}, {""token"": ""bluetongue virus"", ""start_span"": 155, ""end_span"": 171, ""type"": ""Organism/Species""}, {""token"": ""nonstructural tubular protein NS1"", ""start_span"": 173, ""end_span"": 206, ""type"": ""Gene/Protein""}]"
In support of this notion, our data show that overexpression of RBSDV tubular protein P7 - 1 in Arabidopsis causes male sterility, which mimics the phenotype observed in rice flowers infected with the virus.	"RBSDV	64	69	Organism/Species"	"tubular protein P7 - 1	70	92	Gene/Protein"	"Arabidopsis	96	107	Organism/Species"	"rice	170	174	Organism/Species"	"virus	201	206	Organism/Species"	"[{""token"": ""RBSDV"", ""start_span"": 64, ""end_span"": 69, ""type"": ""Organism/Species""}, {""token"": ""tubular protein P7 - 1"", ""start_span"": 70, ""end_span"": 92, ""type"": ""Gene/Protein""}, {""token"": ""Arabidopsis"", ""start_span"": 96, ""end_span"": 107, ""type"": ""Organism/Species""}, {""token"": ""rice"", ""start_span"": 170, ""end_span"": 174, ""type"": ""Organism/Species""}, {""token"": ""virus"", ""start_span"": 201, ""end_span"": 206, ""type"": ""Organism/Species""}]"
Activated microglia, in turn, secrete cytokines and chemokines, generate oxidative stress molecules and alter local metabolic processes. 11 Disruption in the balance of tryptophan metabolism along the kynurenine pathway is a putative mechanism linking inflammation, microglia and depression.	"cytokines	38	47	Gene/Protein"	"chemokines	52	62	Gene/Protein"	"tryptophan	169	179	Chemical/Drug"	"kynurenine	201	211	Chemical/Drug"	"depression	280	290	Disease/Disorder"	"[{""token"": ""cytokines"", ""start_span"": 38, ""end_span"": 47, ""type"": ""Gene/Protein""}, {""token"": ""chemokines"", ""start_span"": 52, ""end_span"": 62, ""type"": ""Gene/Protein""}, {""token"": ""tryptophan"", ""start_span"": 169, ""end_span"": 179, ""type"": ""Chemical/Drug""}, {""token"": ""kynurenine"", ""start_span"": 201, ""end_span"": 211, ""type"": ""Chemical/Drug""}, {""token"": ""depression"", ""start_span"": 280, ""end_span"": 290, ""type"": ""Disease/Disorder""}]"
A neurotoxic shift in kynurenine metabolism favoring the production of KMO - dependent metabolites is hypothesized to mediate inflammation - associated behavior changes. 27 Increased levels of cerebrospinal fluid ( CSF) QA in patients undergoing interferon - α immunotherapy were positively correlated to more severe depression scores. 19 A similar elevation in central QA and its neurotoxic precursor, 3 - hydroxykynurenine ( 3 - HK ), was measured in mice injected peripherally with lipopolysaccharide ( LPS ).	"kynurenine	22	32	Chemical/Drug"	"KMO	71	74	Gene/Protein"	"interferon - α	246	260	Gene/Protein"	"severe depression	310	327	Disease/Disorder"	"mice	453	457	Organism/Species"	"[{""token"": ""kynurenine"", ""start_span"": 22, ""end_span"": 32, ""type"": ""Chemical/Drug""}, {""token"": ""KMO"", ""start_span"": 71, ""end_span"": 74, ""type"": ""Gene/Protein""}, {""token"": ""interferon - \u03b1"", ""start_span"": 246, ""end_span"": 260, ""type"": ""Gene/Protein""}, {""token"": ""severe depression"", ""start_span"": 310, ""end_span"": 327, ""type"": ""Disease/Disorder""}, {""token"": ""mice"", ""start_span"": 453, ""end_span"": 457, ""type"": ""Organism/Species""}]"
Inflammation - induced depressive behaviors were precipitated in control or transgenic mice using the well - established peripheral LPS challenge model. 29, 30 3 - HK, the initial substrate for neurotoxic kynurenine pathway metabolism, was directly administered to naive mice to determine the behavioral consequences of increased KMO - dependent kynurenine metabolites.	"mice	87	91	Organism/Species"	"kynurenine	205	215	Chemical/Drug"	"mice	271	275	Organism/Species"	"KMO	330	333	Gene/Protein"	"kynurenine	346	356	Chemical/Drug"	"[{""token"": ""mice"", ""start_span"": 87, ""end_span"": 91, ""type"": ""Organism/Species""}, {""token"": ""kynurenine"", ""start_span"": 205, ""end_span"": 215, ""type"": ""Chemical/Drug""}, {""token"": ""mice"", ""start_span"": 271, ""end_span"": 275, ""type"": ""Organism/Species""}, {""token"": ""KMO"", ""start_span"": 330, ""end_span"": 333, ""type"": ""Gene/Protein""}, {""token"": ""kynurenine"", ""start_span"": 346, ""end_span"": 356, ""type"": ""Chemical/Drug""}]"
HAAO −/− mice had similar LPS treatment responses as WT mice when assessed for anhedonia and anxiety - like behavior.	"HAAO	0	4	Gene/Protein"	"mice	9	13	Organism/Species"	"mice	56	60	Organism/Species"	"anhedonia	79	88	Disease/Disorder"	"anxiety	93	100	Disease/Disorder"	"[{""token"": ""HAAO"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 9, ""end_span"": 13, ""type"": ""Organism/Species""}, {""token"": ""mice"", ""start_span"": 56, ""end_span"": 60, ""type"": ""Organism/Species""}, {""token"": ""anhedonia"", ""start_span"": 79, ""end_span"": 88, ""type"": ""Disease/Disorder""}, {""token"": ""anxiety"", ""start_span"": 93, ""end_span"": 100, ""type"": ""Disease/Disorder""}]"
3 - HK ( μM, Row 3) was not detected in the brain of KMO −/− mice, and was higher in HAAO −/− mice relative to WT mice.	"KMO	53	56	Gene/Protein"	"mice	61	65	Organism/Species"	"HAAO	85	89	Gene/Protein"	"mice	94	98	Organism/Species"	"mice	114	118	Organism/Species"	"[{""token"": ""KMO"", ""start_span"": 53, ""end_span"": 56, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 61, ""end_span"": 65, ""type"": ""Organism/Species""}, {""token"": ""HAAO"", ""start_span"": 85, ""end_span"": 89, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 94, ""end_span"": 98, ""type"": ""Organism/Species""}, {""token"": ""mice"", ""start_span"": 114, ""end_span"": 118, ""type"": ""Organism/Species""}]"
These findings are consistent with the contemporary hypothesis that disrupting the metabolic balance of the kynurenine pathway, rather than simply increasing overall kynurenine metabolism, defines the functional pathogenic context by which kynurenine metabolism mediates the behavioral effects of inflammation. 27, 28 Further, these data support recent findings from our laboratory, demonstrating that peripheral LPS induces brain region - dependent changes in the balance of kynurenine metabolites, specifically favoring neurotoxic metabolite production in the hippocampus. 34 Recent data characterizing the regional characteristics of microglia throughout the brain demonstrated that not all microglia express the same functional expression markers. 54 Specifically, it was noted that microglia in the hippocampus were more responsive to pro - inflammatory stimuli, earning them the label ‘ immunovigilant '. 54 This hyper - responsive state of hippocampal microglia could underlie the region - specific elevation in neurotoxic kynurenine metabolism described in Table 2.	"kynurenine	108	118	Chemical/Drug"	"kynurenine	166	176	Chemical/Drug"	"kynurenine	240	250	Chemical/Drug"	"kynurenine	476	486	Chemical/Drug"	"kynurenine	1030	1040	Chemical/Drug"	"[{""token"": ""kynurenine"", ""start_span"": 108, ""end_span"": 118, ""type"": ""Chemical/Drug""}, {""token"": ""kynurenine"", ""start_span"": 166, ""end_span"": 176, ""type"": ""Chemical/Drug""}, {""token"": ""kynurenine"", ""start_span"": 240, ""end_span"": 250, ""type"": ""Chemical/Drug""}, {""token"": ""kynurenine"", ""start_span"": 476, ""end_span"": 486, ""type"": ""Chemical/Drug""}, {""token"": ""kynurenine"", ""start_span"": 1030, ""end_span"": 1040, ""type"": ""Chemical/Drug""}]"
Direct administration of exogenous kynurenine has been utilized in a number of contexts that result in behavioral changes. 40, 41, 59 Our previous work demonstrated that exogenous kynurenine acutely precipitates a depressive - like phenotype similar to LPS. 16 Chronic administration of kynurenine during early development or to adult mice has also been used to elevate KA levels in the brain, resulting in deficits in sensorimotor gating, attentional processing of environmental stimuli, spatial working memory and contextual learning memory. 40, 41, 61 The data here are the first to demonstrate that exogenously administered peripheral 3 - HK is able to precipitate the development of behavioral despair in the TST, impair working memory in the Y - maze and induce anxiety - like behavior assessed in the OF.	"kynurenine	35	45	Chemical/Drug"	"kynurenine	180	190	Chemical/Drug"	"kynurenine	287	297	Chemical/Drug"	"mice	335	339	Organism/Species"	"anxiety	768	775	Disease/Disorder"	"[{""token"": ""kynurenine"", ""start_span"": 35, ""end_span"": 45, ""type"": ""Chemical/Drug""}, {""token"": ""kynurenine"", ""start_span"": 180, ""end_span"": 190, ""type"": ""Chemical/Drug""}, {""token"": ""kynurenine"", ""start_span"": 287, ""end_span"": 297, ""type"": ""Chemical/Drug""}, {""token"": ""mice"", ""start_span"": 335, ""end_span"": 339, ""type"": ""Organism/Species""}, {""token"": ""anxiety"", ""start_span"": 768, ""end_span"": 775, ""type"": ""Disease/Disorder""}]"
In the kynurenine pathway, tryptophan is metabolized to kynurenine by indoleamine 2, 3 - dioxygenase ( IDO ), an enzyme that is upregulated by pro - inflammatory cytokines.	"kynurenine	7	17	Chemical/Drug"	"tryptophan	27	37	Chemical/Drug"	"kynurenine	56	66	Chemical/Drug"	"IDO	103	106	Gene/Protein"	"pro - inflammatory cytokines	143	171	Gene/Protein"	"[{""token"": ""kynurenine"", ""start_span"": 7, ""end_span"": 17, ""type"": ""Chemical/Drug""}, {""token"": ""tryptophan"", ""start_span"": 27, ""end_span"": 37, ""type"": ""Chemical/Drug""}, {""token"": ""kynurenine"", ""start_span"": 56, ""end_span"": 66, ""type"": ""Chemical/Drug""}, {""token"": ""IDO"", ""start_span"": 103, ""end_span"": 106, ""type"": ""Gene/Protein""}, {""token"": ""pro - inflammatory cytokines"", ""start_span"": 143, ""end_span"": 171, ""type"": ""Gene/Protein""}]"
Then, further metabolism occurs to 3 - hydroxyanthranilic acid ( 3 - HAA) by kynureninase ( KYNU ), and then 3 - HAA is metabolized to quinolinic acid ( QA, red) by 3 - hydroxyanthranilic acid dioxygenase ( HAAO, purple ).	"kynureninase	77	89	Gene/Protein"	"KYNU	92	96	Gene/Protein"	"quinolinic acid	135	150	Chemical/Drug"	"3 - hydroxyanthranilic acid dioxygenase	165	204	Gene/Protein"	"HAAO	207	211	Gene/Protein"	"[{""token"": ""kynureninase"", ""start_span"": 77, ""end_span"": 89, ""type"": ""Gene/Protein""}, {""token"": ""KYNU"", ""start_span"": 92, ""end_span"": 96, ""type"": ""Gene/Protein""}, {""token"": ""quinolinic acid"", ""start_span"": 135, ""end_span"": 150, ""type"": ""Chemical/Drug""}, {""token"": ""3 - hydroxyanthranilic acid dioxygenase"", ""start_span"": 165, ""end_span"": 204, ""type"": ""Gene/Protein""}, {""token"": ""HAAO"", ""start_span"": 207, ""end_span"": 211, ""type"": ""Gene/Protein""}]"
A study by Leon et al. [ 8] suggested that compared with that of healthy individuals, the concentration of ccfDNA was significantly increased in cancer patients; furthermore, this phenomenon was confirmed by other studies on breast tumors [ 9 ], colorectal cancer [ 10 ], lung cancer [ 11 ], and other cancer types [ 12 ].	"cancer	145	151	Disease/Disorder"	"breast tumors	225	238	Disease/Disorder"	"colorectal cancer	246	263	Disease/Disorder"	"lung cancer	272	283	Disease/Disorder"	"cancer	302	308	Disease/Disorder"	"[{""token"": ""cancer"", ""start_span"": 145, ""end_span"": 151, ""type"": ""Disease/Disorder""}, {""token"": ""breast tumors"", ""start_span"": 225, ""end_span"": 238, ""type"": ""Disease/Disorder""}, {""token"": ""colorectal cancer"", ""start_span"": 246, ""end_span"": 263, ""type"": ""Disease/Disorder""}, {""token"": ""lung cancer"", ""start_span"": 272, ""end_span"": 283, ""type"": ""Disease/Disorder""}, {""token"": ""cancer"", ""start_span"": 302, ""end_span"": 308, ""type"": ""Disease/Disorder""}]"
Among the included lymphoma cases, 126 were B cell non - Hodgkin lymphoma ( B - NHL ), with diffuse large B cell lymphoma ( DLBCL, n = 98) as the most common subtype.	"lymphoma	19	27	Disease/Disorder"	"B cell non - Hodgkin lymphoma	44	73	Disease/Disorder"	"B - NHL	76	83	Disease/Disorder"	"diffuse large B cell lymphoma	92	121	Disease/Disorder"	"DLBCL	124	129	Disease/Disorder"	"[{""token"": ""lymphoma"", ""start_span"": 19, ""end_span"": 27, ""type"": ""Disease/Disorder""}, {""token"": ""B cell non - Hodgkin lymphoma"", ""start_span"": 44, ""end_span"": 73, ""type"": ""Disease/Disorder""}, {""token"": ""B - NHL"", ""start_span"": 76, ""end_span"": 83, ""type"": ""Disease/Disorder""}, {""token"": ""diffuse large B cell lymphoma"", ""start_span"": 92, ""end_span"": 121, ""type"": ""Disease/Disorder""}, {""token"": ""DLBCL"", ""start_span"": 124, ""end_span"": 129, ""type"": ""Disease/Disorder""}]"
There were 18, 9, and 21 patients diagnosed with HL, T cell non - HL ( T - NHL ), and extranodal NK / T cell lymphoma ( NK / TCL ), respectively.	"HL	49	51	Disease/Disorder"	"T cell non - HL	53	68	Disease/Disorder"	"T - NHL	71	78	Disease/Disorder"	"extranodal NK / T cell lymphoma	86	117	Disease/Disorder"	"NK / TCL	120	128	Disease/Disorder"	"[{""token"": ""HL"", ""start_span"": 49, ""end_span"": 51, ""type"": ""Disease/Disorder""}, {""token"": ""T cell non - HL"", ""start_span"": 53, ""end_span"": 68, ""type"": ""Disease/Disorder""}, {""token"": ""T - NHL"", ""start_span"": 71, ""end_span"": 78, ""type"": ""Disease/Disorder""}, {""token"": ""extranodal NK / T cell lymphoma"", ""start_span"": 86, ""end_span"": 117, ""type"": ""Disease/Disorder""}, {""token"": ""NK / TCL"", ""start_span"": 120, ""end_span"": 128, ""type"": ""Disease/Disorder""}]"
Elevated DII values were observed in patients with HL ( median 0. 37, mean 0. 40, P < 0. 0001 ), DLBCL ( median 0. 43, mean 0. 46, P < 0. 0001 ), other types of B - NHL ( median 0. 34, mean 0. 35, P = 0. 002 ), T - NHL ( median 0. 42, mean 0. 41, P = 0. 008 ), and NK / TCL ( median 0. 33, mean 0. 38, P = 0. 001 ), respectively ( Fig. 1b ).	"HL	51	53	Disease/Disorder"	"DLBCL	97	102	Disease/Disorder"	"B - NHL	161	168	Disease/Disorder"	"T - NHL	211	218	Disease/Disorder"	"NK / TCL	265	273	Disease/Disorder"	"[{""token"": ""HL"", ""start_span"": 51, ""end_span"": 53, ""type"": ""Disease/Disorder""}, {""token"": ""DLBCL"", ""start_span"": 97, ""end_span"": 102, ""type"": ""Disease/Disorder""}, {""token"": ""B - NHL"", ""start_span"": 161, ""end_span"": 168, ""type"": ""Disease/Disorder""}, {""token"": ""T - NHL"", ""start_span"": 211, ""end_span"": 218, ""type"": ""Disease/Disorder""}, {""token"": ""NK / TCL"", ""start_span"": 265, ""end_span"": 273, ""type"": ""Disease/Disorder""}]"
Black lines indicate admixture between wisent and cattle / aurochs, yellow lines / arrow — between Caucasian and founding or modern wisent respectively, and the blue arrow — from founders to modern wisent.	"wisent	39	45	Organism/Species"	"cattle	50	56	Organism/Species"	"aurochs	59	66	Organism/Species"	"wisent	132	138	Organism/Species"	"wisent	198	204	Organism/Species"	"[{""token"": ""wisent"", ""start_span"": 39, ""end_span"": 45, ""type"": ""Organism/Species""}, {""token"": ""cattle"", ""start_span"": 50, ""end_span"": 56, ""type"": ""Organism/Species""}, {""token"": ""aurochs"", ""start_span"": 59, ""end_span"": 66, ""type"": ""Organism/Species""}, {""token"": ""wisent"", ""start_span"": 132, ""end_span"": 138, ""type"": ""Organism/Species""}, {""token"": ""wisent"", ""start_span"": 198, ""end_span"": 204, ""type"": ""Organism/Species""}]"
Although sometimes controversial, the concept of de - extinction has generated considerable interest ( Sherkow and Greely 2013 ), and attempts are currently underway to generate animals that, at least superficially, resemble the quagga ( Equus quagga; Heywood 2013 ), an extinct subspecies of plains zebra, and also the aurochs ( van Vuure 2005 ), by careful selective breeding of their living relatives.	"animals	178	185	Organism/Species"	"quagga	229	235	Organism/Species"	"Equus quagga	238	250	Organism/Species"	"plains zebra	293	305	Organism/Species"	"aurochs	320	327	Organism/Species"	"[{""token"": ""animals"", ""start_span"": 178, ""end_span"": 185, ""type"": ""Organism/Species""}, {""token"": ""quagga"", ""start_span"": 229, ""end_span"": 235, ""type"": ""Organism/Species""}, {""token"": ""Equus quagga"", ""start_span"": 238, ""end_span"": 250, ""type"": ""Organism/Species""}, {""token"": ""plains zebra"", ""start_span"": 293, ""end_span"": 305, ""type"": ""Organism/Species""}, {""token"": ""aurochs"", ""start_span"": 320, ""end_span"": 327, ""type"": ""Organism/Species""}]"
Wisent sequences were aligned with those of 12 other bovin taxa, including the extinct steppe bison ( Bison priscus) and aurochs ( Bos primigenius) ( supplementary table S1, Supplementary Material online ).	"Wisent	0	6	Organism/Species"	"steppe bison	87	99	Organism/Species"	"Bison priscus	102	115	Organism/Species"	"aurochs	121	128	Organism/Species"	"Bos primigenius	131	146	Organism/Species"	"[{""token"": ""Wisent"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Organism/Species""}, {""token"": ""steppe bison"", ""start_span"": 87, ""end_span"": 99, ""type"": ""Organism/Species""}, {""token"": ""Bison priscus"", ""start_span"": 102, ""end_span"": 115, ""type"": ""Organism/Species""}, {""token"": ""aurochs"", ""start_span"": 121, ""end_span"": 128, ""type"": ""Organism/Species""}, {""token"": ""Bos primigenius"", ""start_span"": 131, ""end_span"": 146, ""type"": ""Organism/Species""}]"
CD4 + T Cells Expressing PD - 1, TIGIT and LAG - 3 Contribute to HIV Persistence during ART	"CD4	0	3	Gene/Protein"	"PD - 1	25	31	Gene/Protein"	"TIGIT	33	38	Gene/Protein"	"LAG - 3	43	50	Gene/Protein"	"HIV	65	68	Organism/Species"	"[{""token"": ""CD4"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 25, ""end_span"": 31, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 33, ""end_span"": 38, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 43, ""end_span"": 50, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 65, ""end_span"": 68, ""type"": ""Organism/Species""}]"
The frequency of CD4 + T cells co - expressing PD - 1, TIGIT and LAG - 3 independently predicted the frequency of cells harboring integrated HIV DNA.	"CD4	17	20	Gene/Protein"	"PD - 1	47	53	Gene/Protein"	"TIGIT	55	60	Gene/Protein"	"LAG - 3	65	72	Gene/Protein"	"HIV	141	144	Organism/Species"	"[{""token"": ""CD4"", ""start_span"": 17, ""end_span"": 20, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 47, ""end_span"": 53, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 55, ""end_span"": 60, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 65, ""end_span"": 72, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 141, ""end_span"": 144, ""type"": ""Organism/Species""}]"
Our data provide evidence that CD4 + T cells expressing PD - 1, TIGIT and LAG - 3 alone or in combination are enriched for persistent HIV during ART and suggest that immune checkpoint blockers directed against these receptors may represent valuable tools to target latently infected cells in virally suppressed individuals.	"CD4	31	34	Gene/Protein"	"PD - 1	56	62	Gene/Protein"	"TIGIT	64	69	Gene/Protein"	"LAG - 3	74	81	Gene/Protein"	"HIV	134	137	Organism/Species"	"[{""token"": ""CD4"", ""start_span"": 31, ""end_span"": 34, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 56, ""end_span"": 62, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 64, ""end_span"": 69, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 74, ""end_span"": 81, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 134, ""end_span"": 137, ""type"": ""Organism/Species""}]"
The functional and homing capacities of CD4 + T cells also dictate their capacity to serve as persistent reservoirs for HIV: Th17 and Th1 / Th17 CD4 + T cells as well as cells expressing CCR6 and CXCR3 show increasing contribution to the viral reservoir with duration of ART [ 11, 12 ].	"CD4	40	43	Gene/Protein"	"HIV	120	123	Organism/Species"	"CD4	145	148	Gene/Protein"	"CCR6	187	191	Gene/Protein"	"CXCR3	196	201	Gene/Protein"	"[{""token"": ""CD4"", ""start_span"": 40, ""end_span"": 43, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 120, ""end_span"": 123, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 145, ""end_span"": 148, ""type"": ""Gene/Protein""}, {""token"": ""CCR6"", ""start_span"": 187, ""end_span"": 191, ""type"": ""Gene/Protein""}, {""token"": ""CXCR3"", ""start_span"": 196, ""end_span"": 201, ""type"": ""Gene/Protein""}]"
We hypothesized that ICs, through their ability to inhibit T - cell activation, will favour HIV latency during ART, and that CD4 + T cells expressing ICs would be enriched for persistent HIV in individuals receiving ART.	"ICs	21	24	Gene/Protein"	"HIV	92	95	Organism/Species"	"CD4	125	128	Gene/Protein"	"ICs	150	153	Gene/Protein"	"HIV	187	190	Organism/Species"	"[{""token"": ""ICs"", ""start_span"": 21, ""end_span"": 24, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 92, ""end_span"": 95, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 125, ""end_span"": 128, ""type"": ""Gene/Protein""}, {""token"": ""ICs"", ""start_span"": 150, ""end_span"": 153, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 187, ""end_span"": 190, ""type"": ""Organism/Species""}]"
PD - 1, a member of the B7 - CD28 superfamily, enforces an inhibitory program that blocks further TCR - induced T - cell proliferation and cytokine production [ 18, 19 ].	"PD - 1	0	6	Gene/Protein"	"B7	24	26	Gene/Protein"	"CD28	29	33	Gene/Protein"	"TCR	98	101	Gene/Protein"	"cytokine	139	147	Gene/Protein"	"[{""token"": ""PD - 1"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Gene/Protein""}, {""token"": ""B7"", ""start_span"": 24, ""end_span"": 26, ""type"": ""Gene/Protein""}, {""token"": ""CD28"", ""start_span"": 29, ""end_span"": 33, ""type"": ""Gene/Protein""}, {""token"": ""TCR"", ""start_span"": 98, ""end_span"": 101, ""type"": ""Gene/Protein""}, {""token"": ""cytokine"", ""start_span"": 139, ""end_span"": 147, ""type"": ""Gene/Protein""}]"
CTLA - 4, a CD28 homolog, regulates the amplitude of T - cell activation by both outcompeting CD28 in binding CD80 and CD86, as well as actively delivering inhibitory signals to T cells [ 13 ].	"CTLA - 4	0	8	Gene/Protein"	"CD28 homolog	12	24	Gene/Protein"	"CD28	94	98	Gene/Protein"	"CD80	110	114	Gene/Protein"	"CD86	119	123	Gene/Protein"	"[{""token"": ""CTLA - 4"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Gene/Protein""}, {""token"": ""CD28 homolog"", ""start_span"": 12, ""end_span"": 24, ""type"": ""Gene/Protein""}, {""token"": ""CD28"", ""start_span"": 94, ""end_span"": 98, ""type"": ""Gene/Protein""}, {""token"": ""CD80"", ""start_span"": 110, ""end_span"": 114, ""type"": ""Gene/Protein""}, {""token"": ""CD86"", ""start_span"": 119, ""end_span"": 123, ""type"": ""Gene/Protein""}]"
The expression of 2B4 ( CD244 ), a member of the signalling lymphocyte activation molecule ( SLAM) is also modulated on T cells during HIV infection [ 17, 25 ].	"2B4	18	21	Gene/Protein"	"CD244	24	29	Gene/Protein"	"signalling lymphocyte activation molecule	49	90	Gene/Protein"	"SLAM	93	97	Gene/Protein"	"HIV infection	135	148	Disease/Disorder"	"[{""token"": ""2B4"", ""start_span"": 18, ""end_span"": 21, ""type"": ""Gene/Protein""}, {""token"": ""CD244"", ""start_span"": 24, ""end_span"": 29, ""type"": ""Gene/Protein""}, {""token"": ""signalling lymphocyte activation molecule"", ""start_span"": 49, ""end_span"": 90, ""type"": ""Gene/Protein""}, {""token"": ""SLAM"", ""start_span"": 93, ""end_span"": 97, ""type"": ""Gene/Protein""}, {""token"": ""HIV infection"", ""start_span"": 135, ""end_span"": 148, ""type"": ""Disease/Disorder""}]"
TIM - 3 is also an immunoglobulin superfamily member and its expression is increased on HIV - specific CD8 + and CD4 + T cells [ 29, 30 ].	"TIM - 3	0	7	Gene/Protein"	"immunoglobulin	19	33	Gene/Protein"	"HIV	88	91	Organism/Species"	"CD8	103	106	Gene/Protein"	"CD4	113	116	Gene/Protein"	"[{""token"": ""TIM - 3"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Gene/Protein""}, {""token"": ""immunoglobulin"", ""start_span"": 19, ""end_span"": 33, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 88, ""end_span"": 91, ""type"": ""Organism/Species""}, {""token"": ""CD8"", ""start_span"": 103, ""end_span"": 106, ""type"": ""Gene/Protein""}, {""token"": ""CD4"", ""start_span"": 113, ""end_span"": 116, ""type"": ""Gene/Protein""}]"
( B) Size of the HIV reservoir measured by integrated HIV DNA, total HIV DNA, 2 - LTR circles represented as copies per million CD4 + T cells and cell - associated US HIV RNA represented as copies per million copies of 18S.	"HIV	17	20	Organism/Species"	"HIV	54	57	Organism/Species"	"HIV	69	72	Organism/Species"	"CD4	128	131	Gene/Protein"	"HIV	167	170	Organism/Species"	"[{""token"": ""HIV"", ""start_span"": 17, ""end_span"": 20, ""type"": ""Organism/Species""}, {""token"": ""HIV"", ""start_span"": 54, ""end_span"": 57, ""type"": ""Organism/Species""}, {""token"": ""HIV"", ""start_span"": 69, ""end_span"": 72, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 128, ""end_span"": 131, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 167, ""end_span"": 170, ""type"": ""Organism/Species""}]"
The size of the HIV reservoir was determined by measuring the frequencies of CD4 + T cells harboring integrated HIV DNA, total HIV DNA and 2 - LTR circles as well as cell - associated unspliced ( CA - US) HIV RNA ( Fig 1B and S1 Table ).	"HIV	16	19	Organism/Species"	"CD4	77	80	Gene/Protein"	"HIV	112	115	Organism/Species"	"HIV	127	130	Organism/Species"	"HIV	205	208	Organism/Species"	"[{""token"": ""HIV"", ""start_span"": 16, ""end_span"": 19, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 77, ""end_span"": 80, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 112, ""end_span"": 115, ""type"": ""Organism/Species""}, {""token"": ""HIV"", ""start_span"": 127, ""end_span"": 130, ""type"": ""Organism/Species""}, {""token"": ""HIV"", ""start_span"": 205, ""end_span"": 208, ""type"": ""Organism/Species""}]"
The frequency of PD - 1 expressing CD4 + T cells was also associated with the frequency of CD4 + T cells harboring total HIV DNA ( S3 Table ), but only marginally ( 1. 23 - fold effect, p = 0. 07) when the model was adjusted for current CD4 + T - cell count.	"PD - 1	17	23	Gene/Protein"	"CD4	35	38	Gene/Protein"	"CD4	91	94	Gene/Protein"	"HIV	121	124	Organism/Species"	"CD4	237	240	Gene/Protein"	"[{""token"": ""PD - 1"", ""start_span"": 17, ""end_span"": 23, ""type"": ""Gene/Protein""}, {""token"": ""CD4"", ""start_span"": 35, ""end_span"": 38, ""type"": ""Gene/Protein""}, {""token"": ""CD4"", ""start_span"": 91, ""end_span"": 94, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 121, ""end_span"": 124, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 237, ""end_span"": 240, ""type"": ""Gene/Protein""}]"
Using a Boolean gating strategy, we determined the frequency of CD4 + T cells co - expressing PD - 1 and / or TIGIT and / or LAG - 3 in our cohort of 48 HIV - infected participants receiving suppressive ART ( Fig 2A and 2B ).	"CD4	64	67	Gene/Protein"	"PD - 1	94	100	Gene/Protein"	"TIGIT	110	115	Gene/Protein"	"LAG - 3	125	132	Gene/Protein"	"HIV	153	156	Organism/Species"	"[{""token"": ""CD4"", ""start_span"": 64, ""end_span"": 67, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 94, ""end_span"": 100, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 110, ""end_span"": 115, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 125, ""end_span"": 132, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 153, ""end_span"": 156, ""type"": ""Organism/Species""}]"
Although several of these associations were less or no longer statistically significant when the model was adjusted for the current CD4 + T - cell count, the association between the size of the HIV reservoir and the frequency of triple positive cells ( PD - 1 +, LAG - 3 + and TIGIT +) remained statistically significant after adjustment ( p = 0. 038 ).	"CD4	132	135	Gene/Protein"	"HIV	194	197	Organism/Species"	"PD - 1	253	259	Gene/Protein"	"LAG - 3	263	270	Gene/Protein"	"TIGIT	277	282	Gene/Protein"	"[{""token"": ""CD4"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 194, ""end_span"": 197, ""type"": ""Organism/Species""}, {""token"": ""PD - 1"", ""start_span"": 253, ""end_span"": 259, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 263, ""end_span"": 270, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 277, ""end_span"": 282, ""type"": ""Gene/Protein""}]"
All together, these results indicate that the co - expression of PD - 1, TIGIT and LAG - 3 identifies a unique subset of CD4 + T cells that strongly predicts the frequency of cells harboring integrated HIV DNA during ART.	"PD - 1	65	71	Gene/Protein"	"TIGIT	73	78	Gene/Protein"	"LAG - 3	83	90	Gene/Protein"	"CD4	121	124	Gene/Protein"	"HIV	202	205	Organism/Species"	"[{""token"": ""PD - 1"", ""start_span"": 65, ""end_span"": 71, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 73, ""end_span"": 78, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 83, ""end_span"": 90, ""type"": ""Gene/Protein""}, {""token"": ""CD4"", ""start_span"": 121, ""end_span"": 124, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 202, ""end_span"": 205, ""type"": ""Organism/Species""}]"
Negative binomial regression models to assess the relationship between Integrated HIV DNA and the frequency of CD4 + T cells expressing PD - 1 and / or TIGIT and / or LAG - 3.	"HIV	82	85	Organism/Species"	"CD4	111	114	Gene/Protein"	"PD - 1	136	142	Gene/Protein"	"TIGIT	152	157	Gene/Protein"	"LAG - 3	167	174	Gene/Protein"	"[{""token"": ""HIV"", ""start_span"": 82, ""end_span"": 85, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 111, ""end_span"": 114, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 136, ""end_span"": 142, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 152, ""end_span"": 157, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 167, ""end_span"": 174, ""type"": ""Gene/Protein""}]"
Expressions of PD - 1, TIGIT and LAG - 3 are associated with HIV - infected cells in distinct memory CD4 + T - cell subsets during ART	"PD - 1	15	21	Gene/Protein"	"TIGIT	23	28	Gene/Protein"	"LAG - 3	33	40	Gene/Protein"	"HIV	61	64	Organism/Species"	"CD4	101	104	Gene/Protein"	"[{""token"": ""PD - 1"", ""start_span"": 15, ""end_span"": 21, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 23, ""end_span"": 28, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 33, ""end_span"": 40, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 61, ""end_span"": 64, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 101, ""end_span"": 104, ""type"": ""Gene/Protein""}]"
PD - 1, TIGIT and LAG - 3 identify HIV - infected cells in distinct memory CD4 + T - cell subsets during ART.	"PD - 1	0	6	Gene/Protein"	"TIGIT	8	13	Gene/Protein"	"LAG - 3	18	25	Gene/Protein"	"HIV	35	38	Organism/Species"	"CD4	75	78	Gene/Protein"	"[{""token"": ""PD - 1"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 8, ""end_span"": 13, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 18, ""end_span"": 25, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 35, ""end_span"": 38, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 75, ""end_span"": 78, ""type"": ""Gene/Protein""}]"
( D ), ( E ), ( F) Frequencies of cells harboring integrated HIV DNA in TCM, TTM and TEM CD4 + T - cell subsets sorted based on their expression of PD - 1 ( n = 12 ), TIGIT ( n = 9) or LAG - 3 ( n = 7 ), respectively.	"HIV	61	64	Organism/Species"	"CD4	89	92	Gene/Protein"	"PD - 1	148	154	Gene/Protein"	"TIGIT	167	172	Gene/Protein"	"LAG - 3	185	192	Gene/Protein"	"[{""token"": ""HIV"", ""start_span"": 61, ""end_span"": 64, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 89, ""end_span"": 92, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 148, ""end_span"": 154, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 167, ""end_span"": 172, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 185, ""end_span"": 192, ""type"": ""Gene/Protein""}]"
We calculated the contribution of cells expressing PD - 1, TIGIT or LAG - 3 to the total reservoir by taking into account the frequency of these subsets within the CD4 compartment and their relative infection frequencies.	"PD - 1	51	57	Gene/Protein"	"TIGIT	59	64	Gene/Protein"	"LAG - 3	68	75	Gene/Protein"	"CD4	164	167	Gene/Protein"	"infection	199	208	Disease/Disorder"	"[{""token"": ""PD - 1"", ""start_span"": 51, ""end_span"": 57, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 59, ""end_span"": 64, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 68, ""end_span"": 75, ""type"": ""Gene/Protein""}, {""token"": ""CD4"", ""start_span"": 164, ""end_span"": 167, ""type"": ""Gene/Protein""}, {""token"": ""infection"", ""start_span"": 199, ""end_span"": 208, ""type"": ""Disease/Disorder""}]"
Co - expression of PD - 1, TIGIT and LAG - 3 highly enriches in HIV - infected memory CD4 + T cells during ART	"PD - 1	19	25	Gene/Protein"	"TIGIT	27	32	Gene/Protein"	"LAG - 3	37	44	Gene/Protein"	"HIV	64	67	Organism/Species"	"CD4	86	89	Gene/Protein"	"[{""token"": ""PD - 1"", ""start_span"": 19, ""end_span"": 25, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 27, ""end_span"": 32, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 37, ""end_span"": 44, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 64, ""end_span"": 67, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 86, ""end_span"": 89, ""type"": ""Gene/Protein""}]"
We then determined if the combination of PD - 1, TIGIT and LAG - 3 would further enrich memory CD4 + T cells for HIV - infected cells during ART.	"PD - 1	41	47	Gene/Protein"	"TIGIT	49	54	Gene/Protein"	"LAG - 3	59	66	Gene/Protein"	"CD4	95	98	Gene/Protein"	"HIV	113	116	Organism/Species"	"[{""token"": ""PD - 1"", ""start_span"": 41, ""end_span"": 47, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 49, ""end_span"": 54, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 59, ""end_span"": 66, ""type"": ""Gene/Protein""}, {""token"": ""CD4"", ""start_span"": 95, ""end_span"": 98, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 113, ""end_span"": 116, ""type"": ""Organism/Species""}]"
As the majority of HIV genomes, even when integrated, are defective [ 40 ], we assessed if PD - 1, TIGIT and LAG - 3 identify cells in which HIV production can be induced.	"HIV	19	22	Organism/Species"	"PD - 1	91	97	Gene/Protein"	"TIGIT	99	104	Gene/Protein"	"LAG - 3	109	116	Gene/Protein"	"HIV	141	144	Organism/Species"	"[{""token"": ""HIV"", ""start_span"": 19, ""end_span"": 22, ""type"": ""Organism/Species""}, {""token"": ""PD - 1"", ""start_span"": 91, ""end_span"": 97, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 99, ""end_span"": 104, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 109, ""end_span"": 116, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 141, ""end_span"": 144, ""type"": ""Organism/Species""}]"
As the frequency of triple positive cells was too low to perform this experiment, we sorted memory CD4 + T cells ( CD45RA -) expressing any ( i. e. at least one) versus none of PD - 1, TIGIT or LAG - 3 ( mLPT + and mLPT - respectively ).	"CD4	99	102	Gene/Protein"	"CD45RA	115	121	Gene/Protein"	"PD - 1	177	183	Gene/Protein"	"TIGIT	185	190	Gene/Protein"	"LAG - 3	194	201	Gene/Protein"	"[{""token"": ""CD4"", ""start_span"": 99, ""end_span"": 102, ""type"": ""Gene/Protein""}, {""token"": ""CD45RA"", ""start_span"": 115, ""end_span"": 121, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 177, ""end_span"": 183, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 185, ""end_span"": 190, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 194, ""end_span"": 201, ""type"": ""Gene/Protein""}]"
We found positive associations between the expression of PD - 1, LAG - 3 and TIGIT in CD4 + T cells and the frequency of cells harboring integrated HIV DNA.	"PD - 1	57	63	Gene/Protein"	"LAG - 3	65	72	Gene/Protein"	"TIGIT	77	82	Gene/Protein"	"CD4	86	89	Gene/Protein"	"HIV	148	151	Organism/Species"	"[{""token"": ""PD - 1"", ""start_span"": 57, ""end_span"": 63, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 65, ""end_span"": 72, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 77, ""end_span"": 82, ""type"": ""Gene/Protein""}, {""token"": ""CD4"", ""start_span"": 86, ""end_span"": 89, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 148, ""end_span"": 151, ""type"": ""Organism/Species""}]"
By sorting TCM, TTM and TEM cells expressing PD - 1, TIGIT and LAG - 3, we observed that cells expressing these markers were enriched for HIV - infected cells in different memory CD4 + T - cells subsets during ART.	"PD - 1	45	51	Gene/Protein"	"TIGIT	53	58	Gene/Protein"	"LAG - 3	63	70	Gene/Protein"	"HIV	138	141	Organism/Species"	"CD4	179	182	Gene/Protein"	"[{""token"": ""PD - 1"", ""start_span"": 45, ""end_span"": 51, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 53, ""end_span"": 58, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 63, ""end_span"": 70, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 138, ""end_span"": 141, ""type"": ""Organism/Species""}, {""token"": ""CD4"", ""start_span"": 179, ""end_span"": 182, ""type"": ""Gene/Protein""}]"
While LAG - 3 enriched for integrated HIV DNA in all memory subsets ( TCM, TTM, and TEM ), PD - 1 and TIGIT enriched for HIV genomes exclusively in TTM and TEM cells, respectively.	"LAG - 3	6	13	Gene/Protein"	"HIV	38	41	Organism/Species"	"PD - 1	91	97	Gene/Protein"	"TIGIT	102	107	Gene/Protein"	"HIV	121	124	Organism/Species"	"[{""token"": ""LAG - 3"", ""start_span"": 6, ""end_span"": 13, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 38, ""end_span"": 41, ""type"": ""Organism/Species""}, {""token"": ""PD - 1"", ""start_span"": 91, ""end_span"": 97, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 102, ""end_span"": 107, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 121, ""end_span"": 124, ""type"": ""Organism/Species""}]"
Indeed, LAG - 3 and PD - 1 are commonly co - expressed on exhausted or dysfunctional T cells in models of chronic infections [ 45 ], autoimmune diseases [ 46 ], and cancers [ 47, 48 ].	"LAG - 3	8	15	Gene/Protein"	"PD - 1	20	26	Gene/Protein"	"chronic infections	106	124	Disease/Disorder"	"autoimmune diseases	133	152	Disease/Disorder"	"cancers	165	172	Disease/Disorder"	"[{""token"": ""LAG - 3"", ""start_span"": 8, ""end_span"": 15, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 20, ""end_span"": 26, ""type"": ""Gene/Protein""}, {""token"": ""chronic infections"", ""start_span"": 106, ""end_span"": 124, ""type"": ""Disease/Disorder""}, {""token"": ""autoimmune diseases"", ""start_span"": 133, ""end_span"": 152, ""type"": ""Disease/Disorder""}, {""token"": ""cancers"", ""start_span"": 165, ""end_span"": 172, ""type"": ""Disease/Disorder""}]"
Additionally, TIGIT is co - expressed with PD - 1 on activated CD8 + tumor - infiltrating lymphocytes from patients with melanoma [ 50 ].	"TIGIT	14	19	Gene/Protein"	"PD - 1	43	49	Gene/Protein"	"CD8	63	66	Gene/Protein"	"tumor	69	74	Disease/Disorder"	"melanoma	121	129	Disease/Disorder"	"[{""token"": ""TIGIT"", ""start_span"": 14, ""end_span"": 19, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 43, ""end_span"": 49, ""type"": ""Gene/Protein""}, {""token"": ""CD8"", ""start_span"": 63, ""end_span"": 66, ""type"": ""Gene/Protein""}, {""token"": ""tumor"", ""start_span"": 69, ""end_span"": 74, ""type"": ""Disease/Disorder""}, {""token"": ""melanoma"", ""start_span"": 121, ""end_span"": 129, ""type"": ""Disease/Disorder""}]"
Blockages of TIGIT and PD - 1 synergize to improve T cell proliferation, cytokines production and degranulation in vivo in melanoma treatment and in vitro in HIV infection [ 24, 50 ].	"TIGIT	13	18	Gene/Protein"	"PD - 1	23	29	Gene/Protein"	"cytokines	73	82	Gene/Protein"	"melanoma	123	131	Disease/Disorder"	"HIV infection	158	171	Disease/Disorder"	"[{""token"": ""TIGIT"", ""start_span"": 13, ""end_span"": 18, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 23, ""end_span"": 29, ""type"": ""Gene/Protein""}, {""token"": ""cytokines"", ""start_span"": 73, ""end_span"": 82, ""type"": ""Gene/Protein""}, {""token"": ""melanoma"", ""start_span"": 123, ""end_span"": 131, ""type"": ""Disease/Disorder""}, {""token"": ""HIV infection"", ""start_span"": 158, ""end_span"": 171, ""type"": ""Disease/Disorder""}]"
The expression of PD - 1, LAG - 3 and TIM - 3 on CD4 + and CD8 + T cells prior to ART was recently identified as a strong predictor of time to viral rebound after treatment interruption in the SPARTAC study [ 43 ].	"PD - 1	18	24	Gene/Protein"	"LAG - 3	26	33	Gene/Protein"	"TIM - 3	38	45	Gene/Protein"	"CD4	49	52	Gene/Protein"	"CD8	59	62	Gene/Protein"	"[{""token"": ""PD - 1"", ""start_span"": 18, ""end_span"": 24, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 26, ""end_span"": 33, ""type"": ""Gene/Protein""}, {""token"": ""TIM - 3"", ""start_span"": 38, ""end_span"": 45, ""type"": ""Gene/Protein""}, {""token"": ""CD4"", ""start_span"": 49, ""end_span"": 52, ""type"": ""Gene/Protein""}, {""token"": ""CD8"", ""start_span"": 59, ""end_span"": 62, ""type"": ""Gene/Protein""}]"
In our study, we identified a discrete subset of CD4 + T cells co - expressing PD - 1, TIGIT and LAG - 3 as an important predictor of the frequency of cells harboring integrated HIV DNA during ART.	"CD4	49	52	Gene/Protein"	"PD - 1	79	85	Gene/Protein"	"TIGIT	87	92	Gene/Protein"	"LAG - 3	97	104	Gene/Protein"	"HIV	178	181	Organism/Species"	"[{""token"": ""CD4"", ""start_span"": 49, ""end_span"": 52, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 79, ""end_span"": 85, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 87, ""end_span"": 92, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 97, ""end_span"": 104, ""type"": ""Gene/Protein""}, {""token"": ""HIV"", ""start_span"": 178, ""end_span"": 181, ""type"": ""Organism/Species""}]"
( A ), ( B ), ( C) Associations between the current CD4 + T cell counts and the frequency of CD4 + T cells expressing PD - 1, TIGIT and LAG - 3, respectively.	"CD4	52	55	Gene/Protein"	"CD4	93	96	Gene/Protein"	"PD - 1	118	124	Gene/Protein"	"TIGIT	126	131	Gene/Protein"	"LAG - 3	136	143	Gene/Protein"	"[{""token"": ""CD4"", ""start_span"": 52, ""end_span"": 55, ""type"": ""Gene/Protein""}, {""token"": ""CD4"", ""start_span"": 93, ""end_span"": 96, ""type"": ""Gene/Protein""}, {""token"": ""PD - 1"", ""start_span"": 118, ""end_span"": 124, ""type"": ""Gene/Protein""}, {""token"": ""TIGIT"", ""start_span"": 126, ""end_span"": 131, ""type"": ""Gene/Protein""}, {""token"": ""LAG - 3"", ""start_span"": 136, ""end_span"": 143, ""type"": ""Gene/Protein""}]"
Simultaneously, we also observed a significant decrease in the population of Closrtridium coccoides subgroup ( p = 0. 002 ), Clostridium leptum subgroup ( p = 0. 0001 ), Lactobacillus ( p = 0. 037 ), Campylobacter ( p = 0. 0014) and Eubacterium ( p = 0. 038) in E. histolytica positive samples in comparison to control ( Figure 4B, C, D, E and F respectively ).	"Closrtridium coccoides	77	99	Organism/Species"	"Clostridium leptum	125	143	Organism/Species"	"Lactobacillus	170	183	Organism/Species"	"Campylobacter	200	213	Organism/Species"	"Eubacterium	233	244	Organism/Species"	"[{""token"": ""Closrtridium coccoides"", ""start_span"": 77, ""end_span"": 99, ""type"": ""Organism/Species""}, {""token"": ""Clostridium leptum"", ""start_span"": 125, ""end_span"": 143, ""type"": ""Organism/Species""}, {""token"": ""Lactobacillus"", ""start_span"": 170, ""end_span"": 183, ""type"": ""Organism/Species""}, {""token"": ""Campylobacter"", ""start_span"": 200, ""end_span"": 213, ""type"": ""Organism/Species""}, {""token"": ""Eubacterium"", ""start_span"": 233, ""end_span"": 244, ""type"": ""Organism/Species""}]"
Members of both Bifidobacteria and Ruminococcus - Ruminococcus torques and Bifidobacterium bifidum are thought to ferment mucin and compete to colonise this substrate for their energy source [ 33 ].	"Bifidobacteria	16	30	Organism/Species"	"Ruminococcus	35	47	Organism/Species"	"Ruminococcus torques	50	70	Organism/Species"	"Bifidobacterium bifidum	75	98	Organism/Species"	"mucin	122	127	Gene/Protein"	"[{""token"": ""Bifidobacteria"", ""start_span"": 16, ""end_span"": 30, ""type"": ""Organism/Species""}, {""token"": ""Ruminococcus"", ""start_span"": 35, ""end_span"": 47, ""type"": ""Organism/Species""}, {""token"": ""Ruminococcus torques"", ""start_span"": 50, ""end_span"": 70, ""type"": ""Organism/Species""}, {""token"": ""Bifidobacterium bifidum"", ""start_span"": 75, ""end_span"": 98, ""type"": ""Organism/Species""}, {""token"": ""mucin"", ""start_span"": 122, ""end_span"": 127, ""type"": ""Gene/Protein""}]"
As a result, the intestinal epithelial cells tend to produce more of mucin for protection that promotes colonization of Bifidobacteria in one hand and on the other hand the parasite competes to more release of mucin for its adhesion to epithelial layer. Bifidobacteria longum are known to protect the gut from enteropathogenic infection through production of acetate [ 32] and acetate is major energy source for colonocytes but a fine balance in population of different bacterial genera of gut is needed for healthy colon.	"mucin	69	74	Gene/Protein"	"Bifidobacteria	120	134	Organism/Species"	"mucin	210	215	Gene/Protein"	"Bifidobacteria longum	254	275	Organism/Species"	"infection	327	336	Disease/Disorder"	"[{""token"": ""mucin"", ""start_span"": 69, ""end_span"": 74, ""type"": ""Gene/Protein""}, {""token"": ""Bifidobacteria"", ""start_span"": 120, ""end_span"": 134, ""type"": ""Organism/Species""}, {""token"": ""mucin"", ""start_span"": 210, ""end_span"": 215, ""type"": ""Gene/Protein""}, {""token"": ""Bifidobacteria longum"", ""start_span"": 254, ""end_span"": 275, ""type"": ""Organism/Species""}, {""token"": ""infection"", ""start_span"": 327, ""end_span"": 336, ""type"": ""Disease/Disorder""}]"
It has been suggested that the low and variable prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae DNA in human stool contrasts with the paramount role of these methanogenic archaea in digestion processes and hypothesized that this contrast is a consequence of the inefficiencies of current protocols for archaea DNA extraction [ 41 ].	"Methanobrevibacter smithii	62	88	Organism/Species"	"Methanosphaera stadtmanae	93	118	Organism/Species"	"human	126	131	Organism/Species"	"methanogenic archaea	181	201	Organism/Species"	"archaea	325	332	Organism/Species"	"[{""token"": ""Methanobrevibacter smithii"", ""start_span"": 62, ""end_span"": 88, ""type"": ""Organism/Species""}, {""token"": ""Methanosphaera stadtmanae"", ""start_span"": 93, ""end_span"": 118, ""type"": ""Organism/Species""}, {""token"": ""human"", ""start_span"": 126, ""end_span"": 131, ""type"": ""Organism/Species""}, {""token"": ""methanogenic archaea"", ""start_span"": 181, ""end_span"": 201, ""type"": ""Organism/Species""}, {""token"": ""archaea"", ""start_span"": 325, ""end_span"": 332, ""type"": ""Organism/Species""}]"
Intestinal SRB ’ s growth and resultant hydrogen sulfide production have been implicated to damage the gastrointestinal tract and thereby contribute to chronic intestinal disorders [ 42 ]. Desulfovibrio fairfieldensis and D. desulfuricans have been associated with incidence of bacteremia and D. vulgaris has been associated with intra - abdominal infections [ 43 ].	"SRB	11	14	Organism/Species"	"intestinal disorders	160	180	Disease/Disorder"	"Desulfovibrio fairfieldensis	189	217	Organism/Species"	"bacteremia	278	288	Disease/Disorder"	"intra - abdominal infections	330	358	Disease/Disorder"	"[{""token"": ""SRB"", ""start_span"": 11, ""end_span"": 14, ""type"": ""Organism/Species""}, {""token"": ""intestinal disorders"", ""start_span"": 160, ""end_span"": 180, ""type"": ""Disease/Disorder""}, {""token"": ""Desulfovibrio fairfieldensis"", ""start_span"": 189, ""end_span"": 217, ""type"": ""Organism/Species""}, {""token"": ""bacteremia"", ""start_span"": 278, ""end_span"": 288, ""type"": ""Disease/Disorder""}, {""token"": ""intra - abdominal infections"", ""start_span"": 330, ""end_span"": 358, ""type"": ""Disease/Disorder""}]"
The genus Campylobacter is notorious for causing gastroenritis by C. jejuni but uncultured Campylobacter species e. g. Campylobacter hominis whose role is not clear yet, do exist in lower gastrointestinal tract of healthy humans [ 44 ].	"Campylobacter	10	23	Organism/Species"	"gastroenritis	49	62	Disease/Disorder"	"Campylobacter	91	104	Organism/Species"	"Campylobacter hominis	119	140	Organism/Species"	"humans	222	228	Organism/Species"	"[{""token"": ""Campylobacter"", ""start_span"": 10, ""end_span"": 23, ""type"": ""Organism/Species""}, {""token"": ""gastroenritis"", ""start_span"": 49, ""end_span"": 62, ""type"": ""Disease/Disorder""}, {""token"": ""Campylobacter"", ""start_span"": 91, ""end_span"": 104, ""type"": ""Organism/Species""}, {""token"": ""Campylobacter hominis"", ""start_span"": 119, ""end_span"": 140, ""type"": ""Organism/Species""}, {""token"": ""humans"", ""start_span"": 222, ""end_span"": 228, ""type"": ""Organism/Species""}]"
Several species of Bacteroides are known to harbor nim genes e. g. B. fragilis, B. distasonis, B. thetaiotaomicron, B. vulgatus, B. ovatus but wide differences in MIC values of metronidazole are observed, ranging from 1. 5 to > 256 mg / L and some are also found above the therapeutic breakpoint of 16 mg / L [ 45 ]. Though the population of Bacteroides is decreased significantly in E. histolytica positive patients however we have observed high copy no. of nimE gene in the same.	"Bacteroides	19	30	Organism/Species"	"nim	51	54	Gene/Protein"	"metronidazole	177	190	Chemical/Drug"	"Bacteroides	342	353	Organism/Species"	"nimE	459	463	Gene/Protein"	"[{""token"": ""Bacteroides"", ""start_span"": 19, ""end_span"": 30, ""type"": ""Organism/Species""}, {""token"": ""nim"", ""start_span"": 51, ""end_span"": 54, ""type"": ""Gene/Protein""}, {""token"": ""metronidazole"", ""start_span"": 177, ""end_span"": 190, ""type"": ""Chemical/Drug""}, {""token"": ""Bacteroides"", ""start_span"": 342, ""end_span"": 353, ""type"": ""Organism/Species""}, {""token"": ""nimE"", ""start_span"": 459, ""end_span"": 463, ""type"": ""Gene/Protein""}]"
"It has been also demonstrated that CMV - seropositive offspring of long - lived people have reduced levels of CD8 + T cells expressing CD57 and KLRG1, sometimes referred as """""""" marker of senescence """""","" when compared to their CMV - infected age - matched controls."	"CMV	35	38	Organism/Species"	"CD8	110	113	Gene/Protein"	"CD57	135	139	Gene/Protein"	"KLRG1	144	149	Gene/Protein"	"CMV	228	231	Organism/Species"	"[{""token"": ""CMV"", ""start_span"": 35, ""end_span"": 38, ""type"": ""Organism/Species""}, {""token"": ""CD8"", ""start_span"": 110, ""end_span"": 113, ""type"": ""Gene/Protein""}, {""token"": ""CD57"", ""start_span"": 135, ""end_span"": 139, ""type"": ""Gene/Protein""}, {""token"": ""KLRG1"", ""start_span"": 144, ""end_span"": 149, ""type"": ""Gene/Protein""}, {""token"": ""CMV"", ""start_span"": 228, ""end_span"": 231, ""type"": ""Organism/Species""}]"
Alterations in insulin pathway are known to be involved in metabolic disease, such as metabolic syndrome, insulin resistance and type 2 diabetes.	"insulin	15	22	Gene/Protein"	"metabolic disease	59	76	Disease/Disorder"	"metabolic syndrome	86	104	Disease/Disorder"	"insulin resistance	106	124	Disease/Disorder"	"type 2 diabetes	129	144	Disease/Disorder"	"[{""token"": ""insulin"", ""start_span"": 15, ""end_span"": 22, ""type"": ""Gene/Protein""}, {""token"": ""metabolic disease"", ""start_span"": 59, ""end_span"": 76, ""type"": ""Disease/Disorder""}, {""token"": ""metabolic syndrome"", ""start_span"": 86, ""end_span"": 104, ""type"": ""Disease/Disorder""}, {""token"": ""insulin resistance"", ""start_span"": 106, ""end_span"": 124, ""type"": ""Disease/Disorder""}, {""token"": ""type 2 diabetes"", ""start_span"": 129, ""end_span"": 144, ""type"": ""Disease/Disorder""}]"
The amino acid sequence of the products predicted from GmPT1 and GmPT2 share 61% and 63% identity, respectively, with the PHO84 in amino acid sequence.	"amino acid	4	14	Chemical/Drug"	"GmPT1	55	60	Gene/Protein"	"GmPT2	65	70	Gene/Protein"	"PHO84	122	127	Gene/Protein"	"amino acid	131	141	Chemical/Drug"	"[{""token"": ""amino acid"", ""start_span"": 4, ""end_span"": 14, ""type"": ""Chemical/Drug""}, {""token"": ""GmPT1"", ""start_span"": 55, ""end_span"": 60, ""type"": ""Gene/Protein""}, {""token"": ""GmPT2"", ""start_span"": 65, ""end_span"": 70, ""type"": ""Gene/Protein""}, {""token"": ""PHO84"", ""start_span"": 122, ""end_span"": 127, ""type"": ""Gene/Protein""}, {""token"": ""amino acid"", ""start_span"": 131, ""end_span"": 141, ""type"": ""Chemical/Drug""}]"
GmPT1 shows 76% and 61% and GmPT2 shows 76% and 63% amino acid sequence identity with GvPT ( accession number Q00908) and PHO84 ( accession number P25297 ), respectively.	"GmPT1	0	5	Gene/Protein"	"GmPT2	28	33	Gene/Protein"	"amino acid	52	62	Chemical/Drug"	"GvPT	86	90	Gene/Protein"	"PHO84	122	127	Gene/Protein"	"[{""token"": ""GmPT1"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Gene/Protein""}, {""token"": ""GmPT2"", ""start_span"": 28, ""end_span"": 33, ""type"": ""Gene/Protein""}, {""token"": ""amino acid"", ""start_span"": 52, ""end_span"": 62, ""type"": ""Chemical/Drug""}, {""token"": ""GvPT"", ""start_span"": 86, ""end_span"": 90, ""type"": ""Gene/Protein""}, {""token"": ""PHO84"", ""start_span"": 122, ""end_span"": 127, ""type"": ""Gene/Protein""}]"
Images showing onion epidermal cells expressing GmPT1 / GFP ( A – C ), empty vector ( D – F) and GmPT2 / GFP ( G – I) fusion protein examined under fluorescent - field illumination ( A, D and G) to examine GFP fluorescence; under bright - field illumination ( B, E and H) and by confocal microscopy for the overlay of bright and fluorescent illumination ( C, F and I ).	"GmPT1	48	53	Gene/Protein"	"GFP	56	59	Gene/Protein"	"GmPT2	97	102	Gene/Protein"	"GFP	105	108	Gene/Protein"	"GFP	206	209	Gene/Protein"	"[{""token"": ""GmPT1"", ""start_span"": 48, ""end_span"": 53, ""type"": ""Gene/Protein""}, {""token"": ""GFP"", ""start_span"": 56, ""end_span"": 59, ""type"": ""Gene/Protein""}, {""token"": ""GmPT2"", ""start_span"": 97, ""end_span"": 102, ""type"": ""Gene/Protein""}, {""token"": ""GFP"", ""start_span"": 105, ""end_span"": 108, ""type"": ""Gene/Protein""}, {""token"": ""GFP"", ""start_span"": 206, ""end_span"": 209, ""type"": ""Gene/Protein""}]"
The rate of uptake was reduced to 77% ( GmPT1) and 80% ( GmPT2) by 100 µM CCCP and, to 82% ( GmPT1) and 83% ( GmPT2) by 100 µM Vanadate, an inhibitor of P - type H +- ATPases.	"GmPT1	40	45	Gene/Protein"	"GmPT2	57	62	Gene/Protein"	"GmPT1	93	98	Gene/Protein"	"GmPT2	110	115	Gene/Protein"	"P - type H +- ATPases	153	174	Gene/Protein"	"[{""token"": ""GmPT1"", ""start_span"": 40, ""end_span"": 45, ""type"": ""Gene/Protein""}, {""token"": ""GmPT2"", ""start_span"": 57, ""end_span"": 62, ""type"": ""Gene/Protein""}, {""token"": ""GmPT1"", ""start_span"": 93, ""end_span"": 98, ""type"": ""Gene/Protein""}, {""token"": ""GmPT2"", ""start_span"": 110, ""end_span"": 115, ""type"": ""Gene/Protein""}, {""token"": ""P - type H +- ATPases"", ""start_span"": 153, ""end_span"": 174, ""type"": ""Gene/Protein""}]"
The expression of GmPT1 and GmPT2 in seedling tissues was increased during the 3 h after the Pi - sufficient treated seedlings were transferred to a Pi - deficient solution at 48 h compared to the expression measured in Pi - sufficient plants ( Figure 7A, C and E for GmPT1 and G, I and K for GmPT2 ).	"GmPT1	18	23	Gene/Protein"	"GmPT2	28	33	Gene/Protein"	"plants	236	242	Organism/Species"	"GmPT1	268	273	Gene/Protein"	"GmPT2	293	298	Gene/Protein"	"[{""token"": ""GmPT1"", ""start_span"": 18, ""end_span"": 23, ""type"": ""Gene/Protein""}, {""token"": ""GmPT2"", ""start_span"": 28, ""end_span"": 33, ""type"": ""Gene/Protein""}, {""token"": ""plants"", ""start_span"": 236, ""end_span"": 242, ""type"": ""Organism/Species""}, {""token"": ""GmPT1"", ""start_span"": 268, ""end_span"": 273, ""type"": ""Gene/Protein""}, {""token"": ""GmPT2"", ""start_span"": 293, ""end_span"": 298, ""type"": ""Gene/Protein""}]"
A decrease in the transcript abundance of GmPT1 and GmPT2 in the leaf, stem and root of hydroponically grown soybean seedlings was apparent within 3 h of Pi deprivation ( Figure 7 B, D and F for GmPT1 and H, J and L for GmPT2 ).	"GmPT1	42	47	Gene/Protein"	"GmPT2	52	57	Gene/Protein"	"soybean	109	116	Organism/Species"	"GmPT1	195	200	Gene/Protein"	"GmPT2	220	225	Gene/Protein"	"[{""token"": ""GmPT1"", ""start_span"": 42, ""end_span"": 47, ""type"": ""Gene/Protein""}, {""token"": ""GmPT2"", ""start_span"": 52, ""end_span"": 57, ""type"": ""Gene/Protein""}, {""token"": ""soybean"", ""start_span"": 109, ""end_span"": 116, ""type"": ""Organism/Species""}, {""token"": ""GmPT1"", ""start_span"": 195, ""end_span"": 200, ""type"": ""Gene/Protein""}, {""token"": ""GmPT2"", ""start_span"": 220, ""end_span"": 225, ""type"": ""Gene/Protein""}]"
By complementation of a knock - out of endogenous high - affinity Pi transporters of various yeast mutants, or by measuring the increase of Pi uptake in transformed plant cells, several Pi transporters of many plant species have shown common properties, indicating that there is an electrochemical proton gradient across the plasma membrane [ 6 ], [ 20 ], [ 26 ], [ 27 ], [ 30 ], [ 31 ], [ 45 ].	"Pi transporters	66	81	Gene/Protein"	"yeast	93	98	Organism/Species"	"plant	165	170	Organism/Species"	"Pi transporters	186	201	Gene/Protein"	"plant	210	215	Organism/Species"	"[{""token"": ""Pi transporters"", ""start_span"": 66, ""end_span"": 81, ""type"": ""Gene/Protein""}, {""token"": ""yeast"", ""start_span"": 93, ""end_span"": 98, ""type"": ""Organism/Species""}, {""token"": ""plant"", ""start_span"": 165, ""end_span"": 170, ""type"": ""Organism/Species""}, {""token"": ""Pi transporters"", ""start_span"": 186, ""end_span"": 201, ""type"": ""Gene/Protein""}, {""token"": ""plant"", ""start_span"": 210, ""end_span"": 215, ""type"": ""Organism/Species""}]"
Over - expression of OsPT2 ( PT2 ( O )) in transgenic plants resulted in accumulation of excess shoot Pi and growth retardation similar to that of rice pho2 mutants under Pi - sufficient conditions.	"OsPT2	21	26	Gene/Protein"	"PT2	29	32	Gene/Protein"	"plants	54	60	Organism/Species"	"rice	147	151	Organism/Species"	"pho2	152	156	Gene/Protein"	"[{""token"": ""OsPT2"", ""start_span"": 21, ""end_span"": 26, ""type"": ""Gene/Protein""}, {""token"": ""PT2"", ""start_span"": 29, ""end_span"": 32, ""type"": ""Gene/Protein""}, {""token"": ""plants"", ""start_span"": 54, ""end_span"": 60, ""type"": ""Organism/Species""}, {""token"": ""rice"", ""start_span"": 147, ""end_span"": 151, ""type"": ""Organism/Species""}, {""token"": ""pho2"", ""start_span"": 152, ""end_span"": 156, ""type"": ""Gene/Protein""}]"
The presence or absence of different DGK isozymes in members from different kingdoms and main phyla of eukaryotes was assessed by carrying out Blastp searches on sequences of different DGK isozymes from human and mouse species against annotated members of specific kingdoms or phyla present in the NCBI nr database.	"DGK	37	40	Gene/Protein"	"eukaryotes	103	113	Organism/Species"	"DGK	185	188	Gene/Protein"	"human	203	208	Organism/Species"	"mouse	213	218	Organism/Species"	"[{""token"": ""DGK"", ""start_span"": 37, ""end_span"": 40, ""type"": ""Gene/Protein""}, {""token"": ""eukaryotes"", ""start_span"": 103, ""end_span"": 113, ""type"": ""Organism/Species""}, {""token"": ""DGK"", ""start_span"": 185, ""end_span"": 188, ""type"": ""Gene/Protein""}, {""token"": ""human"", ""start_span"": 203, ""end_span"": 208, ""type"": ""Organism/Species""}, {""token"": ""mouse"", ""start_span"": 213, ""end_span"": 218, ""type"": ""Organism/Species""}]"
In addition, somework has been carried out on documenting and studying the functions of DGK isozymes in other eukaryotic organisms such as Drosophila, nematodes, slime molds and plants [ 3, 6, 10, 14 – 16, 33 – 35 ].	"DGK	88	91	Gene/Protein"	"Drosophila	139	149	Organism/Species"	"nematodes	151	160	Organism/Species"	"slime molds	162	173	Organism/Species"	"plants	178	184	Organism/Species"	"[{""token"": ""DGK"", ""start_span"": 88, ""end_span"": 91, ""type"": ""Gene/Protein""}, {""token"": ""Drosophila"", ""start_span"": 139, ""end_span"": 149, ""type"": ""Organism/Species""}, {""token"": ""nematodes"", ""start_span"": 151, ""end_span"": 160, ""type"": ""Organism/Species""}, {""token"": ""slime molds"", ""start_span"": 162, ""end_span"": 173, ""type"": ""Organism/Species""}, {""token"": ""plants"", ""start_span"": 178, ""end_span"": 184, ""type"": ""Organism/Species""}]"
Retrograde labeling and functional tests showed that LM + MP. NGF / NT3 increased the number of regenerated sensory neurons and improved sensory functional recovery, whereas FN + MP. BDNF preferentially increased regenerated motoneurons and enhanced motor functional recovery.	"LM	53	55	Gene/Protein"	"NGF	62	65	Gene/Protein"	"NT3	68	71	Gene/Protein"	"FN	174	176	Gene/Protein"	"BDNF	183	187	Gene/Protein"	"[{""token"": ""LM"", ""start_span"": 53, ""end_span"": 55, ""type"": ""Gene/Protein""}, {""token"": ""NGF"", ""start_span"": 62, ""end_span"": 65, ""type"": ""Gene/Protein""}, {""token"": ""NT3"", ""start_span"": 68, ""end_span"": 71, ""type"": ""Gene/Protein""}, {""token"": ""FN"", ""start_span"": 174, ""end_span"": 176, ""type"": ""Gene/Protein""}, {""token"": ""BDNF"", ""start_span"": 183, ""end_span"": 187, ""type"": ""Gene/Protein""}]"
On the other hand, the interaction between NTFs and their different receptors, such as Trk / p75 receptors or GDNFR / RET receptors, promotes survival and axonal regeneration of different neuronal populations.	"NTFs	43	47	Gene/Protein"	"Trk	87	90	Gene/Protein"	"p75	93	96	Gene/Protein"	"GDNFR	110	115	Gene/Protein"	"RET	118	121	Gene/Protein"	"[{""token"": ""NTFs"", ""start_span"": 43, ""end_span"": 47, ""type"": ""Gene/Protein""}, {""token"": ""Trk"", ""start_span"": 87, ""end_span"": 90, ""type"": ""Gene/Protein""}, {""token"": ""p75"", ""start_span"": 93, ""end_span"": 96, ""type"": ""Gene/Protein""}, {""token"": ""GDNFR"", ""start_span"": 110, ""end_span"": 115, ""type"": ""Gene/Protein""}, {""token"": ""RET"", ""start_span"": 118, ""end_span"": 121, ""type"": ""Gene/Protein""}]"
Briefly, addition of both LM and NGF / NT3 or FN and BDNF increased the amount of sensory and motor neurite outgrowth, respectively, in culture models.	"LM	26	28	Gene/Protein"	"NGF	33	36	Gene/Protein"	"NT3	39	42	Gene/Protein"	"FN	46	48	Gene/Protein"	"BDNF	53	57	Gene/Protein"	"[{""token"": ""LM"", ""start_span"": 26, ""end_span"": 28, ""type"": ""Gene/Protein""}, {""token"": ""NGF"", ""start_span"": 33, ""end_span"": 36, ""type"": ""Gene/Protein""}, {""token"": ""NT3"", ""start_span"": 39, ""end_span"": 42, ""type"": ""Gene/Protein""}, {""token"": ""FN"", ""start_span"": 46, ""end_span"": 48, ""type"": ""Gene/Protein""}, {""token"": ""BDNF"", ""start_span"": 53, ""end_span"": 57, ""type"": ""Gene/Protein""}]"
It is noteworthy that only LM + NGF / NT3 group showed differences in maximum neurite length with respect to all the other culture conditions except with LM + BDNF.	"LM	27	29	Gene/Protein"	"NGF	32	35	Gene/Protein"	"NT3	38	41	Gene/Protein"	"LM	154	156	Gene/Protein"	"BDNF	159	163	Gene/Protein"	"[{""token"": ""LM"", ""start_span"": 27, ""end_span"": 29, ""type"": ""Gene/Protein""}, {""token"": ""NGF"", ""start_span"": 32, ""end_span"": 35, ""type"": ""Gene/Protein""}, {""token"": ""NT3"", ""start_span"": 38, ""end_span"": 41, ""type"": ""Gene/Protein""}, {""token"": ""LM"", ""start_span"": 154, ""end_span"": 156, ""type"": ""Gene/Protein""}, {""token"": ""BDNF"", ""start_span"": 159, ""end_span"": 163, ""type"": ""Gene/Protein""}]"
The addition of NGF and NT3 enhanced significantly the density of neurites in all the substrates, being LM + NGF / NT3 the most prominent.	"NGF	16	19	Gene/Protein"	"NT3	24	27	Gene/Protein"	"LM	104	106	Gene/Protein"	"NGF	109	112	Gene/Protein"	"NT3	115	118	Gene/Protein"	"[{""token"": ""NGF"", ""start_span"": 16, ""end_span"": 19, ""type"": ""Gene/Protein""}, {""token"": ""NT3"", ""start_span"": 24, ""end_span"": 27, ""type"": ""Gene/Protein""}, {""token"": ""LM"", ""start_span"": 104, ""end_span"": 106, ""type"": ""Gene/Protein""}, {""token"": ""NGF"", ""start_span"": 109, ""end_span"": 112, ""type"": ""Gene/Protein""}, {""token"": ""NT3"", ""start_span"": 115, ""end_span"": 118, ""type"": ""Gene/Protein""}]"
These results indicate that combination of FN + BDNF shows synergistic effects on motor neurons promoting neurite elongation and arborization, with weaker effect on sensory elongation, whereas LM + NGF / NT3 is the only condition that exhibits a synergistic effects on sensory but not on motor neurons based on the enhancement observed in neurite elongation and arborization.	"FN	43	45	Gene/Protein"	"BDNF	48	52	Gene/Protein"	"LM	193	195	Gene/Protein"	"NGF	198	201	Gene/Protein"	"NT3	204	207	Gene/Protein"	"[{""token"": ""FN"", ""start_span"": 43, ""end_span"": 45, ""type"": ""Gene/Protein""}, {""token"": ""BDNF"", ""start_span"": 48, ""end_span"": 52, ""type"": ""Gene/Protein""}, {""token"": ""LM"", ""start_span"": 193, ""end_span"": 195, ""type"": ""Gene/Protein""}, {""token"": ""NGF"", ""start_span"": 198, ""end_span"": 201, ""type"": ""Gene/Protein""}, {""token"": ""NT3"", ""start_span"": 204, ""end_span"": 207, ""type"": ""Gene/Protein""}]"
Regarding the number of regenerated motor neurons, all groups with addition of ECM and NTFs showed significant differences with respect to the COL group ( p < 0. 001, Figure 3G ), being the FN + MP. BDNF group the one with the highest effect, that was also significantly higher compared to all other groups except with FN.	"NTFs	87	91	Gene/Protein"	"COL	143	146	Gene/Protein"	"FN	190	192	Gene/Protein"	"BDNF	199	203	Gene/Protein"	"FN	319	321	Gene/Protein"	"[{""token"": ""NTFs"", ""start_span"": 87, ""end_span"": 91, ""type"": ""Gene/Protein""}, {""token"": ""COL"", ""start_span"": 143, ""end_span"": 146, ""type"": ""Gene/Protein""}, {""token"": ""FN"", ""start_span"": 190, ""end_span"": 192, ""type"": ""Gene/Protein""}, {""token"": ""BDNF"", ""start_span"": 199, ""end_span"": 203, ""type"": ""Gene/Protein""}, {""token"": ""FN"", ""start_span"": 319, ""end_span"": 321, ""type"": ""Gene/Protein""}]"
Despite the preferential effects observed in vitro appear less marked in vivo, these results indicate that FN + MP. BDNF mainly favors motor axon regeneration, whereas LM + MP. NGF / NT3 is more effective to promote sensory axon regeneration.	"FN	107	109	Gene/Protein"	"BDNF	116	120	Gene/Protein"	"LM	168	170	Gene/Protein"	"NGF	177	180	Gene/Protein"	"NT3	183	186	Gene/Protein"	"[{""token"": ""FN"", ""start_span"": 107, ""end_span"": 109, ""type"": ""Gene/Protein""}, {""token"": ""BDNF"", ""start_span"": 116, ""end_span"": 120, ""type"": ""Gene/Protein""}, {""token"": ""LM"", ""start_span"": 168, ""end_span"": 170, ""type"": ""Gene/Protein""}, {""token"": ""NGF"", ""start_span"": 177, ""end_span"": 180, ""type"": ""Gene/Protein""}, {""token"": ""NT3"", ""start_span"": 183, ""end_span"": 186, ""type"": ""Gene/Protein""}]"
Similarly, the number of reinnervated SGs was highest in group LM + MP. NGF / NT3, although only significantly from groups COL and LM ( Figure 4L ).	"LM	63	65	Gene/Protein"	"NGF	72	75	Gene/Protein"	"NT3	78	81	Gene/Protein"	"COL	123	126	Gene/Protein"	"LM	131	133	Gene/Protein"	"[{""token"": ""LM"", ""start_span"": 63, ""end_span"": 65, ""type"": ""Gene/Protein""}, {""token"": ""NGF"", ""start_span"": 72, ""end_span"": 75, ""type"": ""Gene/Protein""}, {""token"": ""NT3"", ""start_span"": 78, ""end_span"": 81, ""type"": ""Gene/Protein""}, {""token"": ""COL"", ""start_span"": 123, ""end_span"": 126, ""type"": ""Gene/Protein""}, {""token"": ""LM"", ""start_span"": 131, ""end_span"": 133, ""type"": ""Gene/Protein""}]"
To corroborate the preferential effect of NGF, NT - 3 and LM on sensory neurons and BDNF and FN on motor neurons [ 15, 24, 25, 26, 27 ], we cultured DRG explants and spinal cord slices.	"NGF	42	45	Gene/Protein"	"NT - 3	47	53	Gene/Protein"	"LM	58	60	Gene/Protein"	"BDNF	84	88	Gene/Protein"	"FN	93	95	Gene/Protein"	"[{""token"": ""NGF"", ""start_span"": 42, ""end_span"": 45, ""type"": ""Gene/Protein""}, {""token"": ""NT - 3"", ""start_span"": 47, ""end_span"": 53, ""type"": ""Gene/Protein""}, {""token"": ""LM"", ""start_span"": 58, ""end_span"": 60, ""type"": ""Gene/Protein""}, {""token"": ""BDNF"", ""start_span"": 84, ""end_span"": 88, ""type"": ""Gene/Protein""}, {""token"": ""FN"", ""start_span"": 93, ""end_span"": 95, ""type"": ""Gene/Protein""}]"
However, the preferential effect mediated by LM + MP. NGF / NT3 and FN + MP. BDNF treatments was more modest compared to the in vitro experiments.	"LM	45	47	Gene/Protein"	"NGF	54	57	Gene/Protein"	"NT3	60	63	Gene/Protein"	"FN	68	70	Gene/Protein"	"BDNF	77	81	Gene/Protein"	"[{""token"": ""LM"", ""start_span"": 45, ""end_span"": 47, ""type"": ""Gene/Protein""}, {""token"": ""NGF"", ""start_span"": 54, ""end_span"": 57, ""type"": ""Gene/Protein""}, {""token"": ""NT3"", ""start_span"": 60, ""end_span"": 63, ""type"": ""Gene/Protein""}, {""token"": ""FN"", ""start_span"": 68, ""end_span"": 70, ""type"": ""Gene/Protein""}, {""token"": ""BDNF"", ""start_span"": 77, ""end_span"": 81, ""type"": ""Gene/Protein""}]"
In conclusion, this study demonstrates that the interaction between FN + BDNF and between LM + NGF / NT3 has synergistic effects to preferentially enhance motor and sensory axon regeneration, respectively, in vitro.	"FN	68	70	Gene/Protein"	"BDNF	73	77	Gene/Protein"	"LM	90	92	Gene/Protein"	"NGF	95	98	Gene/Protein"	"NT3	101	104	Gene/Protein"	"[{""token"": ""FN"", ""start_span"": 68, ""end_span"": 70, ""type"": ""Gene/Protein""}, {""token"": ""BDNF"", ""start_span"": 73, ""end_span"": 77, ""type"": ""Gene/Protein""}, {""token"": ""LM"", ""start_span"": 90, ""end_span"": 92, ""type"": ""Gene/Protein""}, {""token"": ""NGF"", ""start_span"": 95, ""end_span"": 98, ""type"": ""Gene/Protein""}, {""token"": ""NT3"", ""start_span"": 101, ""end_span"": 104, ""type"": ""Gene/Protein""}]"
Plasmids were propagated in Escherichia. coli JM109. S. cerevisiae CEN. PK2 - 1D ( MATα, Δura3 - 52; Δtrp1 - 289; Δleu2 - 3, 112; Δhis3 - 1; MAL2 - 8C; SUC2) from EUROSARF ( Frankfurt, Germany) and the pY13 - TEF1 plasmid was used for heterologous expression of potential transporters.	"MATα	83	87	Gene/Protein"	"MAL2	141	145	Gene/Protein"	"SUC2	152	156	Gene/Protein"	"TEF1	209	213	Gene/Protein"	"transporters	272	284	Gene/Protein"	"[{""token"": ""MAT\u03b1"", ""start_span"": 83, ""end_span"": 87, ""type"": ""Gene/Protein""}, {""token"": ""MAL2"", ""start_span"": 141, ""end_span"": 145, ""type"": ""Gene/Protein""}, {""token"": ""SUC2"", ""start_span"": 152, ""end_span"": 156, ""type"": ""Gene/Protein""}, {""token"": ""TEF1"", ""start_span"": 209, ""end_span"": 213, ""type"": ""Gene/Protein""}, {""token"": ""transporters"", ""start_span"": 272, ""end_span"": 284, ""type"": ""Gene/Protein""}]"
MATα Δura3 - 52; Δtrp1 - 289; Δleu2 - 3, 112; Δhis3 - 1; MAL2 - 8C; SUC2; Δjen1 :: URA3; Δady2 :: LEU2	"MATα	0	4	Gene/Protein"	"MAL2	57	61	Gene/Protein"	"SUC2	68	72	Gene/Protein"	"URA3	83	87	Gene/Protein"	"LEU2	98	102	Gene/Protein"	"[{""token"": ""MAT\u03b1"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Gene/Protein""}, {""token"": ""MAL2"", ""start_span"": 57, ""end_span"": 61, ""type"": ""Gene/Protein""}, {""token"": ""SUC2"", ""start_span"": 68, ""end_span"": 72, ""type"": ""Gene/Protein""}, {""token"": ""URA3"", ""start_span"": 83, ""end_span"": 87, ""type"": ""Gene/Protein""}, {""token"": ""LEU2"", ""start_span"": 98, ""end_span"": 102, ""type"": ""Gene/Protein""}]"
To determine whether the cMSCs could promote human tumor growth, we injected the cMSCs into immune deficient mice with human carcinoma cells, while untreated MSCs were used as controls.	"human	45	50	Organism/Species"	"tumor	51	56	Disease/Disorder"	"mice	109	113	Organism/Species"	"human	119	124	Organism/Species"	"carcinoma	125	134	Disease/Disorder"	"[{""token"": ""human"", ""start_span"": 45, ""end_span"": 50, ""type"": ""Organism/Species""}, {""token"": ""tumor"", ""start_span"": 51, ""end_span"": 56, ""type"": ""Disease/Disorder""}, {""token"": ""mice"", ""start_span"": 109, ""end_span"": 113, ""type"": ""Organism/Species""}, {""token"": ""human"", ""start_span"": 119, ""end_span"": 124, ""type"": ""Organism/Species""}, {""token"": ""carcinoma"", ""start_span"": 125, ""end_span"": 134, ""type"": ""Disease/Disorder""}]"
A previous study reported a new MSCs paradigm by specific TLR - priming: TLR4 - primed MSC1 and TLR3 - primed MSC2 [ 17 ].	"TLR	58	61	Gene/Protein"	"TLR4	73	77	Gene/Protein"	"MSC1	87	91	Gene/Protein"	"TLR3	96	100	Gene/Protein"	"MSC2	110	114	Gene/Protein"	"[{""token"": ""TLR"", ""start_span"": 58, ""end_span"": 61, ""type"": ""Gene/Protein""}, {""token"": ""TLR4"", ""start_span"": 73, ""end_span"": 77, ""type"": ""Gene/Protein""}, {""token"": ""MSC1"", ""start_span"": 87, ""end_span"": 91, ""type"": ""Gene/Protein""}, {""token"": ""TLR3"", ""start_span"": 96, ""end_span"": 100, ""type"": ""Gene/Protein""}, {""token"": ""MSC2"", ""start_span"": 110, ""end_span"": 114, ""type"": ""Gene/Protein""}]"
To determine whether monocytes / macrophages mediated the tumor - promoting effect of the cMSCs, we depleted systemic monocytes / macrophages with clodronate liposomes ( Clo - Lip) followed by injecting mixtures of cMSCs or MSCs with 4T1 tumor cells into mice 14 days after transplantation which detected the tumor growth by BLI.	"tumor	58	63	Disease/Disorder"	"clodronate	147	157	Chemical/Drug"	"tumor	238	243	Disease/Disorder"	"mice	255	259	Organism/Species"	"tumor	309	314	Disease/Disorder"	"[{""token"": ""tumor"", ""start_span"": 58, ""end_span"": 63, ""type"": ""Disease/Disorder""}, {""token"": ""clodronate"", ""start_span"": 147, ""end_span"": 157, ""type"": ""Chemical/Drug""}, {""token"": ""tumor"", ""start_span"": 238, ""end_span"": 243, ""type"": ""Disease/Disorder""}, {""token"": ""mice"", ""start_span"": 255, ""end_span"": 259, ""type"": ""Organism/Species""}, {""token"": ""tumor"", ""start_span"": 309, ""end_span"": 314, ""type"": ""Disease/Disorder""}]"
To establish the role of cMSCs - expressed MCP1 in tumor growth promotion and macrophage infiltration in vivo, we co - transplanted MCP1 siRNA treated cMSCs and 4T1 - FLUC tumor cells into C57BL / 6 mice.	"MCP1	43	47	Gene/Protein"	"tumor	51	56	Disease/Disorder"	"MCP1	132	136	Gene/Protein"	"tumor	172	177	Disease/Disorder"	"C57BL / 6 mice	189	203	Organism/Species"	"[{""token"": ""MCP1"", ""start_span"": 43, ""end_span"": 47, ""type"": ""Gene/Protein""}, {""token"": ""tumor"", ""start_span"": 51, ""end_span"": 56, ""type"": ""Disease/Disorder""}, {""token"": ""MCP1"", ""start_span"": 132, ""end_span"": 136, ""type"": ""Gene/Protein""}, {""token"": ""tumor"", ""start_span"": 172, ""end_span"": 177, ""type"": ""Disease/Disorder""}, {""token"": ""C57BL / 6 mice"", ""start_span"": 189, ""end_span"": 203, ""type"": ""Organism/Species""}]"
We found that an MCP1 deficiency led to a significant reduction in CD206 positive macrophages in both tumor tissues and peripheral blood ( Figure 4D ), indicating that MCP1 is critical for trafficking CD206 + macrophages.	"MCP1	17	21	Gene/Protein"	"CD206	67	72	Gene/Protein"	"tumor	102	107	Disease/Disorder"	"MCP1	168	172	Gene/Protein"	"CD206	201	206	Gene/Protein"	"[{""token"": ""MCP1"", ""start_span"": 17, ""end_span"": 21, ""type"": ""Gene/Protein""}, {""token"": ""CD206"", ""start_span"": 67, ""end_span"": 72, ""type"": ""Gene/Protein""}, {""token"": ""tumor"", ""start_span"": 102, ""end_span"": 107, ""type"": ""Disease/Disorder""}, {""token"": ""MCP1"", ""start_span"": 168, ""end_span"": 172, ""type"": ""Gene/Protein""}, {""token"": ""CD206"", ""start_span"": 201, ""end_span"": 206, ""type"": ""Gene/Protein""}]"
We showed that the addition of neutralizing antibodies specific for IL - 6 significantly decreased the mRNA expression of FIZZ - 1, MCP1, SIRPα, and reduced the percentage of CD206 positive cells, as compared with the co - culture control treated with nonspecific antibodies ( Figure 5C, 5D ).	"IL - 6	68	74	Gene/Protein"	"FIZZ - 1	122	130	Gene/Protein"	"MCP1	132	136	Gene/Protein"	"SIRPα	138	143	Gene/Protein"	"CD206	175	180	Gene/Protein"	"[{""token"": ""IL - 6"", ""start_span"": 68, ""end_span"": 74, ""type"": ""Gene/Protein""}, {""token"": ""FIZZ - 1"", ""start_span"": 122, ""end_span"": 130, ""type"": ""Gene/Protein""}, {""token"": ""MCP1"", ""start_span"": 132, ""end_span"": 136, ""type"": ""Gene/Protein""}, {""token"": ""SIRP\u03b1"", ""start_span"": 138, ""end_span"": 143, ""type"": ""Gene/Protein""}, {""token"": ""CD206"", ""start_span"": 175, ""end_span"": 180, ""type"": ""Gene/Protein""}]"
A previous study found that the concomitant presence of TNF - α and IFN - γ could induce the immunosuppressive functions of the MSCs, as these cytokine combinations provoke the expression of high levels of CXCL9, CXCL10 and iNOS [ 18 ].	"TNF - α	56	63	Gene/Protein"	"IFN - γ	68	75	Gene/Protein"	"CXCL9	206	211	Gene/Protein"	"CXCL10	213	219	Gene/Protein"	"iNOS	224	228	Gene/Protein"	"[{""token"": ""TNF - \u03b1"", ""start_span"": 56, ""end_span"": 63, ""type"": ""Gene/Protein""}, {""token"": ""IFN - \u03b3"", ""start_span"": 68, ""end_span"": 75, ""type"": ""Gene/Protein""}, {""token"": ""CXCL9"", ""start_span"": 206, ""end_span"": 211, ""type"": ""Gene/Protein""}, {""token"": ""CXCL10"", ""start_span"": 213, ""end_span"": 219, ""type"": ""Gene/Protein""}, {""token"": ""iNOS"", ""start_span"": 224, ""end_span"": 228, ""type"": ""Gene/Protein""}]"
Animals were divided into two groups ( n = 6 per group ): the si - iNOS / cMSCs group, in which mice received 1 × 106 iNOS siRNA treated cMSCs and 2 × 106 4T1 - FLUC cells in 100 μl of PBS; and the control ( si - control / cMSCs) group also received 1 × 106 control siRNA treated cMSCs and 2 × 106 tumor cells in 100 μl of PBS.	"Animals	0	7	Organism/Species"	"iNOS	67	71	Gene/Protein"	"mice	96	100	Organism/Species"	"iNOS	118	122	Gene/Protein"	"tumor	298	303	Disease/Disorder"	"[{""token"": ""Animals"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Organism/Species""}, {""token"": ""iNOS"", ""start_span"": 67, ""end_span"": 71, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 96, ""end_span"": 100, ""type"": ""Organism/Species""}, {""token"": ""iNOS"", ""start_span"": 118, ""end_span"": 122, ""type"": ""Gene/Protein""}, {""token"": ""tumor"", ""start_span"": 298, ""end_span"": 303, ""type"": ""Disease/Disorder""}]"
Animals were divided into two groups ( n = 6 per group ): the si - MCP1 / cMSCs group, in which mice received 1 × 106 MCP1 siRNA treated cMSCs and 2 × 106 4T1 - FLUC cells in 100 μl of PBS; and the control ( si - control / cMSCs) group also received 1 × 106 control siRNA treated cMSCs and 2 × 106 tumor cells in 100 μl of PBS.	"Animals	0	7	Organism/Species"	"MCP1	67	71	Gene/Protein"	"mice	96	100	Organism/Species"	"MCP1	118	122	Gene/Protein"	"tumor	298	303	Disease/Disorder"	"[{""token"": ""Animals"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Organism/Species""}, {""token"": ""MCP1"", ""start_span"": 67, ""end_span"": 71, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 96, ""end_span"": 100, ""type"": ""Organism/Species""}, {""token"": ""MCP1"", ""start_span"": 118, ""end_span"": 122, ""type"": ""Gene/Protein""}, {""token"": ""tumor"", ""start_span"": 298, ""end_span"": 303, ""type"": ""Disease/Disorder""}]"
For macrophage surface marker analysis, macrophages were incubated with fluorescent labeled rat anti - mouse CD11b, iNOS, and CD206 antibodies ( BD Biosciences Pharmingen, San Diego, CA ).	"rat	92	95	Organism/Species"	"mouse	103	108	Organism/Species"	"CD11b	109	114	Gene/Protein"	"iNOS	116	120	Gene/Protein"	"CD206	126	131	Gene/Protein"	"[{""token"": ""rat"", ""start_span"": 92, ""end_span"": 95, ""type"": ""Organism/Species""}, {""token"": ""mouse"", ""start_span"": 103, ""end_span"": 108, ""type"": ""Organism/Species""}, {""token"": ""CD11b"", ""start_span"": 109, ""end_span"": 114, ""type"": ""Gene/Protein""}, {""token"": ""iNOS"", ""start_span"": 116, ""end_span"": 120, ""type"": ""Gene/Protein""}, {""token"": ""CD206"", ""start_span"": 126, ""end_span"": 131, ""type"": ""Gene/Protein""}]"
The remaining 20% of AMLs develop in association with tuberosclerosis complex ( TSC) or pulmonary lymphangioleiomyomatosis ( LAM) [ 12 ].	"AMLs	21	25	Disease/Disorder"	"tuberosclerosis complex	54	77	Disease/Disorder"	"TSC	80	83	Disease/Disorder"	"pulmonary lymphangioleiomyomatosis	88	122	Disease/Disorder"	"LAM	125	128	Disease/Disorder"	"[{""token"": ""AMLs"", ""start_span"": 21, ""end_span"": 25, ""type"": ""Disease/Disorder""}, {""token"": ""tuberosclerosis complex"", ""start_span"": 54, ""end_span"": 77, ""type"": ""Disease/Disorder""}, {""token"": ""TSC"", ""start_span"": 80, ""end_span"": 83, ""type"": ""Disease/Disorder""}, {""token"": ""pulmonary lymphangioleiomyomatosis"", ""start_span"": 88, ""end_span"": 122, ""type"": ""Disease/Disorder""}, {""token"": ""LAM"", ""start_span"": 125, ""end_span"": 128, ""type"": ""Disease/Disorder""}]"
TSC is caused by mutations in one of two genes, TSC1 and TSC2, which encode the proteins hamartin and tuberin, respectively.	"TSC	0	3	Disease/Disorder"	"TSC1	48	52	Gene/Protein"	"TSC2	57	61	Gene/Protein"	"hamartin	89	97	Gene/Protein"	"tuberin	102	109	Gene/Protein"	"[{""token"": ""TSC"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Disease/Disorder""}, {""token"": ""TSC1"", ""start_span"": 48, ""end_span"": 52, ""type"": ""Gene/Protein""}, {""token"": ""TSC2"", ""start_span"": 57, ""end_span"": 61, ""type"": ""Gene/Protein""}, {""token"": ""hamartin"", ""start_span"": 89, ""end_span"": 97, ""type"": ""Gene/Protein""}, {""token"": ""tuberin"", ""start_span"": 102, ""end_span"": 109, ""type"": ""Gene/Protein""}]"
However, distinction of epithelioid AMLs from RCC is possible by the presence of immunohistochemistry markers, such as smooth muscle markers ( caldesmon and smooth muscle actin) and melanocytic markers ( HMB - 45 antigen and melan - A) [ 2345 ].	"AMLs	36	40	Disease/Disorder"	"RCC	46	49	Disease/Disorder"	"caldesmon	143	152	Gene/Protein"	"smooth muscle actin	157	176	Gene/Protein"	"melan - A	225	234	Gene/Protein"	"[{""token"": ""AMLs"", ""start_span"": 36, ""end_span"": 40, ""type"": ""Disease/Disorder""}, {""token"": ""RCC"", ""start_span"": 46, ""end_span"": 49, ""type"": ""Disease/Disorder""}, {""token"": ""caldesmon"", ""start_span"": 143, ""end_span"": 152, ""type"": ""Gene/Protein""}, {""token"": ""smooth muscle actin"", ""start_span"": 157, ""end_span"": 176, ""type"": ""Gene/Protein""}, {""token"": ""melan - A"", ""start_span"": 225, ""end_span"": 234, ""type"": ""Gene/Protein""}]"
a Abbreviations: BP: blood pressure; CASM: computer - assisted self - management; CASP: computer - assisted self - management + problem solving treatment; CV: cardiovascular; DM: diabetes mellitus; DM2: type 2 diabetes mellitus; GP: general practitioner; HbA1c; glycated hemoglobin A1c; HDL: high - density lipoprotein; LDL: low - density lipoprotein.	"DM	175	177	Disease/Disorder"	"diabetes mellitus	179	196	Disease/Disorder"	"DM2	198	201	Disease/Disorder"	"type 2 diabetes mellitus	203	227	Disease/Disorder"	"hemoglobin	271	281	Gene/Protein"	"[{""token"": ""DM"", ""start_span"": 175, ""end_span"": 177, ""type"": ""Disease/Disorder""}, {""token"": ""diabetes mellitus"", ""start_span"": 179, ""end_span"": 196, ""type"": ""Disease/Disorder""}, {""token"": ""DM2"", ""start_span"": 198, ""end_span"": 201, ""type"": ""Disease/Disorder""}, {""token"": ""type 2 diabetes mellitus"", ""start_span"": 203, ""end_span"": 227, ""type"": ""Disease/Disorder""}, {""token"": ""hemoglobin"", ""start_span"": 271, ""end_span"": 281, ""type"": ""Gene/Protein""}]"
